US20020032208A1 - Chemical compounds - Google Patents
Chemical compounds Download PDFInfo
- Publication number
- US20020032208A1 US20020032208A1 US09/877,005 US87700501A US2002032208A1 US 20020032208 A1 US20020032208 A1 US 20020032208A1 US 87700501 A US87700501 A US 87700501A US 2002032208 A1 US2002032208 A1 US 2002032208A1
- Authority
- US
- United States
- Prior art keywords
- methoxy
- quinazoline
- chloro
- hydroxy
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC.CCc1cc2ncnc(*c3ccccc3)c2c(C)c1C Chemical compound CC.CCc1cc2ncnc(*c3ccccc3)c2c(C)c1C 0.000 description 27
- BZQZLBPQWBUYJZ-UHFFFAOYSA-N CC(=O)C1=C([N+](=O)[O-])C=C(C)C(C)=C1C Chemical compound CC(=O)C1=C([N+](=O)[O-])C=C(C)C(C)=C1C BZQZLBPQWBUYJZ-UHFFFAOYSA-N 0.000 description 2
- OFVHUALAYNDQRX-UHFFFAOYSA-N CC.CC(C)(C)C1=CC=CC=C1 Chemical compound CC.CC(C)(C)C1=CC=CC=C1 OFVHUALAYNDQRX-UHFFFAOYSA-N 0.000 description 2
- XMMWXKVRUITJJN-UHFFFAOYSA-N CC1=NC=NC2=CC(C)=C(C)C(C)=C21 Chemical compound CC1=NC=NC2=CC(C)=C(C)C(C)=C21 XMMWXKVRUITJJN-UHFFFAOYSA-N 0.000 description 2
- VSSWDAXLENDDOU-UHFFFAOYSA-N CCC1=CC2=NC=NC(C)=C2C(C)=C1C Chemical compound CCC1=CC2=NC=NC(C)=C2C(C)=C1C VSSWDAXLENDDOU-UHFFFAOYSA-N 0.000 description 2
- SRHUFJXVXNEMKZ-UHFFFAOYSA-N CC(C)(C)c(c(N)c(c(N)c1)N)c1N Chemical compound CC(C)(C)c(c(N)c(c(N)c1)N)c1N SRHUFJXVXNEMKZ-UHFFFAOYSA-N 0.000 description 1
- DEWUMNBBXGKGSX-UHFFFAOYSA-N CC1=CC2=C(C(=O)NC=N2)C(C)=C1C Chemical compound CC1=CC2=C(C(=O)NC=N2)C(C)=C1C DEWUMNBBXGKGSX-UHFFFAOYSA-N 0.000 description 1
- NQJXBGFBABYXRJ-UHFFFAOYSA-N CC1=NC=NC2=CC(CP)=C(C)C(C)=C21 Chemical compound CC1=NC=NC2=CC(CP)=C(C)C(C)=C21 NQJXBGFBABYXRJ-UHFFFAOYSA-N 0.000 description 1
- ZCTIDTPXEQFXMP-UHFFFAOYSA-N CCC1=CC(N)=C(C(C)=O)C(C)=C1C Chemical compound CCC1=CC(N)=C(C(C)=O)C(C)=C1C ZCTIDTPXEQFXMP-UHFFFAOYSA-N 0.000 description 1
- IQYBNXZWVKTNEK-UHFFFAOYSA-N CCC1=CC2=C(C(=O)NC=N2)C(C)=C1C Chemical compound CCC1=CC2=C(C(=O)NC=N2)C(C)=C1C IQYBNXZWVKTNEK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.
- Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function.
- Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-3 1).
- vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan:Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324).
- Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF).
- aFGF & bFGF acidic and basic fibroblast growth factors
- VEGF vascular endothelial growth factor
- RTKs Receptor tyrosine kinases
- These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses.
- RTK subfamilies defined by amino acid sequence homology.
- One of these subfamilies is presently comprised by the fins-like tyrosine kinase receptor, Flt or Flt1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fins-like tyrosine kinase receptor, Flt4.
- KDR also referred to as Flk-1
- Flt4 fins-like tyrosine kinase receptor
- Two of these related RTKs, Flt and KDR have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Ternan et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187:1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.
- compounds of the present invention possess higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase. Furthermore, compounds of the present invention, possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.
- compounds of the invention possess activity against VEGF receptor tyrosine kinase such that they may be used in an amount sufficient to inhibit VEGF receptor tyrosine kinase whilst demonstrating no significant activity against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.
- Y 1 represents —O—, —S—, —CH 2 —, —SO—, —SO 2 —, —NR 5 CO—, —CONR 6 —, —SO 2 NR 7 —, —NR 8 SO 2 — or —NR 9 — (wherein R 5 , R 6 , R 7 , R 8 and R 9 each independently represents hydrogen, C 1-3 alkyl or C 1-3 alkoxyC 2-3 alkyl);
- m is an integer from 1 to 5;
- R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro;
- R 4 is selected from one of the following eight groups:
- Y represents —O—, —S—, —CH 2 —, —NR 5 CO—, —NR 8 SO 2 — or —NR 9 — (wherein R 5 , R 8 and R 9 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 1 represents —O—, —S—, —CH 2 — or —NH—, especially —O—.
- Y 1 represents —O—, —NR 5 CO— or —NR 8 SO 2 — (wherein R 5 and R 8 each independently represents hydrogen or C 1-2 alkyl).
- Y 1 is —NHCO—.
- R 1 represents hydrogen, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, or NR 10 R 11 (wherein R 10 and R 11 are as defined hereinbefore). Conveniently however R 1 is hydrogen, hydroxy, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy or amino.
- R 1 is preferably hydrogen, hydroxy, methyl, ethyl, methoxy or ethoxy, more preferably hydrogen, hydroxy, methyl or methoxy, particularly hydrogen, methyl or methoxy but especially methoxy.
- R 1 represents hydrogen, hydroxy, cyano, nitro, trifluoromethyl, methyl, ethyl, methoxy or ethoxy.
- R 2 is advantageously hydrogen, halogeno, amino or nitro.
- R 2 is preferably hydrogen, chloro or nitro, but especially hydrogen.
- R 3 represents hydroxy. halogeno, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, cyano, amino or nitro.
- one R 3 substituent is metahydroxy and the other one or more are each selected from halogeno and methyl.
- phenyl group bearing (R 3 ) m is of the formula IIa:
- R a represents hydrogen, methyl, fluoro or chloro
- R b represents hydrogen, methyl, methoxy, bromo, fluoro or chloro
- R c represents hydrogen or hydroxy
- R d represents hydrogen, fluoro or chloro, especially hydrogen or fluoro).
- phenyl group bearing (R 3 ) m is preferably of the formula IIa wherein:
- R a represents hydrogen, fluoro or chloro
- R b represents hydrogen, methyl, methoxy, bromo, fluoro or chloro, especially hydrogen, methyl or chloro;
- R c represents hydrogen or hydroxy
- R d represents hydrogen
- R a , R b and R c do not each represent hydrogen.
- the phenyl group bearing (R 3 ) m is the 3-hydroxy-4-methylphenyl group, the 2-fluoro-5-hydroxy-4-methylphenyl group, the 2-fluoro-4-bromophenyl, the 2-fluoro-4-chloro-5-hydroxyphenyl or the 4-chloro-2-fluorophenyl group.
- the phenyl group bearing (R 3 ) m is the 3-hydroxy-4-methylphenyl group, but especially the 2-fluoro-5-hydroxy-4-methylphenyl group.
- the phenyl group bearing (R 3 ) m is the 4-chloro-2-fluorophenyl group.
- Y 2 represents —O—, —S—, —SO—, —SO 2 —, —NR 16 CO—, —NR 19 SO 2 — or —NR 20 — (wherein R 16 , R 19 and R 20 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y represents, —O—, —S—, —SO—, —SO 2 — or —NR 20 - (wherein R 20 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 2 represents —S—, —O— or —NR 20 — (wherein R 20 represents hydrogen or C 1-2 alkyl), but most preferably is —O—, or —NR 20 (wherein R 20 is as hereinbefore defined).
- Y 3 represents —O—, —S—, —SO—, —SO 2 —, —NR 21 CO—, —NR 24 SO 2 — or —NR 25 — (wherein R 21 , R 24 and R 25 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 3 represents —O—, —S—, —SO—, —SO 2 — or —NR 25 — (wherein R 25 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 3 represents —O— or —NR 25 — (wherein R 25 represents hydrogen or C 1-2 alkyl).
- Y 4 represents —O—, —S—, —SO—, —SO 2 —, —NR 26 CO—, —NR 29 SO 2 — or —NR 30 — (wherein R 26 , R 29 and R 30 each independently represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 4 represents —O—, —S—, —SO—, —SO 2 — or —NR 30 — (wherein R 30 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 4 represents —O— or —NR 30 — (wherein R 30 represents hydrogen or C 1-2 alkyl).
- Y 5 represents —O—, —S—, —SO—, —SO 2 — or —NR 35 — (wherein R 35 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- Y 5 represents —O—, —S— or —NR 35 — (wherein R 35 represents hydrogen, C 1-2 alkyl or C 1-2 alkoxyethyl).
- m is preferably 2 or 3.
- Z may for example represent —NH— or —O— but Z is preferably —NH—.
- X 1 is a 5 or 6-membered aromatic heterocyclic group, it preferably has 1 or 2 heteroatoms, selected from O, N and S, of which more preferably one is N, and may be substituted as hereinbefore defined.
- X 1 is particularly a pyridone, pyridyl, imidazolyl, thiazolyl, thienyl, triazolyl or pyridazinyl group which group may be substituted as hereinbefore defined, more particularly a pyridone, pyridyl, imidazolyl, thiazolyl or triazolyl group, especially a pyridone, pyridyl, imidazolyl or triazolyl group which group may be substituted as hereinbefore defined.
- R 4 is C 1-5 alkylX 1 , C 2-5 alkenylX 1 , C 2-5 alkynylX 1 or C 1-3 alkylY 5 C 1-3 alkylX 1
- X 1 is a nitrogen-containing 6-membered aromatic heterocyclic group
- said group is advantageously linked to the alkyl, alkenyl or alkynyl moiety via a carbon atom of X 1 , said group being such that a nitrogen atom is positioned para- to the carbon atom linked to the alkyl, alkenyl or alkynyl moiety.
- the C 1-5 alkyl moiety may if desired be —(CH 2 ) n —.
- X 1 is pyrimidine which may be substituted as hereinbefore defined.
- X 1 represents a pyridone, phenyl or 5 or 6-membered aromatic heterocyclic group with 1 to 3 heteroatoms selected from O, N and S, which group may preferably carry up to 2 substituents, more preferably up to one substituent, selected from the group of substituents as hereinbefore defined.
- R 4 is selected from one of the following eight groups:
- R 4 is selected from one of the following eight groups:
- n is an integer from 0 to 5 and Y 6 represents a direct bond, —O—, —S—, —SO—, —SO 2 —, —NR 36 CO—, —CONR 37 —, —SO 2 NR 38 —, —NR 39 SO 2 — or —NR 40 — (wherein R 36 , R 37 , R 38 , R 39 and R 40 each independently represents hydrogen, C 1-3 alkyl or C 1-3 alkoxyC 2-3 alkyl)).
- Y 6 is a direct bond, —O—, —S— or —NH—.
- n is advantageously an integer from 0 to 3, preferably 1 to 3.
- [0105] [Y 1 represents —O—, —NH—, —S— or —CH 2 —;
- R 2 represents hydrogen, hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, trifluoromethyl, cyano, amino or nitro;
- Z represents —NH— or —O—
- Y 6 is a direct bond
- Another compound of interest is 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyrimidinylmethoxy)quinazoline and salts thereof especially hydrochloride salts thereof.
- alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term “alkyl” advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms.
- alkoxy as used herein, unless stated otherwise includes “alkyl”—O— groups in which “alkyl” is as hereinbefore defined.
- aryl as used herein unless stated otherwise includes reference to a C 6-10 aryl group which may, if desired, carry one or more substituents selected from halogeno, alkyl, alkoxy, nitro, trifluoromethyl and cyano, (wherein alkyl and alkoxy are as hereinbefore defined).
- aryloxy as used herein unless otherwise stated includes “aryl”—O-groups in which “aryl” is as hereinbefore defined.
- sulphonyloxy as used herein refers to alkylsulphonyloxy and arylsulphonyloxy groups in which “alkyl” and “aryl” are as hereinbefore defined.
- alkenyl includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only.
- alkenyl advantageously refers to chains with 2-6 carbon atoms, preferably 4-5 carbon atoms.
- alkynyl includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only. Unless otherwise stated the term “alkynyl” advantageously refers to chains with 2-6 carbon atoms, preferably 4-5 carbon atoms.
- a quinazoline of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits VEGF receptor tyrosine kinase activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
- R 4 is a group 1-X 1 prop-1-en-3-yl it is the first carbon to which the group X 1 is attached and it is the third carbon which is linked to Y 1 , similarly when R 4 is a group 2-X 1 pent-3-en-5-yl it is the second carbon to which the group X 1 is attached and it is the fifth carbon which is linked to Y 1 , and an analogous convention applies to other groups.
- the present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof.
- Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts.
- Such acid addition salts include for example salts with inorganic acids such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid as well as salts with organic acids affording pharmaceutically acceptable anions, such as for example trifluoroacetic, citric or maleic acid.
- pharmaceutically acceptable salts may be formed with an inorganic substance or organic base which affords a pharmaceutically acceptable cation.
- Such salts include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- an alkali metal salt such as a sodium or potassium salt
- an alkaline earth metal salt such as a calcium or magnesium salt
- an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- a compound of the formula I, or salt thereof, and other compounds of the invention may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications Nos. 0520722, 0566226, 0602851 and 0635498. Such processes, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
- a convenient displaceable group L 1 is, for example, a halogeno, alkoxy (preferably C 1-4 alkoxy), aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.
- the reaction is advantageously effected in the presence of either an acid or a base.
- an acid is, for example, an anhydrous inorganic acid such as hydrogen chloride.
- a base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
- such a base is, for example, an alkali metal hydride, for example sodium hydride, or an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide.
- the reaction is preferably effected in the presence of an inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide.
- the reaction is conveniently effected at a temperature in the range, for example
- the compound of the invention may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H—L 1 wherein L 1 has the meaning defined hereinbefore.
- the salt may be treated with a base as defined hereinbefore using a conventional procedure.
- ethers for example, methyl, methoxymethyl, allyl and benzyl
- silyl ethers for example, t-butyldiphenylsilyl and t-butyldimethylsilyl
- esters for example, acetate and benzoate
- carbonates for example, methyl and benzyl
- the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol.
- a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol.
- Such a reaction can be effected in the presence of an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50° C., conveniently at or near 20° C.
- L 1 is a displaceable group for example a halogeno or sulphonyloxy group such as a bromo or methanesulphonyloxy group.
- the reaction is preferably effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at or near 50° C.
- reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at or near 100° C.
- [0233] may be prepared by reacting a compound of the formula X:
- reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150° C., conveniently at about 50° C.
- Convenient halogenating agents include inorganic acid halides, for example thionyl chloride, phosphorus(III)chloride, phosphorus(V)oxychloride and phosphorus(V)chloride.
- the halogenation reaction is conveniently effected in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, or an aromatic hydrocarbon solvent such as benzene or toluene.
- the reaction is conveniently effected at a temperature in the range, for example 10 to 150° C., preferably in the range 40 to 100° C.
- R 1 , R 2 , R 4 and Y 1 are as hereinbefore defined, and A 1 is an hydroxy, alkoxy (preferably C 1-4 alkoxy) or amino group) whereby to form a compound of formula XII or salt thereof.
- the cyclisation may be effected by reacting a compound of the formula XIV, where A 1 is an hydroxy or alkoxy group, with formamide or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained, such as [3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride.
- the cyclisation is conveniently effected in the presence of a catalytic amount of an anhydrous acid, such as a sulphonic acid for example p-toluenesulphonic acid, and an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as diethylether or tetrahydrofuran, or an aromatic hydrocarbon solvent such as toluene.
- the cyclisation is conveniently effected at a temperature in the range, for example 10 to 100° C., preferably in the range 20 to 50° C.
- the reduction may be effected by heating a mixture of the nitro compound and the activated metal in the presence of a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol, to a temperature in the range, for example 50 to 150° C., conveniently at or near 70° C.
- a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol
- a compound of formula XVIII is conveniently used in which L represents a phenoxy group which may if desired carry up to 5 substituents, preferably up to 2 substituents, selected from halogeno, nitro and cyano.
- the reaction may be conveniently effected under conditions as described for process (c) hereinbefore.
- R 1 , R 2 , P, Y 1 and L 2 are as hereinbefore defined.
- Deprotection may be effected by techniques well known in the literature, for example where P represents a benzyl group deprotection may be effected by hydrogenolysis or by treatment with trifluoroacetic acid.
- One compound of formula III may if desired be converted into another compound of formula III in which the moiety L 1 is different.
- a compound of formula III in which L 1 is other than halogeno, for example optionally substituted phenoxy may be converted to a compound of formula III in which L 1 is halogeno by hydrolysis of a compound of formula III (in which L 1 is other than halogeno) to yield a compound of formula XII as hereinbefore defined, followed by introduction of halide to the compound of formula XII, thus obtained as hereinbefore defined, to yield a compound of formula III in which L 1 represents halogen.
- Compounds of the formula XXV and salts thereof may be made by reacting compounds of the formulae XIX and IV as hereinbefore defined, under the conditions described in (a) hereinbefore, to give a compound of the formula XXV or salt thereof.
- a pharmaceutically acceptable salt of a compound of the formula I it may be obtained, for example, by reaction of said compound with, for example, an acid using a conventional procedure.
- This assay determines the ability of a test compound to inhibit tyrosine kinase activity.
- DNA encoding VEGF or epidermal growth factor (EGF) receptor cytoplasmic domains may be obtained by total gene synthesis (Edwards M, International Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These may then be expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity.
- EGF and EGF receptor cytoplasmic domains which were obtained by expression of recombinant protein in insect cells, were found to display intrinsic tyrosine kinase activity.
- VEGF receptor Flt (Genbank accession number X51602)
- a 1.7 kb DNA fragment encoding most of the cytoplasmic domain, commencing with methionine 783 and including the termination codon, described by Shibuya et al (Oncogene, 1990, 5: 519-524) was isolated from cDNA and cloned into a baculovirus transplacement vector (for example pAcYM1 (see The Baculovirus Expression System: A Laboratory Guide, L. A. King and R. D. Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen Corporation)).
- pAcYM1 see The Baculovirus Expression System: A Laboratory Guide, L. A. King and R. D. Possee, Chapman and Hall, 1992
- pAc360 or pBlueBacHis available from Invitrogen Corporation
- This recombinant construct was co-transfected into insect cells (for example Spodoptera frugiperda 21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare recombinant baculovirus.
- insect cells for example Spodoptera frugiperda 21(Sf21)
- viral DNA eg Pharmingen BaculoGold
- cytoplasmic fragments starting from methionine 806 (KDR, Genbank accession number L04947) and methionine 668 (EGF receptor, Genbank accession number X00588) may be cloned and expressed in a similar manner.
- a stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at ⁇ 20° C. and diluted 1 in 500 with PBS for plate coating.
- a random copolymer containing tyrosine for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899)
- Test compounds were diluted with 10% dimethylsulphoxide (DMSO) and 25 ⁇ l of diluted compound was transferred to wells in the washed assay plates. “Total” control wells contained 10% DMSO instead of compound. Twenty five microliters of 40 mM MnCl 2 containing 8 ⁇ M adenosine-5′-triphosphate (ATP) was added to all test wells except “blank” control wells which contained MnCl 2 without ATP. To start the reactions 50 ⁇ l of freshly diluted enzyme was added to each well and the plates were incubated at room temperature for 20 minutes. The liquid was then discarded and the wells were washed twice with PBST.
- DMSO dimethylsulphoxide
- mice IgG anti-phosphotyrosine antibody Upstate Biotechnology Inc. product 05-321
- PBST bovine serum albumin
- HRP horse radish peroxidase
- SSA bovine serum albumin
- ABTS 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
- This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells (HUVEC).
- HUVEC cells were isolated in MCDB 131 (Gibco BRL)+7.5% v/v foetal calf serum (FCS) and were plated out (at passage 2 to 8), in MCDB 131+2% v/v FCS+3 ⁇ g/ml heparin+1 ⁇ g/ml hydrocortisone, at a concentration of 1000 cells/well in 96 well plates. After a minimum of 4 hours they were dosed with the appropriate growth factor (i.e. VEGF 3 ng/ml, EGF 3 ng/ml or b-FGF 0.3 ng/ml) and compound. The cultures were then incubated for 4 days at 37° C. with 7.5% CO 2 .
- FCS foetal calf serum
- a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically acceptable excipient or carrier.
- the composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intraveous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- parenteral injection including intraveous, subcutaneous, intramuscular, intravascular or infusion
- a sterile solution, suspension or emulsion for topical administration as an ointment or cream or for rectal administration as a suppository.
- the above compositions may be prepared in a conventional manner using conventional excipients.
- compositions of the present invention are advantageously presented in unit dosage form.
- the compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg.
- a unit dose in the range for example. 1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally provides a therapeutically-effective dose.
- a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
- a method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore.
- the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- a daily dose in the range of 1-50 mg/kg is employed.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- the other component(s) of such conjoint treatment in addition to the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
- Such chemotherapy may cover three main categories of therapeutic agent:
- cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 ⁇ -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factor function, (such growth factor
- antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincrisitine and taxoids like taxol, taxotere);
- antimetabolites for example antif
- the compounds defined in the present invention are of interest for their antiangiogenic and/or vascular permeability reducing effects.
- Such compounds of the invention are expected to be useful in a wide range of disease states including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases acute inflammation and ocular diseases with retinal vessel proliferation.
- diseases acute inflammation and ocular diseases with retinal vessel proliferation are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
- Such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
- the compounds of formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of test systems for the evaluation of the effects of inhibitors of VEGF receptor tyrosine kinase activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus;
- the starting material was prepared as follows:
- Example 2 The compound synthesised in Example 2 was further subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 1 to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-pyridylmethoxy)quinazoline (215 mg, 83%).
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Phosphorus oxytrichloride (0.1 ml) was added to a mixture of 6-methoxy-7-(4-pyridylmethoxy)-3,4-dihydroquinazolin-4-one (81 mg, 0.29 mmol) and N,N-dimethylaniline (0.1 ml) in toluene (5 ml), and the mixture heated at reflux for 1 hour. The volatiles were removed by evaporation and the residue partitioned between methylene chloride and aqueous ammonia. The organic extract was separated, dried (MgSO 4 ) and the solvent removed by evaporation.
- the crude product was purified by chromatography on silica eluting with methylene chloride/hexane progressing through increasingly polar mixtures to methanol/methylene chloride (1/19) to give 4-fluoro-2-methyl-5-nitrophenol (2.5 g, 22%) as a solid.
- Triphenylphosphine (5.5 g, 21 mmol) followed by 2-[N-methyl-N-(4-pyridyl)]aminoethanol (1.49 g, 9.8 mmol), (prepared as described in EP 0359389 A1), were added to a stirred solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.23 g, 7 mmol), (prepared as described for the starting material in Example 15), in methylene chloride (60 ml) under nitrogen. Diethyl azodicarboxylate (3.65 g, 21 mmol) was then added dropwise and the mixture was stirred at ambient temperature for 2 hours.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the solid residue was purified by column chromatography eluting with a mixture of methylene chloride/acetonitrile/methanol (50/45/5 followed by 50/40/10). The resulting purified solid was dissolved in methylene chloride/methanol and a solution of 5M hydrogen chloride in isopropanol (1 ml) was added. Partial evaporation led to the precipitation of a white solid. This solid was collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline hydrochloride (240 mg, 35%).
- the crude product was dissolved in methanol (20 ml), 2M sodium hydroxide (1 ml) was added and the mixture stirred for 15 minutes. Concentrated hydrochloric acid (0.5 ml) was added and the solvent was removed by evaporation. The crude product was purified by reverse phase chromatography eluting with methanol/water (1/1). Concentrated hydrochloric acid (0.3 ml) was added to the combined fractions containing the pure product and the solvent was removed by evaporation to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline hydrochloride (100 mg, 21%).
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the resulting precipitate was collected by filtration, washed with water and dried under vacuum.
- the solid was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified product was triturated with ether, collected by filtration and dried. The solid was dissolved in methylene chloride/isopropanol and a 5M solution of hydrogen chloride in isopropanol (0.5 ml) was added.
- triphenylphosphine 143 mg, 0.52 mmol
- diethyl azodicarboxylate 85 ⁇ l, 1 mmol
- the solid product was collected by filtration and washed with methylene chloride.
- the solid was dissolved in a mixture of methylene chloride (25 ml) and methanol (25 ml), and a solution of 2.9M ethereal hydrogen chloride (2 ml) was added.
- the starting material was prepared as follows:
- the solid residue was purified by column chromatography eluting with methylene chloride/methanol (97/3 and 95/5).
- the purified white solid was suspended in methanol (20 ml) and a solution of 7.5M hydrochloric acid in methanol (2 equivalents) was added.
- the solid was collected by filtration, washed with methanol and then pentane and dried under vacuum at 50° C. to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylbenzimidazol-2-yl)methoxy)quinazoline hydrochloride (106 mg, 37%).
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the mixture was diluted with ethyl acetate (5 ml), the solid product was collected by filtration and purified by chromatography on an aluminium oxide column eluting with methylene chloride/acetonitrile/methanol (60/35/5).
- the purified solid was triturated with ether and collected by filtration.
- the solid was dissolved in a mixture of methylene chloride/methanol and 3M ethereal hydrogen chloride (0.5 ml) was added.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the residue was purified by column chromatography eluting with a gradient of methylene chloride/methanol (95/50 to 80/20).
- the purified solid product was triturated with ether and collected by filtration.
- the solid was dissolved in methylene chloride/methanol and 3M ethereal hydrogen chloride (0.5 ml) was added. The volatiles were removed by evaporation and the residue was crystallised from methylene chloride and ether.
- the reaction mixture was poured onto a column of silica and eluted with a gradient of methylene chloride/acetonitrile/methanol (70/30/0 to 70/20/10).
- the partially purified product was further purified by column chromatography eluting with a gradient of methylene chloride/ether/methanol (60/40/0 to 60/10/30).
- the pure oil was crystallised from ether, collected by filtration and washed with ether to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-t-butoxycarbonylamino)ethoxy)quinazoline (450 mg, 63%).
- TFA (4 ml) was added to a solution of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-t-butoxycarbonylamino)ethoxy)quinazoline (390 mg, 0.82 mmol) in methylene chloride (4 ml) and the mixture stirred for 2 hours at ambient temperature. Toluene was added and the volatiles were removed by evaporation. The residue was dissolved in methylene chloride and 3M ethereal hydrogen chloride (1 ml) was added.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Oxalyl chloride (0.3 ml) was added to a mixture of 4-(2-chloropyridine)carboxylic acid (950 mg, 6 mmol) and DMF (0.05 ml) in methylene chloride (20 ml) and the mixture strirred at ambient temperature for 1 hour. The volatiles were removed by evaporation and ethanol (10 ml) was added to the residue and the mixture stirred at ambient temperature for 18 hours. Water was added and the mixture was extracted with ethyl acetate (3 ⁇ 25 ml). The extracts were combined, dried (MgSO 4 ) and the solvent removed by evaporation to give ethyl 4-(2-chloropyridine)carboxylate (700 mg, 63%) as a brown oil.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Tetrabutyl ammonium fluoride (9 ml of a 1M solution in THF, 9 mmol) was added to a solution of 2-cyano-4-dimethyl-t-butylsilyloxymethylpyridine (1.4 g, 5.6 mmol), (J.Het. Chem. 1993, 30, 631), in THF (15 ml) and the mixture was stirred for 2 hours at ambient temperature. Water was added and the volatiles were removed by evaporation. The residue was partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer extracted with ethyl acetate. The combined extracts were dried (MgSO 4 ) and the solvent removed by evaporation to give 2-cyano-4-hydroxymethylpyridine (0.55 g, 73%).
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- Oxalyl chloride (1.9 g, 15 mmol) was added to 2-chloro-6-methyl-pyridine-4-carboxylic acid (1.7 g, 10 mmol) in methylene chloride (30 ml) and the mixture stirred for 2 hours. The volatiles were removed by evaporation and methanol (20 ml) added to the residue. The mixture was stirred for 1 hour and the volatiles removed by evaporation to give methyl 2-chloro-6-methyl-pyridine-4-carboxylate (1.85 g, 100%) as an off-white solid.
- the starting material was prepared as follows:
- the starting material was prepared as follows:
- the starting material was prepared as follows:
Abstract
Description
- The present invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability and to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans.
- Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-3 1). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan:Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF). By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).
- Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fins-like tyrosine kinase receptor, Flt or Flt1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fins-like tyrosine kinase receptor, Flt4. Two of these related RTKs, Flt and KDR, have been shown to bind VEGF with high affinity (De Vries et al, 1992, Science 255: 989-991; Ternan et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187:1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.
- Compounds which have good activity against epidermal growth factor (EGF) receptor tyrosine kinase are disclosed in the European Patent No. 0566226. The present invention is based on the discovery of compounds that surprisingly inhibit the effects of VEGF, a property of value in the treatment of disease states associated with angiogenesis and/or increased vascular permeability such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation and ocular diseases with retinal vessel proliferation. Compounds of the present invention possess higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase. Furthermore, compounds of the present invention, possess substantially higher potency against VEGF receptor tyrosine kinase than against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase. Thus compounds of the invention which have been tested possess activity against VEGF receptor tyrosine kinase such that they may be used in an amount sufficient to inhibit VEGF receptor tyrosine kinase whilst demonstrating no significant activity against EGF receptor tyrosine kinase or FGF R1 receptor tyrosine kinase.
-
- [wherein:
- Y1 represents —O—, —S—, —CH2—, —SO—, —SO2—, —NR5CO—, —CONR6—, —SO2NR7—, —NR8SO2— or —NR9— (wherein R5, R6, R7, R8 and R9 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl);
- R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or NR10R11 (wherein R10 and R11, which may be the same or different, each represents hydrogen or C1-3alkyl);
- R2 represents hydrogen, hydroxy, halogeno, C1-3alkyl, C1-3 alkoxy, trifluoromethyl, cyano, amino or nitro;
- m is an integer from 1 to 5;
- R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro;
- R4 is selected from one of the following eight groups:
- 1) X1 (wherein X1 represents a pyridone group, a phenyl group or a 5 or 6-membered aromatic heterocyclic group with 1 to 3 heteroatoms selected from O, N and S, which pyridone, phenyl or heterocyclic group may carry up to 5 substituents selected from halogeno, amino, C1-4alkyl, C1-4alkoxy, C1-4hydroxyalkyl, C1-4aminoalkyl, C1-4alkylamino, C1-4hydroxyalkoxy, carboxy, cyano, —CONR12R13 and —NR14COR15 (wherein R12, R13, R14 and R15, which may be the same or different, each represents hydrogen, C1-4alkyl or C1-3alkoxyC2-3alkyl));
- 2) C1-5alkylX1 (wherein X1 is as defined hereinbefore);
- 3) C2-5alkenylX1 (wherein X1 is as defined hereinbefore);
- 4) C2-5alkynylX1 (wherein X1 is as defined hereinbefore);
- 5) C1-5alkylY2X1 (wherein Y2 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR16CO—, —CONR17—, —SO2NR18—, —NR19SO2— or —NR20— (wherein R16, R17, R18, R19 and R20 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X1 is as defined hereinbefore);
- 6) C2-5alkenylY3X1 (wherein Y3 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR21CO—, —CONR22—, —SO2NR2—, —NR2SO2 or —NR2— (wherein R21, R22, R23, R24 and R25 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X1 is as defined hereinbefore);
- 7) C2-5alkynylY4X1 (wherein Y4 represents —O—, —S—, —SO—, —SO2—, —OCO—, —NR26CO—, —CONR27—, —SO2NR28—, —NR29SO2— or —NR30— (wherein R26, R27, R28, R29 and R30 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X1 is as defined hereinbefore); and
- 8) C1-3alkylY5C1-3alkylX1 (wherein Y5 represents —O—, —S—, —SO—, —SO2—, —NR31CO—, —CONR32—, —SO2NR33—, —NR SO2— or —NR35— (wherein R31, R32, R33, R34 and R35 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X1 is as defined hereinbefore); Z represents —NH—, —O—, —S—, or —CH2—; with the proviso that where R4 is selected from one of the groups 1), 2), and 5) above and X1 is unsubstituted phenyl or substituted phenyl with 1 to 2 substituents selected from halogeno, C1-4alkyl and C1-4alkoxy, then m is an integer from 3 to 5 and/or Z is —O—, —S—, or —CH2—];
- and salts thereof.
- Advantageously Y represents —O—, —S—, —CH2—, —NR5CO—, —NR8SO2— or —NR9— (wherein R5, R8 and R9 each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y1 represents —O—, —S—, —CH2—, —NR5CO—, —NR8SO2— or —NH— (wherein R5and R8 each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- More preferably Y1 represents —O—, —S—, —CH2— or —NH—, especially —O—.
- In another embodiment of the present invention Y1 represents —O—, —NR5CO— or —NR8SO2— (wherein R5 and R8 each independently represents hydrogen or C1-2alkyl).
- In a further embodiment of the present invention Y1 is —NHCO—.
- In one embodiment of the invention R1 represents hydrogen, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or NR10R11 (wherein R10 and R11 are as defined hereinbefore). Conveniently however R1 is hydrogen, hydroxy, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy or amino.
- R1 is advantageously hydrogen, hydroxy, C1-3alkyl, C1-3alkoxy or amino.
- R1 is preferably hydrogen, hydroxy, methyl, ethyl, methoxy or ethoxy, more preferably hydrogen, hydroxy, methyl or methoxy, particularly hydrogen, methyl or methoxy but especially methoxy.
- In another embodiment of the present invention R1 represents hydrogen, hydroxy, cyano, nitro, trifluoromethyl, methyl, ethyl, methoxy or ethoxy.
- R2 is advantageously hydrogen, halogeno, amino or nitro.
- R2 is preferably hydrogen, chloro or nitro, but especially hydrogen.
- In one embodiment of the present invention R3 represents hydroxy. halogeno, C1-3alkyl, C1-3alkoxy, trifluoromethyl, cyano, amino or nitro.
- Advantageously in another embodiment of the present invention one R3 substituent is metahydroxy and the other one or more are each selected from halogeno and methyl.
-
- (wherein:
- Ra represents hydrogen, methyl, fluoro or chloro;
- Rb represents hydrogen, methyl, methoxy, bromo, fluoro or chloro;
- Rc represents hydrogen or hydroxy;
- Rd represents hydrogen, fluoro or chloro, especially hydrogen or fluoro).
- In a further embodiment of the invention the phenyl group bearing (R3)m is preferably of the formula IIa wherein:
- Ra represents hydrogen, fluoro or chloro; a
- Rb represents hydrogen, methyl, methoxy, bromo, fluoro or chloro, especially hydrogen, methyl or chloro;
- Rc represents hydrogen or hydroxy; and
- Rd represents hydrogen;
- with the proviso that Ra, Rb and Rc do not each represent hydrogen.
- Preferably the phenyl group bearing (R3)m is the 3-hydroxy-4-methylphenyl group, the 2-fluoro-5-hydroxy-4-methylphenyl group, the 2-fluoro-4-bromophenyl, the 2-fluoro-4-chloro-5-hydroxyphenyl or the 4-chloro-2-fluorophenyl group.
- In a particular aspect of the present invention, the phenyl group bearing (R3)m is the 3-hydroxy-4-methylphenyl group, but especially the 2-fluoro-5-hydroxy-4-methylphenyl group.
- In a further embodiment of the present invention the phenyl group bearing (R3)m is the 4-chloro-2-fluorophenyl group.
- Advantageously Y2represents —O—, —S—, —SO—, —SO2—, —NR16CO—, —NR19SO2— or —NR20— (wherein R16, R19 and R20 each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y represents, —O—, —S—, —SO—, —SO2— or —NR20- (wherein R20 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- More preferably Y2 represents —S—, —O— or —NR20— (wherein R20 represents hydrogen or C1-2alkyl), but most preferably is —O—, or —NR20 (wherein R20 is as hereinbefore defined).
- Advantageously Y3 represents —O—, —S—, —SO—, —SO2—, —NR21CO—, —NR24SO2— or —NR25— (wherein R21, R24 and R25 each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y3 represents —O—, —S—, —SO—, —SO2— or —NR25— (wherein R25 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- More preferably Y3 represents —O— or —NR25— (wherein R25 represents hydrogen or C1-2alkyl).
- Advantageously Y4 represents —O—, —S—, —SO—, —SO2—, —NR26CO—, —NR29SO2— or —NR30— (wherein R26, R29 and R30 each independently represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y4 represents —O—, —S—, —SO—, —SO2— or —NR30— (wherein R30 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- More preferably Y4 represents —O— or —NR30— (wherein R30 represents hydrogen or C1-2alkyl).
- Advantageously Y5 represents —O—, —S—, —SO—, —SO2— or —NR35— (wherein R35 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y5 represents —O—, —S— or —NR35— (wherein R35 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- m is preferably 2 or 3.
- Z may for example represent —NH— or —O— but Z is preferably —NH—.
- X1 preferably represents a pyridone group or a 5 or 6-membered aromatic heterocyclic group with 1 to 3 heteroatoms selected from O, N and S, which pyridone group or heterocyclic group may be substituted as hereinbefore defined.
- Where X1 is a 5 or 6-membered aromatic heterocyclic group, it preferably has 1 or 2 heteroatoms, selected from O, N and S, of which more preferably one is N, and may be substituted as hereinbefore defined.
- X1 is particularly a pyridone, pyridyl, imidazolyl, thiazolyl, thienyl, triazolyl or pyridazinyl group which group may be substituted as hereinbefore defined, more particularly a pyridone, pyridyl, imidazolyl, thiazolyl or triazolyl group, especially a pyridone, pyridyl, imidazolyl or triazolyl group which group may be substituted as hereinbefore defined.
- Where R4 is C1-5alkylX1, C2-5alkenylX1, C2-5alkynylX1 or C1-3alkylY5C1-3alkylX1, and X1 is a nitrogen-containing 6-membered aromatic heterocyclic group, said group is advantageously linked to the alkyl, alkenyl or alkynyl moiety via a carbon atom of X1, said group being such that a nitrogen atom is positioned para- to the carbon atom linked to the alkyl, alkenyl or alkynyl moiety. The C1-5alkyl moiety may if desired be —(CH2)n—.
- Where R4—Y1 is X1—(CH2)n—Y1— and n is an integer from 0 to 5, Y1 is —O— —NH—, —S— or —CH2— and X1 is a nitrogen-containing 6-membered aromatic heterocyclic group, said group is advantageously linked to —(CH2)n—Y1— via a carbon atom of X1, said group being such that a nitrogen atom is positioned para- to the carbon atom linked to —(CH2)n—Y1—.
- In another example of interest, X1 is pyrimidine which may be substituted as hereinbefore defined.
- In one embodiment of the invention X1 represents a pyridone, phenyl or 5 or 6-membered aromatic heterocyclic group with 1 to 3 heteroatoms selected from O, N and S, which group may preferably carry up to 2 substituents, more preferably up to one substituent, selected from the group of substituents as hereinbefore defined.
- In the definition of X1, conveniently substituents are selected from halogeno, C1-4alkyl, C1-4alkoxy and cyano, more conveniently substituents are selected from chloro, fluoro, methyl and ethyl.
- Conveniently R4 is selected from one of the following eight groups:
- 1) X1 (wherein X1 is as defined hereinbefore);
- 2) C1-5alkylX1 (wherein X1 is as defined hereinbefore);
- 3) C3-5alkenylX1 (wherein X1 is as defined hereinbefore);
- 4) C3-5alkynylX1 (wherein X1 is as defined hereinbefore);
- 5) C1-5alkylY2X1 (wherein Y2 and X1 are as defined hereinbefore);
- 6) C3-5alkenylY3X1 (wherein Y3 and X1 are as defined hereinbefore);
- 7) C3-5alkynylY4X1 (wherein Y4 and X1 are as defined hereinbefore); and
- 8) C2-3alkylY5C1-2alkylX1 (wherein Y5 and X1 are as defined hereinbefore).
- Advantageously R4 is selected from one of the following eight groups:
- 1) X1 (wherein X1 is as defined hereinbefore);
- 2) C1-5alkylX1 (wherein X1 is as defined hereinbefore);
- 3) 1-X1prop-1-en-3-yl, 1-X1but-2-en-4-yl, 1-X1but-1-en-3-yl, 1-X1pent-2-en-4-yl or 2-X pent-3-en-5-yl (wherein X1 is as defined hereinbefore with the proviso that when R4 is 1-X1prop-1-en-3-yl, X1 is linked to the alkenyl group via a carbon atom);
- 4) 1-X1prop-1-yn-3-yl, 1-X1but-2-yn-4-yl, 1-X1but-1-yn-3-yl, 1-X1pent-2-yn-4-yl or 2-X1pent-3-yn-5-yl (wherein X1 is as defined hereinbefore with the proviso that when R4 is 1-X1prop-1-yn-3-yl, X1 is linked to the alkynyl group via a carbon atom);
- 5) C1-5alkylY2X1 (wherein Y2 and X1 are as defined hereinbefore);
- 6) 1-(X1Y3)prop-1-en-3-yl, 1-(X1Y3)but-2-en-4-yl, 1-(X1Y3)but-1-en-3-yl, 1-(X1Y3)pent-2-en-4-yl or 2-(X1Y3)pent-3-en-5-yl (wherein Y3 and X1 are as defined hereinbefore);
- 7) 1-(X1Y4)prop-1-yn-3-yl, 1-(X1Y4)but-2-yn-4-yl, 1-(X1Y4)but-1-yn-3-yl, 1-(X1Y4)pent-2-yn-4-yl or 2-(X1Y4)pent-3-yn-5-yl (wherein Y4 and X1 are as defined hereinbefore); and
- 8) C2 alkylY5C1-2alkylX1 (wherein Y5 and X1 are as defined hereinbefore).
- Preferably R4 is selected from one of the following eight groups:
- 1) X1 (wherein X1 is as defined hereinbefore);
- 2) C1-5alkylX1 (wherein X1 is as defined hereinbefore);
- 3) 1-X1but-2-en-4-yl (wherein X1 is as defined hereinbefore);
- 4) 1-X1but-2-yn-4-yl (wherein X1 is as defined hereinbefore);
- 5) C1-5alkylY2X1 (wherein Y2 and X are as defined hereinbefore);
- 6) 1-(X1Y3)but-2-en-4-yl (wherein Y3 and X1 are as defined hereinbefore);
- 7) 1-(X1Y4)but-2-yn-4-yl (wherein Y4 and X1 are as defined hereinbefore); and
- 8) ethylY5 methylX1 (wherein Y5 and X1 are as defined hereinbefore).
-
- (wherein R1, R2, R3, m, X1, Y1 and Z are as defined hereinbefore n is an integer from 0 to 5 and Y6 represents a direct bond, —O—, —S—, —SO—, —SO2—, —NR36CO—, —CONR37—, —SO2NR38—, —NR39SO2— or —NR40— (wherein R36, R37, R38, R39 and R40 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl)).
- Advantageously Y6 is a direct bond, —O—, —S—, —SO—, —SO2— or —NR40— (wherein R40 represents hydrogen, C1-2alkyl or C1-2alkoxyethyl).
- Preferably Y6 is a direct bond, —O—, —S— or —NH—.
- More preferably Y6 is a direct bond.
- n is advantageously an integer from 0 to 3, preferably 1 to 3.
- Therefore, for example, in a particular embodiment of the invention the compounds of formula I are of the formula Ia wherein:
- [Y1 represents —O—, —NH—, —S— or —CH2—;
- n is an integer from 0 to 5;
- X1 represents a phenyl group or a 5 or 6-membered aromatic heterocyclic group with 1 to 3 heteroatoms selected from O, N and S, which phenyl or heterocyclic group may carry up to 5 substituents selected from halogeno, C1-4alkyl, C1-4alkoxy, C1-4hydroxyalkyl, C1-4hydroxyalkoxy, carboxy, cyano, —CONR41R42 and —NR43COR44 (wherein R41, R42, R43 and R44, which may be the same or different, each represents hydrogen or C1-4alkyl);
- R1 represents hydrogen, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or NR45R46 (wherein R45 and R46, which may be the same or different, each represents hydrogen or C1-3alkyl);
- R2 represents hydrogen, hydroxy, halogeno, C1-3alkyl, C1-3 alkoxy, trifluoromethyl, cyano, amino or nitro;
- m is an integer from 1 to 5;
- R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro;
- Z represents —NH— or —O—; and
- Y6 is a direct bond;
- with the proviso that where X1 is unsubstituted phenyl or substituted phenyl with 1 to 2 substituents selected from halogeno, C1-4alkyl and C1-4alkoxy, m is an integer from 3 to 5 or Z is —O—];
- and salts thereof.
- Preferred compounds of the present invention are:
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-pyridylmethoxy)quinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-pyridyloxy)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-[N-methyl-N-(4-pyridyl)]aminoethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[2-(2-oxo-1,2-dihydro-1-pyridyl)ethoxy]quinazoline
- 7-(4 cyanobenzyloxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-methylimidazol-1-yl)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((2-methyl-4-pyridyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-oxo-1,2-dihydro-1-pyridyl)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(1-methylimidazol-2-ylthio)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-pyridyloxy)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridylthio)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-pyridyloxy)ethoxy)quinazoline
- 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylanilino)quinazoline
- 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)quinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-(pyridazin-4-yl)amino)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(3,5-dimethyl-[1,2,4]-triazol-4-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(2,4-dimethylimidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(2,5-dimethylimidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(3-hydroxyanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1,2,4-triazol-4-yl)ethoxy)quinazoline
- 4-(4-bromo-2-fluoroanilino)-7-(2-([1,2,4]-triazol-1-yl)ethoxy)-6-methoxyquinazoline
- and salts thereof, especially hydrochloride salts thereof.
- The following compounds of the present invention are especially preferred:
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-pyridylmethoxy)quinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylimidazol-2-ylmethoxy)quinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(1-methylimidazol-2-ylmethoxy)quinazoline
- 7-(2-acetamidothiazol-4-ylmethoxy)-4-(3-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylpropoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylpropoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline
- 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[2-(4-oxo-1,4-dihydro-1-pyridyl)ethoxy]quinazoline
- 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylphenoxy)-6-methoxyquinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(4-pyridylmethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline
- 7-((2-acetamidothiazol4-yl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline
- 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylbenzimidazol-2-yl)methoxy)quinazoline
- 7-((2-chloro-6-methyl-4-pyridyl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-((4 pyridyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((4 pyridyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-methylimidazol-1-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((4-pyridyl)methoxy)quinazoline
- 7-((2-chloro-4-pyridyl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1-methylimidazol-2-ylthio)ethoxy)quinazoline
- 7-(3,4-difluorobenzyloxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-((1-methylimidazol-2-yl)methoxy)quinazoline
- 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline
- 4-(2-fluoro-2-hydroxy-4-methylanilino)-7-((4-pyridyl)carboxamido)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-(4-pyridyl)amino)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(l -methylimidazol-2-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-((2-cyano4-pyridyl)methoxy)-6-methoxyquinazoline
- and salts thereof, especially hydrochloride salts thereof, of which the following are particularly preferred:
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[2-(4-oxo-1,4-dihydro-1-pyridyl)ethoxy]quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((4-pyridyl)methoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-methylimidazol-1-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1-methylimidazol-2-ylthio)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-(4-pyridyl)amino)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1-methylimidazol-2-yl)ethoxy)quinazoline
- 4-(4-chloro-2-fluoroanilino)-7-((2-cyano-4-pyridyl)methoxy)-6-methoxyquinazoline
- and salts thereof, especially hydrochloride salts thereof.
- Another compound of interest is 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyrimidinylmethoxy)quinazoline and salts thereof especially hydrochloride salts thereof.
- For the avoidance of doubt it is to be understood that where in this specification a group is qualified by ‘defined hereinbefore’ the said group encompasses the first occurring and broadest definition as well as each and all of the preferred definitions for that group.
- In this specification the term “alkyl” includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term “alkyl” advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms. The term “alkoxy” as used herein, unless stated otherwise includes “alkyl”—O— groups in which “alkyl” is as hereinbefore defined. The term “aryl” as used herein unless stated otherwise includes reference to a C6-10 aryl group which may, if desired, carry one or more substituents selected from halogeno, alkyl, alkoxy, nitro, trifluoromethyl and cyano, (wherein alkyl and alkoxy are as hereinbefore defined). The term “aryloxy” as used herein unless otherwise stated includes “aryl”—O-groups in which “aryl” is as hereinbefore defined. The term “sulphonyloxy” as used herein refers to alkylsulphonyloxy and arylsulphonyloxy groups in which “alkyl” and “aryl” are as hereinbefore defined. The term “alkanoyl” as used herein unless otherwise stated includes alkylC=O groups in which “alkyl” is as defined hereinbefore, for example ethanoyl refers to CH3C═O. In this specification unless stated otherwise the term “alkenyl” includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only. Unless otherwise stated the term “alkenyl” advantageously refers to chains with 2-6 carbon atoms, preferably 4-5 carbon atoms. In this specification unless stated otherwise the term “alkynyl” includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only. Unless otherwise stated the term “alkynyl” advantageously refers to chains with 2-6 carbon atoms, preferably 4-5 carbon atoms.
- In formula I, as hereinbefore defined, hydrogen will be present at positions 2 and 8 of the quinazoline group.
- Within the present invention it is to be understood that a quinazoline of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits VEGF receptor tyrosine kinase activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
- It is also to be understood that certain quinazolines of the formula I and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit VEGF receptor tyrosine kinase activity.
- For the avoidance of any doubt, it is to be understood that when Y1 is, for example, a group of formula —NR5CO—, it is the nitrogen atom bearing the R5 group which is attached to the quinazoline ring and the carbonyl (CO) group is attached to R4, whereas when Y1 is, for example, a group of formula —CONR6—, it is the carbonyl group which is attached to the quinazoline ring and the nitrogen atom bearing the R6 group is attached to R4. A similar convention applies to the other two atom Y1 linking groups such as —NR8SO2— and —SO2NR7—. When Y1 is —NR9— it is the nitrogen atom bearing the R9 group which is linked to the quinazoline ring and to R4. An analogous convention applies to other groups. It is further to be understood that when Y1 represents —NR9— and R9 is C1-3alkoxyC2-3alkyl it is the C2-3alkyl moiety which is linked to the nitrogen atom of Y1 and an analogous convention applies to other groups.
- For the avoidance of any doubt, it is to be understood that in a compound of the formula I when R4 is, for example, a group of formula C1-5alkylY5C1-5alkylX1, it is the terminal C1-5alkyl moiety which is bound to Y1, similarly when R4 is, for example, a group of formula C2-5alkenylX1 it is the C2-5alkenyl moiety which is bound to Y1 and an analgous convention applies to other groups. When R4 is a group 1-X1prop-1-en-3-yl it is the first carbon to which the group X1 is attached and it is the third carbon which is linked to Y1, similarly when R4 is a group 2-X1pent-3-en-5-yl it is the second carbon to which the group X1 is attached and it is the fifth carbon which is linked to Y1, and an analogous convention applies to other groups.
- For the avoidance of any doubt, it is to be understood that when X1 carries a C1-4aminoalkyl substituent it is the C1-4alkyl moiety which is attached to X1 whereas when X1 carries a C1-4alkylamino substituent it is the amino moiety which is attached to X1 and an analogous convention applies to other groups.
- The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic acids such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid as well as salts with organic acids affording pharmaceutically acceptable anions, such as for example trifluoroacetic, citric or maleic acid. In addition where the compounds of formula I are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic substance or organic base which affords a pharmaceutically acceptable cation. Such salts include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- A compound of the formula I, or salt thereof, and other compounds of the invention (as hereinafter defined) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications Nos. 0520722, 0566226, 0602851 and 0635498. Such processes, are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
- Thus the following processes (a) to (g) and (i) to (v) constitute further features of the present invention.
- Synthesis of Compounds of Formula I
-
-
- (wherein Z, R3 and m are as defined hereinbefore) whereby to obtain compounds of the formula I and salts thereof. A convenient displaceable group L1 is, for example, a halogeno, alkoxy (preferably C1-4alkoxy), aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.
- The reaction is advantageously effected in the presence of either an acid or a base. Such an acid is, for example, an anhydrous inorganic acid such as hydrogen chloride. Such a base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or for example, an alkali metal or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide. Alternatively such a base is, for example, an alkali metal hydride, for example sodium hydride, or an alkali metal or alkaline earth metal amide, for example sodium amide or sodium bis(trimethylsilyl)amide. The reaction is preferably effected in the presence of an inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently effected at a temperature in the range, for example, 10 to 150° C., preferably in the range 20 to 80° C.
- The compound of the invention may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H—L1 wherein L1 has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a base as defined hereinbefore using a conventional procedure.
-
-
- (wherein Y1, m, R1, R2, R3, R4 and Z are as hereinbefore defined, P represents a phenolic hydroxy protecting group and p1 is an integer from 1 to 5 equal to the number of protected hydroxy groups and such that m-p1 is equal to the number of R3 substituents which are not protected hydroxy). The choice of phenolic hydroxy protecting group P is within the standard knowledge of an organic chemist, for example those included in standard texts such as “Protective Groups in Organic Synthesis” T. W. Greene and R. G. M. Wuts, 2nd Ed. Wiley 1991, including ethers (for example, methyl, methoxymethyl, allyl and benzyl), silyl ethers (for example, t-butyldiphenylsilyl and t-butyldimethylsilyl), esters (for example, acetate and benzoate) and carbonates (for example, methyl and benzyl). The removal of such a phenolic hydroxy protecting group may be effected by any of the procedures known for such a transformation, including those reaction conditions indicated in standard texts such as that indicated hereinbefore, or by a related procedure. The reaction conditions preferably being such that the hydroxy derivative is produced without unwanted reactions at other sites within the starting or product compounds. For example, where the protecting group P is acetate, the transformation may conveniently be effected by treatment of the quinazoline derivative with a base as defined hereinbefore and including ammonia, and its mono and di-alkylated derivatives, preferably in the presence of a protic solvent or co-solvent such as water or an alcohol, for example methanol or ethanol. Such a reaction can be effected in the presence of an additional inert solvent or diluent as defined hereinbefore and at a temperature in the range 0 to 50° C., conveniently at or near 20° C.
-
- (wherein m, Y1, R1, R2, R3 and Z are as hereinbefore defined) with a compound of formula VII:
- R4—L1 (VII)
- (wherein R4 and L1 are as hereinbefore defined); L1 is a displaceable group for example a halogeno or sulphonyloxy group such as a bromo or methanesulphonyloxy group. The reaction is preferably effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at or near 50° C.
-
- with a compound of the formula IX:
- R4—Y1—H (IX)
- (wherein L1, R1, R2, R3, R4, Z, m and Y1 are all as hereinbefore defined). The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at or near 100° C.
- (e) Compounds of the formula I and salts thereof wherein R4 is C1-5alkylX2, [wherein X2 is selected from one of the following three groups:
- 1) X1 (wherein X1 is as defined hereinbefore);
- 2) Y7X1 (wherein Y7 represents —O—, —S—, —SO2—, —NR47CO—, —NR48SO2— or —NR49— (wherein R47, R48 and R49 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and X1 is as defined hereinbefore); and
- 3) Y8C1-5alkylY5X1 (wherein Y8 represents —O—, —S—, —SO2—, —NR50CO—, —NR51SO2— or —NR52— (wherein R50, R51 and R52 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and Y5 and X1 are as defined hereinbefore);]
-
- (wherein L1, Y1, R1, R2, R3, Z and m are as hereinbefore defined and R53 is C1-5alkyl) with a compound of the formula XI:
- X2—H (XI)
- (wherein X2 is as defined hereinbefore) to give a compound of the formula I. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), and at a temperature in the range, for example 0 to 150° C., conveniently at about 50° C.
- (f) The production of those compounds of the formula I and salts thereof wherein the substituent R1 is represented by NR10R11, where one or both of R10 and R11 are C1-3alkyl, may be effected by the reaction of compounds of formula I wherein the substituent R1 is an amino group and an alkylating agent, preferably in the presence of a base as defined hereinbefore. Such alkylating agents are C1-3alkyl moieties bearing a displaceable moiety as defined hereinbefore such as C1-3alkyl halides for example C1-3alkyl chloride, bromide or iodide. The reaction is preferably effected in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)) and at a temperature in the range, for example, 10 to 100° C., conveniently at about ambient temperature.
- (g) The production of compounds of formula I and salts thereof wherein one or more of the substituents R1, R2 or R3 is an amino group may be effected by the reduction of a corresponding compound of formula I wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s). The reduction may conveniently be effected as described in process (i) hereinafter. The production of a compound of formula I and salts thereof wherein the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s) may be effected by the processes described hereinbefore and hereinafter in processes (a-e) and (i-v) using a quinazoline compound selected from the compounds of the formulae (I-XXVII) in which the substituent(s) at the corresponding position(s) of the quinazoline and/or phenyl ring is/are a nitro group(s).
- Synthesis of Intermediates
-
- (wherein R1, R2, R4 and Y1 are as hereinbefore defined).
- Convenient halogenating agents include inorganic acid halides, for example thionyl chloride, phosphorus(III)chloride, phosphorus(V)oxychloride and phosphorus(V)chloride. The halogenation reaction is conveniently effected in the presence of an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, or an aromatic hydrocarbon solvent such as benzene or toluene. The reaction is conveniently effected at a temperature in the range, for example 10 to 150° C., preferably in the range 40 to 100° C.
-
- (wherein R1, R2 and L1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined. The reaction may conveniently be effected in the presence of a base (as defined hereinbefore in process (a)) and advantageously in the presence of an inert solvent or diluent (as defined hereinbefore in process (a)), advantageously at a temperature in the range, for example 10 to 150° C., conveniently at or near 100° C.
-
- (wherein R1, R2, R4 and Y1 are as hereinbefore defined, and A1 is an hydroxy, alkoxy (preferably C1-4alkoxy) or amino group) whereby to form a compound of formula XII or salt thereof. The cyclisation may be effected by reacting a compound of the formula XIV, where A1 is an hydroxy or alkoxy group, with formamide or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained, such as [3-(dimethylamino)-2-azaprop-2-enylidene]dimethylammonium chloride. The cyclisation is conveniently effected in the presence of formamide as solvent or in the presence of an inert solvent or diluent such as an ether for example 1,4-dioxan. The cyclisation is conveniently effected at an elevated temperature, preferably in the range 80 to 200° C. The compounds of formula XII may also be prepared by cyclising a compound of the formula XIV, where A1 is an amino group, with formic acid or an equivalent thereof effective to cause cyclisation whereby a compound of formula XII or salt thereof is obtained. Equivalents of formic acid effective to cause cyclisation include for example a tri-C1-4alkoxymethane, for example triethoxymethane and trimethoxymethane. The cyclisation is conveniently effected in the presence of a catalytic amount of an anhydrous acid, such as a sulphonic acid for example p-toluenesulphonic acid, and an inert solvent or diluent such as for example a halogenated solvent such as methylene chloride, trichloromethane or carbon tetrachloride, an ether such as diethylether or tetrahydrofuran, or an aromatic hydrocarbon solvent such as toluene. The cyclisation is conveniently effected at a temperature in the range, for example 10 to 100° C., preferably in the range 20 to 50° C.
-
- (wherein R1, R2, R4, Y1 and A1 are as hereinbefore defined) to yield a compound of formula XIV as hereinbefore defined. The reduction of the nitro group may conveniently be effected by any of the procedures known for such a transformation.
- The reduction of the nitro group may conveniently be effected by any of the procedures known for such a transformation. The reduction may be carried out, for example, by the hydrogenation of a solution of the nitro compound in the presence of an inert solvent or diluent as defined hereinbefore in the presence of a metal catalyst such as palladium or platinum. A further reducing agent is, for example, an activated metal such as activated iron (produced for example by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be effected by heating a mixture of the nitro compound and the activated metal in the presence of a solvent or diluent such as a mixture of water and alcohol, for example methanol or ethanol, to a temperature in the range, for example 50 to 150° C., conveniently at or near 70° C.
-
- (wherein R1, R2, L1 and A1 are as hereinbefore defined) with a compound of the formula IX as hereinbefore defined to give a compound of the formual XV. The reaction of the compounds of formulae XVI and IX is conveniently effected under conditions as described for process (d) hereinbefore.
-
- (wherein R1, R2, Y1 and A1 are as hereinbefore defined with the proviso that Y1 is not —CH2—) with a compound of the formula VII as hereinbefore defined to yield a compound of formula XV as hereinbefore defined. The reaction of the compounds of formulae XVII and VII is conveniently effected under conditions as described for process (c) hereinbefore.
-
- (wherein R1, R2 and Y1 are as hereinbefore defined with the proviso that Y1 is not —CH2— and L2 represents a displaceable protecting group) with a compound of the formula VII as hereinbefore defined, whereby to obtain a compound of formula III in which L1 is represented by L2.
- A compound of formula XVIII is conveniently used in which L represents a phenoxy group which may if desired carry up to 5 substituents, preferably up to 2 substituents, selected from halogeno, nitro and cyano. The reaction may be conveniently effected under conditions as described for process (c) hereinbefore.
-
- (wherein R1, R2, P, Y1 and L2 are as hereinbefore defined). Deprotection may be effected by techniques well known in the literature, for example where P represents a benzyl group deprotection may be effected by hydrogenolysis or by treatment with trifluoroacetic acid.
- One compound of formula III may if desired be converted into another compound of formula III in which the moiety L1 is different. Thus for example a compound of formula III in which L1 is other than halogeno, for example optionally substituted phenoxy, may be converted to a compound of formula III in which L1 is halogeno by hydrolysis of a compound of formula III (in which L1 is other than halogeno) to yield a compound of formula XII as hereinbefore defined, followed by introduction of halide to the compound of formula XII, thus obtained as hereinbefore defined, to yield a compound of formula III in which L1 represents halogen.
-
- (wherein R3, m, p1, P and Z are as hereinbefore defined). The reaction may for example be effected as described for process (a) hereinbefore.
-
- (wherein R1, R2, L1, Z, R3, m, p1 and P are as hereinbefore defined) with a compound of formula IX as hereinbefore defined. The reaction may for example be effected as described for process (d) above.
-
- (wherein R1, R2, R3, Y1, Z, P, p1 and m are as hereinbefore defined with the proviso that Y1 is not —CH2—) with a compound of the formula VII as hereinbefore defined. The reaction may for example be effected as described for process (c) hereinbefore.
-
- (wherein R1, R2, and L1 are as hereinbefore defined, and L1 in the 4- and 7-positions may be the same or different) with a compound of the formula XX as hereinbefore defined. The reaction may be effected for example by a process as described in (a) above.
-
- (wherein R1, R2, R3, P, Z, Y1, p1 and m are as hereinbefore defined with the proviso that Y1 is not —CH2—) and then deprotecting the compound of formula XXIV for example as described in (i) above.
-
- (wherein R1, R2, R3, P, Z, Y1 and m are as hereinbefore defined) by a process for example as described in (i) above.
- Compounds of the formula XXV and salts thereof may be made by reacting compounds of the formulae XIX and IV as hereinbefore defined, under the conditions described in (a) hereinbefore, to give a compound of the formula XXV or salt thereof.
- (iv) Compounds of the formula VIII and salts thereof as hereinbefore defined may be made by reacting compounds of the formulae XXIII and IV as hereinbefore defined, the reaction may be effected by a process as described in (a) above.
- (v) Compounds of the formula X as defined hereinbefore and salts thereof may for example be made by the reaction of a compound of formula VI as defined hereinbefore with a compound of the formula XXVI:
- L1—R53—L1 (XXVI)
- (wherein L1 and R53 are as hereinbefore defined) to give a compound of the formula X. The reaction may be effected for example by a process as described in (c) above.
-
- (wherein L1, R53, Y1, R1, R2, R3, P, m and p1 are as defined hereinbefore) by a process for example as described in (b) above.
- Compounds of the formula XXVII and salts thereof may be made for example by reacting compounds of the formulae XXII and XXVI as defined hereinbefore, under the conditions described in (c) above.
- When a pharmaceutically acceptable salt of a compound of the formula I is required, it may be obtained, for example, by reaction of said compound with, for example, an acid using a conventional procedure.
- Many of the intermediates defined herein are novel, for example, those of the formulae III, V, XII, XIV and XV and these are provided as a further feature of the invention.
- Intermediates of the formulae VIII, X, XXI, XXII, XXIV, XXV and XXVII are also provided as a further feature of the invention.
- The identification of compounds which potently inhibit the tyrosine kinase activity associated with the VEGF receptors such as Flt and/or KDR and which inhibit angiogenesis and/or increased vascular permeability is desirable and is the subject of the present invention. These properties may be assessed, for example, using one or more of the procedures set out below:
- (a) In Vitro Receptor Tyrosine Kinase Inhibition Test
- This assay determines the ability of a test compound to inhibit tyrosine kinase activity. DNA encoding VEGF or epidermal growth factor (EGF) receptor cytoplasmic domains may be obtained by total gene synthesis (Edwards M, International Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These may then be expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity. For example VEGF and EGF receptor cytoplasmic domains, which were obtained by expression of recombinant protein in insect cells, were found to display intrinsic tyrosine kinase activity. In the case of the VEGF receptor Flt (Genbank accession number X51602), a 1.7 kb DNA fragment encoding most of the cytoplasmic domain, commencing with methionine 783 and including the termination codon, described by Shibuya et al (Oncogene, 1990, 5: 519-524), was isolated from cDNA and cloned into a baculovirus transplacement vector (for example pAcYM1 (see The Baculovirus Expression System: A Laboratory Guide, L. A. King and R. D. Possee, Chapman and Hall, 1992) or pAc360 or pBlueBacHis (available from Invitrogen Corporation)). This recombinant construct was co-transfected into insect cells (for exampleSpodoptera frugiperda 21(Sf21)) with viral DNA (eg Pharmingen BaculoGold) to prepare recombinant baculovirus. (Details of the methods for the assembly of recombinant DNA molecules and the preparation and use of recombinant baculovirus can be found in standard texts for example Sambrook et al, 1989, Molecular cloning—A Laboratory Manual, 2nd edition, Cold Spring Harbour Laboratory Press and O'Reilly et al, 1992, Baculovirus Expression Vectors—A Laboratory Manual, W. H. Freeman and Co, New York). For other tyrosine kinases for use in assays, cytoplasmic fragments starting from methionine 806 (KDR, Genbank accession number L04947) and methionine 668 (EGF receptor, Genbank accession number X00588) may be cloned and expressed in a similar manner.
- For expression of cFlt tyrosine kinase activity, Sf21 cells were infected with plaque-pure cFlt recombinant virus at a multiplicity of infection of 3 and harvested 48 hours later. Harvested cells were washed with ice cold phosphate buffered saline solution (PBS) (10 mM sodium phosphate pH7.4, 138 mM NaCl, 2.7 mM KCl) then resuspended in ice cold HNTG/PMSF (20 mM Hepes pH7.5, 150 mM NaCl, 10% v/v glycerol, 1% v/v Triton X100, 1.5 mM MgCl2, 1 mM ethylene glycol-bis(Daminoethyl ether) N,N,N′,N′-tetraacetic acid (EGTA), 1 mM PMSF (phenylmethylsulphonyl fluoride); the PMSF is added just before use from a freshly-prepared 100 mM solution in methanol) using 1 ml HNTG/PMSF per 10 million cells. The suspension was centrifuged for 10 minutes at 13,000 rpm at 4° C., the supernatant (enzyme stock) was removed and stored in aliquots at −70° C. Each new batch of stock enzyme was titrated in the assay by dilution with enzyme diluent (100 mM Hepes pH 7.4, 0.2 mM Na3VO4, 0.1% v/v Triton X100, 0.2 mM dithiothreitol). For a typical batch, stock enzyme is diluted 1 in 2000 with enzyme diluent and 50 μl of dilute enzyme is used for each assay well.
- A stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at −20° C. and diluted 1 in 500 with PBS for plate coating.
- On the day before the assay 100 μl of diluted substrate solution was dispensed into all wells of assay plates (Nunc maxisorp 96-well immunoplates) which were sealed and left overnight at 4° C.
- On the day of the assay the substrate solution was discarded and the assay plate wells were washed once with PBST (PBS containing 0.05% v/v Tween 20) and once with 50 mM Hepes pH7.4.
- Test compounds were diluted with 10% dimethylsulphoxide (DMSO) and 25 μl of diluted compound was transferred to wells in the washed assay plates. “Total” control wells contained 10% DMSO instead of compound. Twenty five microliters of 40 mM MnCl2 containing 8 μM adenosine-5′-triphosphate (ATP) was added to all test wells except “blank” control wells which contained MnCl2 without ATP. To start the reactions 50 μl of freshly diluted enzyme was added to each well and the plates were incubated at room temperature for 20 minutes. The liquid was then discarded and the wells were washed twice with PBST. One hundred microliters of mouse IgG anti-phosphotyrosine antibody (Upstate Biotechnology Inc. product 05-321), diluted 1 in 6000 with PBST containing 0.5% w/v bovine serum albumin (BSA), was added to each well and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microliters of horse radish peroxidase (HRP)-linked sheep anti-mouse Ig antibody (Amersham product NXA 931), diluted 1 in 500 with PBST containing 0.5% w/v BSA, was added and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with PBST. One hundred microliters of 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) solution, freshly prepared using one 50 mg ABTS tablet (Boehringer 1204 521) in 50 ml freshly prepared 50 mM phosphate-citrate buffer pH5.0+0.03% sodium perborate (made with 1 phosphate citrate buffer with sodium perborate (PCSB) capsule (Sigma P4922) per 100 ml distilled water), was added to each well. Plates were then incubated for 20-60 minutes at room temperature until the optical density value of the “total” control wells, measured at 405 nm using a plate reading spectrophotometer, was approximately 1.0. “Blank” (no ATP) and “total” (no compound) control values were used to determine the dilution range of test compound which gave 50% inhibtion of enzyme activity.
- (b) In Vitro HUVEC Proliferation Assay
- This assay determines the ability of a test compound to inhibit the growth factor-stimulated proliferation of human umbilical vein endothelial cells (HUVEC).
- HUVEC cells were isolated in MCDB 131 (Gibco BRL)+7.5% v/v foetal calf serum (FCS) and were plated out (at passage 2 to 8), in MCDB 131+2% v/v FCS+3 μg/ml heparin+1 μg/ml hydrocortisone, at a concentration of 1000 cells/well in 96 well plates. After a minimum of 4 hours they were dosed with the appropriate growth factor (i.e. VEGF 3 ng/ml, EGF 3 ng/ml or b-FGF 0.3 ng/ml) and compound. The cultures were then incubated for 4 days at 37° C. with 7.5% CO2. On day 4 the cultures were pulsed with 1 μCi/well of tritiated-thymidine (Amersham product TRA 61) and incubated for 4 hours. The cells were harvested using a 96-well plate harvester (Tomtek) and then assayed for incorporation of tritium with a Beta plate counter. Incorporation of radioactivity into cells, expressed as cpm, was used to measure inhibition of growth factor-stimulated cell proliferation by compounds.
- (c) In Vivo Rat Uterine Oedema Assay
- This test measures the capacity of compounds to reduce the acute increase in uterine weight in rats which occurs in the first 4-6 hours following oestrogen stimulation. This early increase in uterine weight has long been known to be due to oedema caused by increased permeability of the uterine vasculature and recently Cullinan-Bove and Koos (Endocrinology, 1993,133:829-837) demonstrated a close temporal relationship with increased expression of VEGF mRNA in the uterus. We have found that prior treatment of the rats with a neutralising monoclonal antibody to VEGF significantly reduces the acute increase in uterine weight, confirming that the increase in weight is substantially mediated by VEGF.
- Groups of 20 to 22-day old rats were treated with a single subcutaneous dose of oestradiol benzoate (2.5 μg/rat) in a solvent, or solvent only. The latter served as unstimulated controls. Test compounds were orally administered at various times prior to the administration of oestradiol benzoate. Five hours after the administration of oestradiol benzoate the rats were humanely sacrificed and their uteri were dissected, blotted and weighed. The increase in uterine weight in groups treated with test compound and oestradiol benzoate and with oestradiol benzoate alone was compared using a Student T test. Inhibition of the effect of oestradiol benzoate was considered significant when p<0.05.
- According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically acceptable excipient or carrier.
- The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intraveous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.
- The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg. A unit dose in the range, for example. 1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
- According to a further aspect of the present invention there is provided a compound of the formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
- We have now found that compounds of the present invention inhibit VEGF receptor tyrosine kinase activity and are therefore of interest for their antiangiogenic effects and/or their ability to cause a reduction in vascular permeability.
- Thus according to this aspect of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being.
- According to a further feature of the invention there is provided a method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as defined hereinbefore.
- As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- The antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the antiangiogenic and/or vascular permeability reducing treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:
- (i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin αvβ3 function, angiostatin, razoxin, thalidomide);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example EGF, FGFs, platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and
- (iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincrisitine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).
- As stated above the compounds defined in the present invention are of interest for their antiangiogenic and/or vascular permeability reducing effects. Such compounds of the invention are expected to be useful in a wide range of disease states including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases acute inflammation and ocular diseases with retinal vessel proliferation. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
- In addition to their use in therapeutic medicine, the compounds of formula I and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of test systems for the evaluation of the effects of inhibitors of VEGF receptor tyrosine kinase activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- It is to be understood that where the term “ether” is used anywhere in this specification it refers to diethyl ether.
- The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:
- [(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, that is in the range 1 8-25° C and under an atmosphere of an inert gas such as argon;
- (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany;
- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus;
- (vi) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet;
- (vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;
- (viii) the following abbreviations have been used:
- DMF N,N-dimethylformamide
- DMSO dimethylsulphoxide
- NMP 1-methyl-2-pyrrolidinone
- THF tetrahydrofuran
- TFA trifluoroacetic acid.]
- To a solution of 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline (93 mg, 0.2 mmol) in a mixture of methanol (6 ml) and methylene chloride (3 ml) was added at ambient temperature a 2M aqueous sodium hydroxide solution (0.3 ml, 0.6 mmol). The mixture was stirred for 10 minutes at ambient temperature, the solvents were partially evaporated, water was added to the residue and the solution was acidified with 0.1 M hydrochloric acid to pH6. The precipitate was filtered off, washed with water and dried under vacuum to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline hydrochloride (67mg, 87%).
- m.p. 249-251 ° C.
-
- MS-ESI: 389 [MH]+
Elemental analysis: Found C 61.4 H 5.3 N 12.8 C22H20N4O3 1.8H2O, 0.2HCl Requires C 61.7 H 5.6 N 13.1% - The starting material was prepared as follows:
- A mixture of 2-amino-4-benzyloxy-5-methoxybenzamide (10 g, 0.04 mol), (J. Med. Chem. 1977, vol 20, 146-149), and Gold's reagent (7.4 g, 0.05 mol) in dioxane (100 ml) was stirred and heated at reflux for 24 hours. Sodium acetate (3.02 g, 0.037 mol) and acetic acid (1.65 ml, 0.029 mol) were added to the reaction mixture and it was heated for a further 3 hours. The mixture was evaporated, water was added to the residue, the solid was filtered off, washed with water and dried (MgSO4). Recrystallisation from acetic acid gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (8.7 g, 84%).
- A mixture of 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (2.82 g, 0.01 mol), thionyl chloride (40 ml) and DMF (0.28 ml) was stirred and heated at reflux for 1 hour. The mixture was evaporated, the residue was taken up in toluene and evaporated to dryness to give 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (3.45 g).
- A mixture of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (2.18 g, 6.47 mmol), 3-acetoxy-4-methylaniline (1.32 g, 8 mmol) and isopropanol (50 ml) was stirred and heated at reflux for 1 hour. The mixture was cooled to ambient temperature. The precipitate was filtered off, washed with isopropanol and ether to give 4-(3-acetoxy-4-methylanilino)-7-benzyloxy-6-methoxyquinazoline hydrochloride (2.69 g, 89%).
- A mixture of 4-(3-acetoxy-4-methylanilino)-7-benzyloxy-6-methoxyquinazoline hydrochloride (2.68 g, 5.75 mmol), 10% palladium-on-charcoal catalyst (0.27 g) in methanol (50 ml), DMF (12 ml) and trichloromethane (50 ml) was stirred at ambient temperature under an atmosphere of hydrogen (1.5 atmospheres) for 30 minutes. The catalyst was filtered off and the filtrate evaporated. The residual solid was triturated in ether, filtered off and dried under vacuum at 50° C. to give 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (2.1 g, 100%).
- To a solution of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (375 mg, 1 mmol) in DMF (16 ml) were added at ambient temperature potassium carbonate (415 mg, 3 mmol) and 4-(bromomethyl)pyridine hydrobromide (J.Org.Chem. 1958, 23, 575, 278 mg, 1.1 mmol). The reaction mixture was heated at 60° C. for 2 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic layer was washed with a saturated aqueous sodium chloride solution, dried (MgSO4) and evaporated. The residue was purified by column flash chromatography, eluting with methylene chloride/methanol (95/5) to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline (93 mg, 22%).
- m.p. 201-202° C.
-
- MS-ESI: 453 [MNa]+, 431 [MH]+
Elemental analysis: Found C 65.4 H 5.5 N 12.7 C24H22N4O4 0.6H2O Requires C 65.3 H 5.3 N 12.7% - 3-Acetoxy-4-methylaniline used as a starting material was prepared as follows:
- To a mixture of 2-methyl-5-nitrophenol (2.5 g, 16.3 mmol) and 1M aqueous sodium hydroxide (24.5 ml) was added at ambient temperature acetic anhydride (1.9 ml, 20.3 mmol). The mixture was stirred for 40 minutes, the solid was filtered off and the filtrate extracted with ethyl acetate. The organic layers were combined, washed with an aqueous saturated sodium chloride solution, dried (MgSO4) and evaporated to yield 2-acetoxy-4-nitrotoluene (3.1 g, 100%). A mixture of this material (3.1 g, 15.9 mmol) and 10% palladium-on-charcoal catalyst (0.12 g) in ethyl acetate (50 ml) was stirred at ambient temperature under an atmosphere of hydrogen for 2 hours. The catalyst was filtered off and the filtrate evaporated to give 3-acetoxy-4-methylaniline (2.45 g, 94%).
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (750 mg) was reacted with 3-(bromomethyl)pyridine hydrobromide (Can. J. Chem. 1978, 56, 3068) (378 mg) to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(3-pyridylmethoxy)quinazoline (293 mg, 34%).
- m.p. 113-115° C.
-
- MS-ESI: 453 [MNa]+, 431 [MH]+
Elemental analysis: Found C 64.4 H 5.7 N 11.7 C24H22N4O4 0.85H2O Requires C 64.7 H 5.4 N 12.6% - The compound synthesised in Example 2 was further subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 1 to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-pyridylmethoxy)quinazoline (215 mg, 83%).
- m.p. 258-259° C.
-
- MS-ESI: 411 [MNa]+, 389 [MH]+
Elemental analysis: Found C 59.2 H 5.5 N 12.6 C22H20N4O3 3H2O 0.07HCl Requires C 59.4 H 5.9 N 12.6% - 4-(3-Acetoxy-4-methylanilino)-6-methoxy-7-(2-pyridylmethoxy)quinazoline (170 mg, 0.39 mmol) was subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 1 to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-pyridylmethoxy)quinazoline hydrochloride (58 mg, 38%).
- m.p. 236-238° C.
-
- MS-ESI: 389 [MH]+
Elemental analysis: Found C 55.8 H 5.5 N 11.8 C22H20N4O3 3H2O 0.75HCl Requires C 56.2 H 5.7 N 11.9% - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (376 mg) was reacted with 2-(chloromethyl)pyridine hydrochloride (328 mg) to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(2-pyridylmethoxy)quinazoline (170 mg, 40%).
-
- 4-(3-Acetoxy-4-methylanilino)-6-methoxy-7-(pyrimidin-4-ylmethoxy)quinazoline (496 mg, 1.15 mmol) was subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 1 to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(pyrimidin-4-ylmethoxy)quinazoline (278 mg, 62%).
- m.p. 290-291° C.
-
- MS-ESI: 390 [MH]+
Elemental analysis: Found C 58.8 H 5.4 N 16.3 C21H19N5O3 2.2H2O Requires C 58.8 H 5.5 N 16.3% - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (560 mg) was reacted in the presence of catalytic potassium iodide with 4-(chloromethyl)pyrimidine (375 mg) to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(pyrimidin-4-ylmethoxy)quinazoline (496 mg, 74%).
-
- 4-(Chloromethyl)pyrimidine was synthesised as follows:
- A mixture of 4-methylpyrimidine (2 g, 21.2 mmol), N-chlorosuccinimide (4.26 g, 31.9 mmol) and dibenzoylperoxide (500 mg) in carbon tetrachloride (100 ml) was heated at 80° C. for 2 hours. After cooling, the mixture was filtered and the filtrate was evaporated. The resulting oil was purified by flash chromatography using methylene chloride as eluant to give 4-(chloromethyl)pyrimidine as an orange oil (1 g, 37%).
- A solution of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg, 1.06 mmol), (prepared as described for the starting material in Example 1), 2-chloromethyl-1-methylimidazole hydrochloride (354 mg. 2.12 mmol), and potassium carbonate (585 mg) in DMF (15 ml) was heated at 60° C. for 15 hours. After cooling to ambient temperature the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and evaporated. The residue was diluted with methanol (20 ml) and 2M sodium hydroxide (1 ml) was added. After stirring for 1 hour, the reaction mixture was diluted with water (20 ml) and 2M hydrochloric acid (3 ml) was added. The resulting solid was filtered off, washed with water and dried under vacuum to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(1-methylimidazol-2-ylmethoxy)quinazoline hydrochloride (150 mg, 29%).
- m.p. 257-260° C.
-
- MS-ESI: 392 [MH]+
Elemental analysis: Found C 51.7 H 5.5 N 14.2 C21H21N5O3 1.65H2O 1.9HCl Requires C 51.4 H 5.4 N 14.3% - A solution of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg, 1.06 mmol), (prepared as described for the starting material in Example 1), 4-chloromethyl-2-methylthiazole hydrochloride (390 mg, 2.12 mmol), potassium carbonate (438 mg) and potassium iodide (40 mg) in DMF (15 ml) was heated at 60° C. for 15 hours. After cooling to ambient temperature the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and evaporated. The residue was diluted with methanol (10 ml) and 2M sodium hydroxide (2 ml) was added. After stirring for 1 hour, the reaction mixture was diluted with water (20 ml) and 2M hydrochloric acid (3 ml) was added. The resulting solid was filtered off, washed with water and dried under vacuum to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(2-methylthiazol-4-ylmethoxy) quinazoline hydrochloride (300 mg, 59%).
- m.p. 243-245° C.
-
- MS-ESI: 409 [MH]+
Elemental Found C 51.9 H 5.0 N 11.6 S 6.8 analysis: C21H20N4O3S Requires C 51.6 H 4.9 N 11.5 S 6.6% 1H2O 1.7HCl - To a solution of 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline (200 mg, 0.45 mmol) in methylene chloride/methanol (1/1) (20 ml) was added, a 2M aqueous sodium hydroxide solution (0.67 ml, 1.35 mmol). The mixture was stirred for 35 minutes at ambient temperature, the solvents were evaporated, water was added to the residue and the solution was extracted with ethyl acetate. The organic layer was washed with water, brine, then dried (MgSO4) and evaporated to give a white solid. This solid was then dissolved into a saturated solution of hydrochloric acid in methanol (10 ml) and stirred for 10 minutes. The solid product was filtered and dried under a vacuum, to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline hydrochloride (127 mg, 66%).
- m.p. 246-248° C.
-
- MS-ESI: 394 [MH]+
Elemental Found C 58.3 H 4.8 N 9.4 S 7.3 Cl 7.5 analysis: C21H19N3 Requires C 58.4 H 4.8 N 9.7 S 7.4 Cl 7.8% O3S 0.2H2O 0.95HCl - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg) was reacted in the presence of catalytic potassium iodide with 3-chloromethylthiophene (Journal of the Chemical Society 1958, 4202) (168 mg) to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline (210 mg, 46%).
- m.p. 201-203° C.
-
- MS-ESI: 436 [MH]+
Elemental analysis: Found C 63.0 H 5.2 N 9.1 S 7.3 C23H21N3O4S 0.3H2O Requires C 62.7 H 5.0 N 9.5 S 7.3% - 7-(2-Acetamidothiazol-4-ylmethoxy)-4-(3-acetoxy-4-methylanilino)-6-methoxyquinazoline (220 mg, 0.44 mmol) was subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 8 to give, 7-(2-acetamidothiazol-4-ylmethoxy)-4-(3-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (41 mg, 19%).
- m.p. 202-204° C.
-
- MS-ESI: 452 [MH]+
Elemental analysis: Found C 47.1 H 4.7 N 12.5 S 5.8 Cl 12.2 C22H21N5O4S 2H2O 2HCl Requires C 47.2 H 4.9 N 12.5 S 5.7 Cl 12.7% - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg) was reacted in the presence of catalytic potassium iodide with 2-acetamido-4-chloromethylthiazole (252 mg) to give 7-(2-acetamidothiazol-4-ylmethoxy)-4-(3-acetoxy-4-methylanilino)-6-methoxyquinazoline (220 mg, 42%).
-
- MS-ESI: 494 [MH]+
- 4-(3-Acetoxy-4-methylanilino)-7-(3,5-dimethylisoxazol-4-ylmethoxy)-6-methoxyquinazoline (342 mg, 0.76 mmol) was subjected to basic cleavage of the acetoxy protecting group using an analogous procedure to that described in Example 8 to give 4-(3-hydroxy-4-methylanilino)-7-(3,5-dimethylisoxazol-4-ylmethoxy)-6-methoxyquinazoline hydrochloride (209 mg, 62%).
- m.p. 252-254° C.
-
- MS-ESI: 407 [MH]+
Elemental analysis: Found C 59.1 H 5.4 N 12.6 Cl 8.0 C22H22N4O40.25H2O1HCl Re- C 59.1 H 5.3 N 12.5 Cl 7.9% quires - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 1, 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg) was reacted in the presence of potassium iodide (1 6 mg) with 4-chloromethyl-3,5-dimethylisoxazole (177 mg) to give 4-(3-acetoxy-4-methylanilino)-7-(3,5-dimethylisoxazol-4-ylmethoxy)-6-methoxyquinazoline (342 mg, 72%).
-
- A solution of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (400 mg, 1.06 mmol), (prepared as described for the starting material in Example 1), 4-(3-chloropropyl)pyridyl hydrochloride 410 mg, 2.1 mmol), potassium carbonate (438 mg) and potassium iodide (40 mg) in DMF (15 ml) was heated at 60° C. for 15 hours. After cooling to ambient temperature the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and evaporated. The residue was diluted with methanol (20 ml) and 2M sodium hydroxide (2 ml) was added. After stirring for 1 hour, the reaction mixture was diluted with water (20 ml) and concentrated hydrochloric acid (1 ml) was added. The resulting solid was filtered off and was purified by preparative C18 HPLC using a gradient of methanol/water (0% to 80%) as eluant. After evaporation of the methanol, concentrated hydrochloric acid (0.3 ml) was added and the solution was evaporated to dryness. After trituration with acetone, the solid was filtered off and dried under vacuum to give 4-(3-hydroxy-4-methylanilino)4-methoxy-7-(4-pyridylpropoxy)quinazoline hydrochloride (305 mg, 59%).
- m.p. 278-282° C.
-
- MS-ESI: 417 [MH]+
Elemental analysis: Found C 57.3 H 5.4 N 11.0 C24H24N4O30.7H2O1.95HCl Requires C 57.6 H 5.5 N 11.2% - The starting material was prepared as follows:
- Thionyl chloride (1.6 ml) was added to a solution of 4-pyridine propanol (2 g, 14.5 mmol) in trichloromethane (20 ml) cooled at 0° C. After stirring for 1 hour at ambient temperature followed by 1 hour at 60° C., the solvent was evaporated and the residue was triturated with ether to give 4-(3-chloropropyl)pyridyl hydrochloride as a white solid.
-
- A solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (410 mg, 1.00 mmol), 4-(3-chloropropyl)pyridyl hydrochloride (480 mg, 2.5 mmol), potassium carbonate (480 mg) and potassium iodide (40 mg) in DMF (15 ml) was heated at 60° C. for 15 hours. After cooling to ambient temperature the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4) and evaporated. The residue was diluted with methanol (10 ml) and 2M sodium hydroxide (2 ml) was added. After stirring for 1 hour, the reaction mixture was diluted with water (20 ml) and concentrated hydrochloric acid (0.5 ml) was added. The resulting solid was filtered off and was purified by preparative C18 HPLC using a gradient of methanol/water (0% to 80%) as eluant. After evaporation of the methanol, concentrated hydrochloric acid (0.3 ml) was added and the solution was evaporated to dryness. After trituration with acetone, the solid was filtered off and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylpropoxy)quinazoline hydrochloride (243 mg, 48%).
- m.p. 246-248° C.
-
- MS-ESI: 435 [MH]+
Elemental analysis: Found C 55.3 H 5.3 N 10.2 Cl 13.0 C24H23N4O3F0.9H2O1.95HCl Requires C 55.3 H 5.2 N 10.7 Cl 13.3% - The starting material was prepared as follows:
- A solution of (4-fluoro-2-methyl-5-nitrophenyl) methyl carbonate (3 g, 13 mmol), (prepared as described in EP 0307777 A2), in ethanol (60 ml) containing platinum(IV)oxide (300 mg) was stirred under hydrogen at 0.3 atmosphere for 1 hour. After filtration and evaporation of the solvent, 2-fluoro-5-methoxycarbonyloxy-4-methylaniline was isolated as a solid (2.6 g, 100%).
-
- A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (800 mg, 2.4 mmol), (prepared as described for the starting material in Example 1), and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (570 mg, 2.89 mmol) in isopropanol (20 ml) was refluxed for 2 hours. After cooling to ambient temperature, the solid was filtered, washed with isopropanol and dried under vacuum to give 7-benzyloxy-4-2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (1.0 g, 87%)
-
- MS-ESI: 464 [MH]+
- A solution of 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (700 mg, 1.45 mmol) in DMF (10 ml), methanol (10 ml) and trichloromethane (10 ml) containing 10% palladium-on-charcoal (100 mg) was stirred under an atmosphere of hydrogen for 1 hour. After filtration and evaporation of the solvent, the residue was triturated with ether, filtered and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (570 mg, 98%).
-
- MS-ESI: 374 [MH]+
- A stirred solution of 4-chloro-6-methoxy-7-(4-pyridylmethoxy)quinazoline (35 mg, 0.1 mmol) and 2-fluoro-5-hydroxy-4-methylaniline (15 mg, 0.1 mmol) in a mixture of ethereal hydrogen chloride (2 ml) and isopropanol (5 ml) was heated at reflux for 4 hours. The precipitated product was collected by filtration, washed with acetone and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline hydrochloride (23 mg, 47%).
- m.p. 257-260° C.
-
- MS-ESI: 407 [MH]+
Elemental analysis: Found C 52.8 H 4.6 N 10.9 C22H19N4O3F1H2O2HCl Requires C 53.1 H 4.6 N 11.3% - The starting chloroquinazoline was prepared as follows:
- Sodium hydride (400 mg of an 80% suspension in paraffin oil, 13.3 mmol) was added to a solution of phenol (1.26 g, 13.3 mmol) in dry N-methylpyrrolidone (20 ml) and the mixture stirred for 10 minutes.
- 7-Benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (1.6 g, 4.7 mmol), (prepared as described for the starting material in Example 1), was then added and the reaction mixture heated at 110° C. for 2 hours. The mixture was allowed to cool, water was added and the mixture extracted with ethyl acetate (3×100 ml). The combined extracts were then washed with 2M sodium hydroxide solution, water and brine. Removal of the solvent under reduced pressure gave 7-benzyloxy-6-methoxy-4-phenoxyquinazoline (1.6 g, 95%) as a yellowish solid.
-
- MS-ESI: 359 [MH]+
- 7-Benzyloxy-6-methoxy-4-phenoxyquinazoline (160 mg, 0.44 mmol) in TFA (3 ml) was heated at reflux for 30 minutes. The solvent was removed by evaporation and the residue treated with aqueous sodium hydrogen carbonate solution. The precipitated product was collected by filtration, washed with water and dried to give 7-hydroxy-6-methoxy-4-phenoxyquinazoline (105 mg, 88%).
-
- MS-ESI: 269 [MH]+
- A mixture of 7-hydroxy-6-methoxy-4-phenoxyquinazoline (95 mg, 0.35 mmol), 4-chloromethyl pyridine hydrochloride (120 mg, 0.74 mmol) and potassium carbonate (200 mg, 1.4 mmol) in DMF (5 ml) were heated at 80° C. for 2 hours. The reaction mixture was allowed to cool, water was added and the mixture extracted with ethyl acetate (3×50 ml). The combined extracts were then washed with water and dried (MgSO4). The solvent was removed by evaporation and the residue trituated with an ethyl acetate/hexane mixture to give 6-methoxy-4-phenoxy-7-(4-pyridylmethoxy)quinazoline (44 mg, 35%) as a white solid.
-
- MS-ESI: 360 [MH]+
- A solution of 6-methoxy-4-phenoxy-7-(4-pyridylmethoxy)quinazoline (200 mg, 0.56 mmol) in 2M hydrochloric acid (15 ml) was heated at reflux for 90 minutes. The reaction mixture was allowed to cool and neutralised to pH6-7 with aqueous ammonia. The precipitated product was extracted with methanol/methylene chloride (1:9) and the extract solution dried (MgSO4). Removal of the solvent by evaporation gave 6-methoxy-7-(4-pyridylmethoxy)-3,4-dihydroquinazolin-4-one (90 mg, 57%) as a grey solid.
-
- MS-ESI: 284 [MH]+
- Phosphorus oxytrichloride (0.1 ml) was added to a mixture of 6-methoxy-7-(4-pyridylmethoxy)-3,4-dihydroquinazolin-4-one (81 mg, 0.29 mmol) and N,N-dimethylaniline (0.1 ml) in toluene (5 ml), and the mixture heated at reflux for 1 hour. The volatiles were removed by evaporation and the residue partitioned between methylene chloride and aqueous ammonia. The organic extract was separated, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by chromatography on silica eluting with ethyl acetate progressing through increasingly polar mixtures to methanol/methylene chloride (1/9) to give 4-chloro-6-methoxy-7-(4-pyridylmethoxy)quinazoline (40 mg, 41%).
-
- MS-ESI: 302 [MH]+
- The starting aniline was prepared as described below:
- Methyl chloroformate (6.8 ml, 88 mmol) was added over 30 minutes to a solution of 4-fluoro-2-methylphenol (10 g, 79 mmol) in 6% aqueous sodium hydroxide solution at 0° C. The mixture was stirred for 2 hours, then extracted with ethyl acetate (100 ml). The ethyl acetate extract was washed with water (100 ml) and dried (MgSO4) and the solvent removed by evaporation to give 4-fluoro-2-methylphenyl methyl carbonate (11.4 g, 78%) as an oil.
-
- A mixture of concentrated nitric acid (6 ml) and concentrated sulphuric acid (6 ml) was added slowly to a solution of 4-fluoro-2-methylphenyl methyl carbonate (11.34 g, 62 mmol) in concentrated sulphuric acid (6 ml) such that the temperature of the reaction mixture was kept below 50° C. The mixture was stirred for 2 hours, then ice/water was added and the precipitated product collected by filtration. The crude product was purified by chromatography on silica eluting with methylene chloride/hexane progressing through increasingly polar mixtures to methanol/methylene chloride (1/19) to give 4-fluoro-2-methyl-5-nitrophenol (2.5 g, 22%) as a solid.
-
- MS-ESI: 171 [MH]+
- A mixture of 4-fluoro-2-methyl-5-nitrophenol (2.1 g, 13 mmol), iron powder (1 g, 18 mmol) and iron(II)sulphate (1.5 g, 10 mmol) in water (40 ml) was refluxed for 4 hours. The reaction mixture was allowed to cool, neutralised with 2M aqueous sodium hydroxide and extracted with ethyl acetate (100 ml). The ethyl acetate extract was dried (MgSO4) and the solvent removed by evaporation to give 2-fluoro-5-hydroxy-4-methylaniline (0.8 g, 47%) as a solid.
-
- MS-ESI: 142 [MH]+
- A solution of 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (259 mg, 0.54 mmol), (prepared as described for the starting material in Example 12), in methanol (15 ml) containing 1M sodium hydroxide (1.6 ml) was stirred at ambient temperature for 1 hour. After addition of water (15 ml), concentrated hydrochloric acid (1 ml) was added and the mixture was stirred at ambient temperature for 15 minutes. After evaporation of methanol, the precipitate was filtered, washed with water and dried under vacuum to give 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (192 mg, 80%).
- m.p. 294-298° C.
-
- MS-ESI: 406 [MH]+
Elemental analysis: Found C 62.3 H 4.9 N 9.3 C23H20N3O3F0.16H2O1HCl Requires C 62.1 H 4.8 N 9.5% - A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.63 mmol), 2-(2-chloroethoxy)pyridine hydrochloride (120 mg, 0.61 mmol) and potassium carbonate (260 mg, 1.9 mmol) in DMF (25 ml) was heated at 90° C. for 16 hours. The mixture was diluted with water and extracted with ethyl acetate. The extract was dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate/methanol mixtures (100/0 increasing to 90/10) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-pyridyloxy)ethoxy)quinazoline (20 mg, 7%) as an off-white solid.
-
- MS-ESI: 441 [MH]+
- The starting material was prepared as follows:
- A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (1.34 g, 4 mmol), (prepared as described for the starting material in Example 1), and 4-chloro-2-fluoroaniline (444 μl, 4 mmol) in isopropanol (40 ml) was refluxed for 1.5 hours. After cooling, the precipitate was collected by filtration, washed with isopropanol then ether and dried under vacuum to give 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (1.13 g, 64%).
- m.p. 239-242° C.
-
- MS-ESI: 410 [MH]+
Elemental analysis: Found C 59.2 H 4.3 N 9.4 C22H17N3ClFO21HCl Requires C 59.2 H 4.1 N 9.41% - A solution of 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (892 mg, 2 mmol) in TFA (10 ml) was refluxed for 50 minutes. After cooling, the mixture was poured onto ice. The precipitate was collected by filtration, dissolved in methanol (10 ml) and basified to pH11 with aqueous ammonia. After concentration by evaporation, the solid product was collected by filtration, washed with water then ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline as a yellow solid (460 mg, 72%).
- m.p. 141-143° C.
-
- MS-ESI: 320-322 [MH]+
- Thionyl chloride (0.55 ml, 7.55 mmol) was added to a solution of2-(2-hydroxyethoxy)pyridine (700 mg, 5.04 mmol), (J. Org. Chem. 1977, 42, 1500), in trichloromethane (20 ml) at 5° C. The mixture was stirred for 1 hour at 5° C., allowed to warm to ambient temperature and stirred for a further 1 hour. The volatiles were removed by evaporation and by azeotroping with toluene to give 2-(2-chloroethoxy)pyridine hydrochloride (970 mg, 99%).
-
- MS-ESI: 158 [MH]+
- Triphenylphosphine (5.5 g, 21 mmol) followed by 2-[N-methyl-N-(4-pyridyl)]aminoethanol (1.49 g, 9.8 mmol), (prepared as described in EP 0359389 A1), were added to a stirred solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (2.23 g, 7 mmol), (prepared as described for the starting material in Example 15), in methylene chloride (60 ml) under nitrogen. Diethyl azodicarboxylate (3.65 g, 21 mmol) was then added dropwise and the mixture was stirred at ambient temperature for 2 hours. Ethyl acetate (200 ml) was added and the mixture was stirred for a further 2 hours. The solid product was collected by filtration, washed with ethyl acetate, dried under vacuum and finally purified by column chromatography eluting with methylene chloride/methanol (75/25 followed by 60/40 and 50/50) to give a white solid. The purified product was dissolved in methylene chloride/methanol and the insolubles removed by filtration. Ethereal hydrogen chloride (10 ml of 3M solution) was added to the filtrate and the volatiles were removed by evaporation. The residue was triturated with ether and the solid product collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-[N-methyl-N-(4-pyridyl)]aminoethoxy)quinazoline hydrochloride (2.75 g, 75%) as a white solid.
- m.p. 222-227° C.
-
- MS-ESI: 454 [MH]+
Elemental Analysis: Found C 51.2 H 4.8 N 12.9 C23H21N5O2ClF0.9H2O2HCl Requires C 50.9 H 4.6 N 12.9% - A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (300 mg, 0.94 mmol), (prepared as described for the starting material in Example 15), 4-(2-chloroethoxy)pyridine hydrochloride (155 mg, 0.79 mmol) and potassium carbonate (260 mg, 1.9 mmol) in NMP (20 ml) was heated at 90° C. for 2 hours, allowed to cool to ambient temperature and stirred for a further 18 hours. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 95/5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline (20 mg, 7%).
- m.p. 200-202° C.
-
- MS-ESI: 441 [MH]+
- The starting material was prepared as follows:
- Thionyl chloride (0.75 ml, 10 mmol) was added to a solution of 4-(2-hydroxyethoxy)pyridine (0.9 g, 6.5 mmol), (J. Chem. Soc. Perkin II, 1987, 1867), in trichloromethane (20 ml) at 5° C. The mixture was stirred for 1 hour at 5° C., allowed to warm to ambient temperature and stirred for a further 2 hours. The volatiles were removed by evaporation and by azeotroping with toluene to give 4-(2-chloroethoxy)pyridine hydrochloride (1.3 g, 100%).
-
- MS-ESI: 158 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (300 mg, 0.94 mmol), (prepared as described for the starting material in Example 15), 1-(2-chloroethyl)-1,2-dihydro-2-pyridone (175 mg, 1.11 mmol), (J. Am. Chem. Soc. 1951, 73, 3635), and potassium carbonate (260 mg, 1.9 mmol) in DMF (30 ml) was heated at 80° C. for 3 hours, allowed to cool to ambient temperature and stirred for a further 18 hours. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol/triethylamine mixtures (100/0/0 increasing to 70/30/0.5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-12-(2-oxo-1,2-dihydro-1-pyridyl)ethoxyl quinazoline (50 mg, 12%).
- m.p. 209-211° C.
-
- MS-ESI: 441 [MH]+
- 1-(3-Hydroxypropyl)-1,4-dihydro-4-pyridone (220 mg, 1.44 mmol) in methylene chloride (4 ml) followed by 1,1′-(Azodicarbonyl)dipiperidine (720 mg, 2.86 mmol) were added to a stirred solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (300 mg, 0.94mmol), (prepared as described for the starting material in Example 15), and tributylphosphine (0.69 ml, 2.8 mmol) in methylene chloride (20 ml) under nitrogen at 5° C. The mixture was stirred at 5° C. for 3 hours, allowed to warm to ambient temperature and stirred for a further 18 hours. The solvent was removed by evaporation and the residue partitioned between ethyl acetate and water. The organic phase was separated, dried (MgSO4), and solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol/triethylamine mixtures (100/0/0 increasing to 70/30/0.5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[3-(4-oxo-1,4-dihydro-1-pyridyl)propoxy]quinazoline (48 mg, 11%).
- m.p. >250° C.
-
- MS-ESI: 455 [MH]+
- The starting material was prepared as follows:
- Sodium hydride (946 mg of a 50% suspension in mineral oil, 19.7mmol) was added to a solution of 4-hydroxypyridine (1.88 g, 19.7 mmol) in DMF (50 ml) and the mixture stirred for 30 minutes. 2-(3-Bromopropoxy)tetrahydropyran (4.0 g, 17.9 mmol), (J. Chem. Soc. 1963, 3440), was added and the mixture heated at 100° C. for 3 hours. The reaction mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The extract was washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 95/5) to give 1-[3-(tetrahydropyran-2-yloxy)propyl]-1,4-dihydro-4-pyridone (1.5 g, 35%).
-
- A solution of 1-[3-(tetrahydropyran-2-yloxy)propyl]-1,4-dihydro-4-pyridone (0.75 g, 3.16 mmol) in acetic acid (8 ml), THF (4 ml) and water (4 ml) was heated at 50° C. for 4 hours. The volatiles were removed by evaporation to give 1-(3-hydroxypropyl)-1,4-dihydro-4-pyridone (480 mg, 99%) as an off-white solid.
-
- MS-ESI: 154 [MH]+
- 1-(2-Hydroxyethyl)-1,4-dihydro-4-pyridone (221 mg, 1.6 mmol) was added to a stirred solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (230 mg, 0.7 mmol), (prepared as described for the starting material in Example 15), and tributylphosphine (0.53 ml, 2.1 mmol) in methylene chloride (20 ml) under nitrogen at 5° C. 1,1′-(Azodicarbonyl)dipiperidine (552 mg, 2.2 mmol) was added in portions over 10 minutes and the mixture was stirred at 5° C. for 2 hours, allowed to warm to ambient temperature and stirred for a further 18 hours. The mixture was diluted with ether, the insolubles removed by filtration and the solvent was removed from the filtrate by evaporation. The residue was partitioned between ethyl acetate and water, the organic phase was separated and dried (MgSO4), and solvent was removed by evaporation. The residue was dissolved in acetone and ethereal hydrogen chloride (1.2 ml of a 3M soultion) was added. The mixture was left to stand for 15 minutes and the precipitated product was collected by filtration, wvashed with ether and dried to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-[2-(4-oxo-1,4-dihydro-1-pyridyl)ethoxy]quinazoline hydrochloride (54 mg, 16%).
-
- MS-ESI: 441 [MH]+
- The starting material was prepared as follows:
- Sodium hydride (1.27 g of a 50% suspension in mineral oil, 26.4 mmol) was added to a solution of 4-hydroxypyridine (2.5 g, 26 mmol) in DMF (50 ml) and the mixture stirred for 30 minutes. 2-(2-Bromoethoxy)tetrahydropyran (5.0 g, 23.9 mmol), (J. Am. Chem. Soc. 1948, 70, 4187), in DMF (5 ml) was added and the mixture heated at 80° C. for 3 hours. The reaction mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The extract was washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give 1-[2-(tetrahydropyran-2-yloxy)ethyl]-1,4-dihydro-4-pyridone (1.5 g, 28%).
-
- MS-ESI: 224 [MH]+
- A solution of 1-[2-(tetrahydropyran-2-yloxy)ethyl]-1,4-dihydro-4-pyridone (500 mg, 2.23 mmol) in acetic acid (4 ml), THF (2 ml) and water (1 ml) was heated at 45° C. for 4 hours. The volatiles were removed by evaporation to give 1-(2-hydroxyethyl)-1,4-dihydro-4-pyridone (221 mg, 71%) as an off-white solid.
-
- A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (132 mg, 0.4mmol), (prepared as described for the starting material in Example 1), and 2-fluoro-5-methoxycarbonyloxy-4-methylphenol (96 mg, 0.48 mmol) in pyridine (2 ml) was heated at reflux for 3 hours. The mixture was allowed to cool, the solvent was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water, brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/ether (70/30). The resulting solid was crystallised from methylene chloride and-methanol to give 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylphenoxy)-6-methoxyquinazoline (120 mg, 64%).
-
- MS-ESI: 454 [MH]+
Elemental Analysis: Found C 67.8 H 4.9 N 6.9 C23H19N2O4F0.1H2O Requires C 67.7 H 4.7 N 6.9% - The starting material was prepared as follows:
- A mixture of (4-fluoro-2-methyl-5-nitrophenyl) methyl carbonate (8 g, 35 mmol), (EP 0307777 A2), and platinum(IV)oxide (174 mg) in ethanol (100 ml) and ethyl acetate (70 ml) was stirred under hydrogen at 1.3 atmospheres pressure for 1.5 hours. The catalyst was removed by filtration through diatomaceous earth and the solvent removed by evaporation. The residue was purified by column chromatography eluting with petroleum ether/ethyl acetate (7/3) to give 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (6.56 g, 94%) as an oil which crystallised.
-
- A solution of sodium nitrite (1.63 g, 23 mmol) in water (19 ml) and ice (48 g) was added dropwsie to a solution of 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (3.93 g, 20 mmol) in 35% sulphuric acid (48 ml) at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes and a solution of copper(II)nitrate trihydrate (467 g, 1.93mol) in water (780 ml) followed by copper(II)oxide (2.65 g, 18 mmol) were added. The solution was extracted with ethyl acetate, the organic layer was washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with petroleum ether/ethyl acetate (8/2) to give 2-fluoro-5-methoxycarbonyloxy-4-methylphenol (2.13 g, 53%) as a yellow solid.
-
- A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (470 mg, 1 mmol), 4-chloromethyl-2-methylthiazole hydrochloride (368 mg, 2 mmol), potassium carbonate (414 mg, 3 mmol) and potassium iodide (40 mg) in DMF (15 ml) was heated at 60° C. for 24 hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The organic layer was washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was dissolved in methanol (15 ml) and 1M sodium hydroxide (2 ml) was added and the mixture stirred for 30 minutes. Concentrated hydrochloric acid (0.5 ml) was added. The solvent was removed by evaporation. The residue was purified by reverse phase HPLC eluting with a gradient (0-70%) of methanol in water. Concentrated hydrochloric acid (0.3 ml) was added to the combined fractions of pure product and the solvent was removed by evaporation. The residue was triturated with acetone, collected by filtration, washed with acetone and dried under vacuum at 55° C. to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline hydrochloride (225 mg, 48%).
-
- MS-ESI: 427 [MH]+
- The starting material was prepared as follows:
- A mixture of (4-fluoro-2-methyl-5-nitrophenyl) methyl carbonate (3 g, 13 mmol), (EP 0307777 A2), and platinum(IV)oxide (300 mg) in ethanol (60 ml) was stirred under hydrogen at 0.3 atmosphere for 1 hour. The catalyst was removed by filtration through diatomaceous earth and the solvent removed by evaporation to give 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (2.6 g, 100%) as a solid.
-
- A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (800 mg, 2.4 mmol), (prepared as described for the starting material in Example 1), and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (570 mg, 2.89 mmol) in isopropanol (20 ml) was heated at reflux for 2 hours. The mixture was allowed to cool to ambient temperature, the precipitated solid was collected by filtration, washed with isopropanol and dried under vacuum to give 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (1.0 g, 77%).
-
- MS-ESI: 464 [MH]+
- A mixture of 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6- methoxyquinazoline hydrochloride (700 mg, 1.4 mmol) and 10% palladium-on-charcoal (100 mg) in DMF (10 ml), methanol (10 ml) and trichloromethane (10 ml) was stirred under hydrogen at 1 atmosphere pressure for 1 hour. The catalyst was removed by filtration through diatomaceous earth and the solvent was removed by evaporation. The residue was triturated with ether, collected by filtration and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (570 mg, 98%).
-
- MS-ESI: 374 [MH]+
- A mixture of 4-chloro-7-(4-pyridylmethoxy)quinazoline hydrochloride (350 mg, 1 mmol) and 2-fluoro-5-hydroxy-4-methylaniline (155 mg, 1.1 mmol), (prepared as described for the starting material in Example 13), in isopropanol (15 ml) was heated at reflux for 1 hour. The resulting precipitate was collected by filtration and purified by reverse phase HPLC using a gradient (0-75%) of methanol in water. Concentrated hydrochloric acid (0.5 ml) was added to the combined fractions of pure product and the solvent was removed by evaporation to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(4-pyridylmethoxy)quinazoline hydrochloride (140 mg, 28%).
-
- MS-ESI: 377 [MH]+
Elemental Analysis: Found C 50.9 H 4.9 N 11.1 C21H17N4O2F2.4H2O2HCl Requires C 51.2 H 4.9 N 11.4% - The starting material was prepared as follows:
- Sodium hydride (0.72 g of a 60% suspension in mineral oil, 18 mmol) was added to a solution of 4-hydroxymethylpyridine (4 g, 36 mmol) in THF (30 ml) and the mixture heated at reflux for 15 minutes. 7-Fluoro-3,4-dihydroquinazolin4-one (1 g, 6 mmol), (J. Chem. Soc. section B 1967, 449), was added, the THF was removed by evaporation, and the mixture was heated at 120° C. for 30 minutes. The mixture was allowed to cool, diluted with water (40 ml) and was adjusted to pH8 with concentrated hydrochloric acid. The resulting precipitate was collected by filtration, washed with water, then ether and dried under vacuum to give 7-(4-pyridylmethoxy)-3,4-dihydroquinazolin-4-one (1.12 g, 71%).
-
- A mixture of 7-(4-pyridylmethoxy)-3,4-dihydroquinazolin-4-one (320 mg, 1.26 mmol), DMF (1 drop) and thionyl chloride (10 ml) was heated at 60° C. for 1 hour. The volatiles were removed by evaporation, the residue was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 4-chloro-7-(4-pyridylmethoxy)quinazoline hydrochloride (435 mg, 98%).
-
- MS-ESI: 272 [MH]+
- A solution of 1,1′-(azodicarbonyl)dipiperidine (378 mg, 1.5 mmol) in methylene chloride (5 ml) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), tributylphosphine (303 mg, 1.5 mmol) and 2-(imidazol-1-yl)ethanol (67 mg, 0.6 mmol), (J. Med. Chem. 1993, 25, 4052-4060), in methylene chloride (8 ml) and the mixture was stirred for 3 hours at ambient temperature. Acetic acid (60 mg, 1 mmol) was added and the solvent was removed by evaporation. The solid residue was adsorbed on silica and purified by column chromatography eluting with methylene chloride/methanol (9/1 followed by 8/2). The resulting white solid was dissolved in methylene chloride/methanol and a solution of 5M hydrochloric acid in isopropanol was added. The solvent was removed by evaporation and the solid was triturated with ether, filtered, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride (180 mg, 74%).
-
- MS-ESI: 414 [MH]+
Elemental Analysis: Found C 48.3 H 4.1 N 14.0 C20H17N5O2ClF 0.4H2O 2HCl Requires C 48.6 H 4.0 N 14.2% - The starting material was prepared as follows:
- A solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (1.2 g, 3.6 mmol), (prepared as described for the starting material in Example 1), and 4-chloro-2-fluoroaniline (444 μl, 4 mmol) in isopropanol (40 ml) was heated at reflux for 1.5 hours. The mixture was allowed to cool, the precipitate was collected by filtration, washed with isopropanol then ether and dried under vacuum to give 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (1.13 g, 71%).
- m.p. 239-242° C.
-
- MS-ESI: 410 [MH]+
Elemental analysis: Found C 59.2 H 4.3 N 9.4 C22H17N3O2ClF HCl Requires C 59.2 H 4.1 N 9.4% - A solution of 7-benzyloxy-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (892 mg, 2 mmol) in TFA (10 ml) was heated at reflux for 50 minutes. The mixture was allowed to cool and then poured on to ice. The precipitate was collected by filtration, dissolved in methanol (10 ml) and basified to pH11 with aqueous ammonia. The mixture was concentrated by evaporation, the resulting solid product was collected by filtration, washed with water then ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (460 mg, 72%) as a yellow solid.
- m.p. 141-143° C.
-
- MS-ESI: 320 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (448 mg, 1.4 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate (676 mg, 4.9 mmol) in DMF (10 ml) was stirred at ambient temperature for 10 minutes. 4-Chloromethyl-2-methylthiazole hydrochloride (310 mg, 1.68 mmol) was added and the mixture was heated at 70° C. for 3.5 hours. The reaction mixture was allowed to cool and was partitioned between ethyl acetate and water. The organic layer was separated, washed with water, brine, dried (MgSO4) and the solvent removed by evaporation. The solid residue was purified by column chromatography eluting with a mixture of methylene chloride/acetonitrile/methanol (50/45/5 followed by 50/40/10). The resulting purified solid was dissolved in methylene chloride/methanol and a solution of 5M hydrogen chloride in isopropanol (1 ml) was added. Partial evaporation led to the precipitation of a white solid. This solid was collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline hydrochloride (240 mg, 35%).
- m.p. 220-225° C.
-
- MS-ESI: 431 [MH]+
Elemental Analysis: Found C 49.3 H 4.0 N 11.3 C20H16N4O2ClFS 0.3H2O 1.5HCl Re- C 48.9 H 3.7 N 11.4% quires - Using an analogous procedure to that described in Example 25, 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (224 mg, 0.7 mmol), (prepared as described for the starting material in Example 24), and 2-chloromethyl-1-methylimidazole hydrochloride (140 mg, 0.8 mmol) were combined to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline hydrochloride (150 mg, 44%).
-
- MS-ESI: 414 [MH]+
Elemental Analysis: Found C 48.7 H 4.6 N 13.6 C20H17N5O2ClF O.5H2O 2HCl Requires C 48.8 H 4.3 N 13.7% - 0.25isopropanol
- A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (470 mg, 1 mmol), (prepared as described for the starting material in Example 22), 2-chloromethyl-1-methylimidazole hydrochloride (335 mg, 2 mmol), potassium carbonate (414 mg, 3 mmol) and potassium iodide (20 mg) in DMF (15 ml) was heated at 60° C. for 2 hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The crude product was dissolved in methanol (20 ml), 2M sodium hydroxide (1 ml) was added and the mixture stirred for 15 minutes. Concentrated hydrochloric acid (0.5 ml) was added and the solvent was removed by evaporation. The crude product was purified by reverse phase chromatography eluting with methanol/water (1/1). Concentrated hydrochloric acid (0.3 ml) was added to the combined fractions containing the pure product and the solvent was removed by evaporation to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline hydrochloride (100 mg, 21%).
-
- MS-ESI: 410 [MH]+
- Using an analogous procedure to that described in Example 27, 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (470 mg 1.14 mmol), (prepared as described for the starting material in Example 22), and 2-acetamido-4-chloromethylthiazole (381 mg, 1.68 mmol) were combined to give 7-((2-acetamidothiazol-4-yl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline (135 mg, 25%).
-
- MS-ESI: 470 [MH]+
Elemental Analysis: Found C 51.5 H 4.5 N 13.8 C22H20N5O4FS 0.4H2O 0.95HCl Requires C 51.7 H 4.3 N 13.7% - A suspension of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (169 mg, 0.5 mmol), (prepared as described for the starting material in Example 1), and 4-chloro-2-fluoro-5-hydroxyaniline (97 mg, 0.6 mmol), (EP 061741 A2), in isopropanol (5 ml) was heated at reflux for 2 hours. The resulting precipitate was collected by filtration, washed with isopropanol and ether and dried under vacuum to give 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxyquinazoline hydrochloride (197 mg, 85%).
-
- MS-ESI: 426 [MH]+
Elemental Analysis: Found C 57.1 H 4.2 N 8.9 C22H17N3O3ClF 0.15H2O 1HCl Requires C 56.8 H 4.0 N 9.0% 0.4 isopropanol - 1,1′-(Azodicarbonyl)dipiperidine (1.06 g, 4.2 mmol) in methylene chloride (15 ml) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (448 mg, 1.4mmol), (prepared as described for the starting material in Example 24), tributylphosphine (848 mg, 4.2 mmol) and 4-(3-hydroxypropyl)pyridine (322 mg, 2.4 mmol) in methylene chloride (15 ml) and the mixture stirred for 3 hours at ambient remperature. Acetic acid (126 mg, 2.1 mmol) was added and the solvent was removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified product was triturated with ether, the resulting solid collected and dissolved in methylene chloride (20 ml). 5M Hydrogen chloride in isopropanol solution (0.7 ml) was added, the solution was diluted with isopropanol (5 ml) and concentrated by evaporation to a total volume of 4 ml. Ether was added and the resulting soild was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline hydrochloride (520 mg, 73%).
-
- MS-ESI: 439 [MH]+
Elemental Analysis: Found C 53.6 H 4.8 N 10.7 C23H20N4O2ClF 0.5H2O 2HCl Requires C 53.1 H 4.6 N 10.6% 0.1 isopropanol - 2M Aqueous sodium hydroxide (1.5 ml, 3 mmol) was added to a solution of 4-(4-chloro-2-fluoro-5-methoxycarbonyloxyanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline (1.28 g, 2.5 mmol) in methanol (13 ml) and the mixture stirred for 2 hours at ambient temperature. Water was added and the mixture was adjusted to pH7 with 2M hydrochloric acid. The resulting precipitate was collected by filtration, washed with water and dried under vacuum. This solid was dissolved in methylene chloride (30 ml) and methanol (5 ml) and a solution of 5M hydrogen chloride in isopropanol (2.5 ml) was added. The solution was diluted with isopropanol and concentrated under vacuum to a total volume of 10 ml. The resulting solid was collected by filtration, washed with isopropanol and then ether and dried under vacuum to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline hydrochloride (924 mg, 70%).
-
- MS-ESI: 455 [MH]+
Elemental Analysis: Found C 51.9 H 4.5 N 10.7 C23H20N4O3ClF 0.55H2O 1.9HCl Re- C 51.5 H 4.7 N 10.5% quires - The starting material was prepared as follows:
- 1,1′-(Azodicarbonyl)dipiperidine (2.52 g, 10 mmol) in methylene chloride (10 ml) was added dropwise to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (1.38 g, 3.5 mmol), (prepared as described for the starting material in Example 22), tributylphosphine (2 g, 10.5 mmol)and 4-(3-hydroxypropyl)pyridine (720 mg, 5.25 mmol) in methylene chloride (25 ml) and the mixture stirred for 2.5 hours at ambient temperature. The solvent was removed by evaporation and the residue was triturated with petroleum ether. The solid product was collected by filtration and purified by column chromatography eluting with methylene chloride/methanol (95/5) to give 4-(4-chloro-2-fluoro-5-methoxycarbonyloxyanilino)-6-methoxy-7-(3-(4-pyridyl)propoxy)quinazoline (1.2 g, 67%).
-
- MS-ESI: 513 [MH]+
- 2M Aqueous sodium hydroxide (0.3 ml, 6 mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (257 mg, 5.5 mmol) in methanol (5 ml) and the mixture stirred for 1 hour at 40° C. Water and 1 M hydrochloric acid (0.6 ml) were added and the mixture concentrated to half volume by evaporation. The resulting solid was collected by filtration, dissolved in methylene chloride/methanol and a solution of 7M hydrogen chloride in isopropanol (0.4 ml) was added. The volatiles were removed by evaporation, the solid residue was triturated with ether, collected by filtration and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride (160 mg, 60%).
- m.p. 195-220° C.
-
- MS-ESI: 410 [MH]+
Elemental Analysis: Found C 52.3 H 5.1 N 13.7 C21H20N5O3F 0.3H2O 1.9HCl Requires C 52.3 H 4.9 N 14.1% 0.22 isopropanol - The starting material was prepared as follows:
- Diethyl azodicarboxylate (160 mg, 1.4 mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (261 mg, 0.7 mmol), (prepared as described for the starting material in Example 22), triphenylphosphine (367 mg, 1.4 mmol) and 2-(imidazol-1-yl)ethanol (94 mg, 0.84 mmol), (J. Med. Chem. 1993, 25, 4052-4060), in methylene chloride (5 ml) and the mixture stirred for 1 hour at ambient temperature. Acetic acid (42 mg, 0.7 mmol) was added and the solvent was removed by evaporation. The residue was triturated with ether, the solid collected by filtration, dried under vacuum and purified by chromatography eluting with methylene chloride/methanol (9/1 followed by 8/2) to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (250 mg, 76%).
- A 1M solution of tetrabutylammonium fluoride in THF (560 μl, 0.56 mmol) was added to a suspension of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (186 mg, 0.28 mmol) in THF (5 ml) and the mixture stirred at 40° C. for 1 hour. Water was added and the organic solvent was removed by evaporation. The resulting precipitate was collected by filtration, washed with water and dried by azeotroping with ethanol. The solid was dissolved in methylene chloride/methanol and a solution of 5M hydrogen chloride in isopropanol (0.5 ml) was added. The volatiles were removed by evaporation and the residue was dissolved in isopropanol (1 ml) and ether was added. The resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride (110 mg, 78%).
-
- MS-ESI: 430 [MH]+
Elemental Analysis: Found C 45.7 H 3.9 N 12.8 C20H17N5O3ClF 1H2O 2HCl Requires C 45.8 H 4.1 N 13.1% 0.09 isopropanol 0.09 methylene chloride - The starting material was prepared as follows:
- A mixture of 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxyquinazoline (2.35 g, 7 mmol), (prepared as described for Example 29), imidazole (1.2 g, 17.5 mmol), t-butyldiphenylsilylchloride (2.1 g, 7.7 mmol) and 4-(dimethylamino)pyridine (20 mg, 0.16 mmol) in DMF (10 ml) was stirred for 2 hours at ambient temperature. Water (100 ml) and ethyl acetate (30 ml) were added, the resulting precipitate was collected by filtration, washed with water and dried under vacuum to give 7-benzyloxy-4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxyquinazoline (2 g, 43%).
-
- MS-ESI: 663 [MH]+
- A mixture of 7-benzyloxy-4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxyquinazoline (2 g, 3 mmol) and 10% palladium-on-charcoal catalyst (400 mg) in DMF (20 ml), methanol (20 ml) and ethyl acetate (20 ml) was stirred under hydrogen at 1.7 atmospheres pressure for 2 hours. The catalyst was removed by filtration and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5 followed by 90/10). The purified product was triturated with ether, collected by filtration and dried under vacuum to give 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (1.65 g, 95%).
-
- Diethyl azodicarboxylate (174 mg, 1 mmol) was added to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (288 mg, 0.5 mmol), triphenylphosphine (262 mg, 1 mmol) and 2-(imidazol-1-yl)ethanol (62 mg, 0.55 mmol), (J. Med. Chem. 1993, 25, 4052-4060), in methylene chloride (5 ml) and the mixture stirred for 1 hour at ambient temperature. Acetic acid (30 mg, 0.5 mmol) was added and the volatiles were removed by evaporation. The residue was triturated with ether, the solid collected by filtration and dried under vacuum to give 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (186 mg, 55%).
- MS-ESI: 668 [MH]+
- A suspension of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline (300 mg, 0.63 mmol) and 2M aqueous sodium hydroxide (0.38 ml, 0.76 mmol) in methanol (6 ml) was stirred at ambient temperature for 2 hours. Water was added and the mixture adjusted to pH7 with 2M hydrochloric acid. The precipitate was collected by filtration, washed with water, and dried under vacuum. The solid was dissolved in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (0.5 ml) was added. The mixture was diluted with isopropanol, and the methylene chloride and methanol solvents were removed by evaporation. The resulting precipitate was collected by filtration, washed with methylene chloride and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline hydrochloride (270 mg, 94%/).
-
- MS-ESI: 421 [MH]+
Elemental Analysis: Found C 55.5 H 5.3 C23H21N4O3F 0.3H2O 1HCl Requires C 55.6 H 5.1 0.3isopropanol - The starting material was prepared as follow:
- Diethyl azodicarboxylate (244 mg, 1.4 mmol) was added to a suspension of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (261 mg, 0.7 mmol), (prepared as described for the starting material in Example 22), triphenylphosphine (367 mg, 1.4 mmol) and 2-(4-pyridyl)ethanol (104 mg, 0.84 mmol), (Zhur. Obshchei. Khim. 1958, 28, 103-110), in methylene chloride and the mixture stirred for 30 minutes at ambient temperature. The solvent was removed by evaporation. The residue was suspended in ether and the ether then decanted. The resulting crude oil was purified by column chromatography eluting with methylene chloride/methanol (90/10) to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline (300 mg, 90%).
-
- MS-ESI: 501 [MNa]+
- Using an analogous procedure to that described in Example 34, 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline (220 mg, 0.47 mmol) was treated with 2M aqueous sodium hydroxide (0.47 ml) to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxy-7-(3-thienylmetboxy)quinazoline hydrochloride (180 mg, 86%).
-
- MS-ESI: 412 [MH]+
Elemental Analysis: Found C 55.5 H 4.5 N 9.0 C21H18N3O3FS 0.2H2O 1HCl Requires C 55.9 H 4.4 N 9.2% 0.09isopropanol - The starting material was prepared as follows:
- Using an analogous procedure to that described for the starting material in Example 34, 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (261 mg, 0.7 mmol), (prepared as described for the starting material in Example 22), was combined with 3-thiophenemethanol (96 mg, 0.84 mmol) to give, after purification by flash chromatography eluting with methylene chloride/methanol (98/2), 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxy-7-(3-thienylmethoxy)quinazoline (220 mg, 67%).
-
- MS-ESI: 492 [MNa]+
- A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (187 mg, 0.75 mmol), (prepared as described for the starting material in Example 22), 4-bromomethylbenzonitrile (147 mg, 0.75 mmol) and potassium carbonate (173 mg, 1.25 mmol) in DMF (5 ml) was heated at 50° C. for 1 hour. Methanol (5 ml) and potassium carbonate (138 mg, 11 mmol) were added and the mixture stirred at 65° C. for 2 hours. The solvent was removed by evaporation, water was added to the residue and the mixture adjusted to pH7 with 2M hydrochloric acid. The resulting precipitate was collected by filtration, washed with water and dried under vacuum. The solid was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified product was triturated with ether, collected by filtration and dried. The solid was dissolved in methylene chloride/isopropanol and a 5M solution of hydrogen chloride in isopropanol (0.5 ml) was added. The mixture was concentrated by evaporation and the resulting precipitate collected by filtration, washed with methylene chloride and dried under vacuum to give 7-(4-cyanobenzyloxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (60 mg, 25%).
- m.p. 265-270° C.
-
- MS-ESI: 431 [MH]+
Elemental Analysis: Found C 61.2 H 4.5 N 11.7 C24H19N4O3F 0.1H2O 1HCl Requires C 61.5 H 4.3 N 12.0% - Diethyl azodicarboxylate (315μl, 2 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (524 mg, 2 mmol) and 2-(4-pyridyl)ethanol (160 mg, 1.25 mmol), (Zhur. Obshchei. Khim. 1958, 28, 103-110), in methylene chloride (7 ml). The mixture was stirred for 1 hour at ambient temperature and the solvent was removed by evaporation. The residue was triturated with ether, the solid collected by filtration and purified by column chromatography eluting with methylene chloride/acetonitrile/methanol (85/10/5). The purified solid product was dissolved in a mixture of methylene chloride (50 ml) and methanol (50 ml) and 5M hydrochloric acid in isopropanol (0.5 ml) was added. After diluting with isopropanol (20 ml), the mixture was concentrated by evaporation. The precipitated solid was collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline hydrochloride (125 mg, 25%).
- m.p. 189-191° C.
-
- MS-ESI: 425 [MH]+
Elemental Analysis: Found C 52.0 H 4.3 N 11.1 C22H18N4O2CIF 0.5H2O 1.95HCl Re- C 52.3 H 4.2 N 11.1% quires - 3-(Chloromethyl)pyridine hydrochloride (328 mg, 2 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the starting material in Example 24), potassium carbonate (442 mg, 3.2 mmol) and potassium iodide (33 mg, 0.2 mmol) in DMF (25 ml) at ambient temperature and the reaction mixture then heated at 80° C. for 2.5 hours. The mixture was allowed to cool and the volatiles were removed by evaporation. The residue was dissolved in a mixture of ethyl acetate (19 ml) and methanol (1 ml) and the insolubles removed by filtration. The solvent was removed from the filtrate by evaporation and the residue was purified by column chromatography eluting with methylene chloride/acetonitrile/methanol (50/45/5). The purified product was dissolved in hot methylene chloride and saturated ethereal hydrogen chloride was added. The mixture was concentrated to half volume by evaporation, the resulting precipitate was collected by filtration and dried under vacuum at 70° C. to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((3-pyridyl)methoxy)quinazoline hydrochloride(103 mg, 25%).
- m.p. 216-221° C.
-
- MS-ESI: 411 [MH]+
Elemental Analysis: Found C 51.9 H 4.2 N 11.4 C21H16N4O2CIF 0.8H2O 1.6HCl Re- C 52.2 H 4.0 N 11.6% quires - Using an analogous procedure to that described in Example 38, 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the starting material in Example 24), was reacted with 2-(chloromethyl)pyridine hydrochloride (310 mg, 1.9 mmol) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((2-pyridyl)methoxy)quinazoline (146 mg, 33%).
- m.p. 215-218° C.
-
- MS-ESI: 411 [MH]+
Elemental Analysis: Found C 59.7 H 3.9 N 13.1 C21H16N4O2CIF 0.5H2O Requires C 60.1 H 4.1 N 13.3% - Diethyl azodicarboxylate (128 μl, 1.5 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250 mg, 0.78 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (410 mg, 1.5 mmol) and 2-(1-methylimidazol-2-yl)ethanol (147 mg, 1.15 mmol), (EP 0675112 A1). in methylene chloride (4 ml) and the mixture was stirred for 30 minutes at ambient temperature. Further triphenylphosphine (143 mg, 0.52 mmol) and diethyl azodicarboxylate (85 μl, 1 mmol) were added and the mixture stirred for 1 hour at ambient temperature. The solid product was collected by filtration and washed with methylene chloride. The solid was dissolved in a mixture of methylene chloride (25 ml) and methanol (25 ml), and a solution of 2.9M ethereal hydrogen chloride (2 ml) was added. The mixture was concentrated by evaporation and the resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-methoxy-7-(2-(1-methylimidazol-2-yl)ethoxy)quinazoline hydrochloride (133 mg, 34%).
- m.p. 224-229° C.
-
- MS-ESI: 428 [MH]+
Elemental Analysis: Found C 48.8 H 4.4 N 13.4 C21H19N5O2CIF 1H2O 2HCl Requires C 48.6 H 4.5 N 13.5% - A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (319.5 mg, 1 mmol), (prepared as described for the starting material in Example 24), potassium carbonate (414 mg, 3 mmol), potassium iodide (16 mg, 0.1 mmol) and 4-chloromethylpyrimidine (257 mg, 2 mmol) in DMF (20 ml) was heated at 80° C. for 2 hours. The solvent was removed by evaporation and the residue was triturated with water. The solid was collected by filtration and dried under vaccum. The solid was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified white solid was suspended in methanol (25 ml) and a solution of 7.5M hydrogen chloride in methanol (20 ml) was added. The resulting solid product was collected by filtration, washed with methanol and then pentane and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((pyrimidin-4-yl)methoxy)quinazoline hydrochloride (172 mg, 42%).
- m.p. 237-239° C.
-
- MS-ESI: 412 [MH]+
Elemental Analysis: Found C 49.5 H 3.6 N 14.1 C20H15N5O2CIF 0.5H2O 1.85HCl Re- C 49.2 H 3.7 N 14.3% quires - The starting material was prepared as follows:
- A solution of 4-methylpyrimidine (2 g, 21.2 mmol), N-chlorosuccinimide (4.26 g, 31.9 mmol) and benzoyl peroxide (500 mg, 2.1 mmol) in carbon tetrachloride (100 ml) was heated at 80° C. for 2 hours. The mixture was allowed to cool, the insolubles were removed by filtration and the solvent was removed from the filtrate by evaporation. The residue was purified by column chromatography eluting with methylene chloride to give 4-chloromethylpyrimidine (257 mg, 10%).
-
- 2M Aqueous sodium hydroxide solution (900 μl) was added to a solution of 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-((1-methylbenzimidazol-2-yl)methoxy)quinazoline (290 mg, 0.6 mmol) in methanol (15 ml) and methylene chloride (12 ml) and the mixture stirred for 25 minutes at ambient temperature. The solvent was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The solid residue was purified by column chromatography eluting with methylene chloride/methanol (97/3 and 95/5). The purified white solid was suspended in methanol (20 ml) and a solution of 7.5M hydrochloric acid in methanol (2 equivalents) was added. The solid was collected by filtration, washed with methanol and then pentane and dried under vacuum at 50° C. to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-((1-methylbenzimidazol-2-yl)methoxy)quinazoline hydrochloride (106 mg, 37%).
-
- MS-ESI: 469 [MNa]+
- The starting material was prepared as follows:
- A solution of 1-methylbenzimidazole (2.5 g, 19 mmol), (J. Chem. Soc. 1929, 2820-2828), and paraformaldehyde (2 g) was heated at 165° C. for 30 minutes. Further paraformaldehyde (1 g) was added and heating continued for 2 hours. The mixture was allowed to cool and was purified by column chromatography eluting with methylene chloride, followed by methylene chloride/methanol (95/5) to give 2-hydroxymethyl-1-methylbenzimidazole (1.34 g, 45%).
-
- MS-ESI: 185 [MNa]+
- A solution of 2-hydroxymethyl-1-methylbenzimidazole (1.1 g, 6.7 mmol) in thionyl chloride (10 ml) was stirred at ambient temperature for 15 minutes and then heated at reflux for 15 minutes. The volatiles were removed by evaporation and the residue purified by column chromatography eluting with methylene chloride/methanol (95/5) to give 2-chloromethyl-1-methylbenzimidazole (506 mg, 36%).
-
- MS-ESI: 181 [MH]+
- A mixture of 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (240 mg, 0.64 mmol), (prepared as described for the starting material in Example 1), potassium carbonate (310 mg, 2.25 mmol), potassium iodide (10 mg, 0.064 mmol) and 2-chloromethyl-1-methylbenzimidazole (153 mg, 0.7 mmol) in DMF (12 ml) was heated at 65° C. for 3 hours. Further 2-chloromethyl-1-methylbenzimidazole (90 mg, 0.41 mmol) and potassium carbonate (165 mg, 1.2 mmol) were added and heating continued for 2 hours. The solvent was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was triturated with water and the solid product collected by filtration, washed with ether and dried under vacuum to give 4-(3-acetoxy-4-methylanilino)-6-methoxy-7-((1-methylbenzoimidazol-2-yl)methoxy)quinazoline (292 mg, 95%).
- MS-ESI: 506 [MNa]+
- 2M Aqueous sodium hydroxide solution (700 μl, 1.4 mmol) was added to a suspension of 7-((2-chloro-6-methyl-4-pyridyl)methoxy)-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline (360 mg, 0.7 mmol) in methanol (10 ml) cooled at 5° C. and the mixture was then stirred for 30 minutes at ambient temperature. The solvent was removed by evaporation, the residue diluted with water (10 ml) and the mixture adjusted to pH7 with 1M hydrochloric acid. The resulting solid was collected by filtration, washed with water and ether, and dried under vacuum. This solid was dissolved in methanol (5 ml) and a 7M solution of hydrogen chloride in methanol (3 ml) was added. The precipitate was collected by filtration, washed with methanol and dried under vacuum to give 7-((2-chloro-6-methyl-4-pyridyl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (273 mg, 74%/).
-
- MS-ESI: 455 [MH]+
Elemental Analysis: Found C 49.8 H 4.8 N 10.0 C23H20N4O3CIF 1.5H2O 1.9HCl Re- C 50.1 H 4.6 N 10.2% quires - The starting material was prepared as follows:
- A solution of 2-chloro-6-methyl-4-pyridinecarboxylic acid (2 g, 122 mmol) in ethanol (100 ml) and concentrated sulphuric acid (10 ml) was heated at reflux for 2 hours. The volatiles were removed by evaporation and the residue was dissolved in methylene chloride. The solution was washed with a saturated aqueous sodium hydrogen carbonate solution and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate/petroleum ether (1/9) to give ethyl 2-chloro-6-methyl-4-pyridinecarboxylate (2 g, 86%).
-
- MS-ESI: 200 [MH]+
Elemental Analysis: Found C 54.4 H 5.3 N 7.0 C9H10NO2Cl Requires C 54.1 H 5.0 N 7.0% - Lithium aluminium hydride (350 mg, 9.26 mmol) was added in portions to a solution of ethyl 2-chloro-6-methyl-4-pyridinecarboxylate (1.85 g, 9.26 mmol) in THF (40 ml) cooled at 0° C. The mixture was stirred for 15 minutes at 0° C. and acetic acid (2 ml) was added. The mixture was partitioned between ethyl acetate and water and the aqueous layer was adjusted to pH7.5 with 5 % aqueous sodium hydrogen carbonate solution. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate/petroleum ether (35/65) to give 2-chloro-4-hydroxymethyl-6-methylpyridine (1.28 g, 88%).
-
- MS-ESI: 157 [MH]+
Elemental Analysis: Found C 53.1 H 5.3 N 8.7 C7H8NOCl Requires C 53.3 H 5.1 N 8.9% - Diethyl azodicarboxylate (296 μl, 1.88 mmol) was added dropwise to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (350 mg, 0.94 mmol), (prepared as described for the starting material in Example 22), triphenylphosphine (492 mg, 1.88 mmol) and 2-chloro4-hydroxymethyl-6-methylpyridine (178 mg, 1.12 mmol) in methylene chloride (30 ml) and the mixture stirred for 30 minutes at ambient temperature. The solvent was removed by evaporation and the residue was purified by column chromatography eluting with ethyl acetate/methylene chloride (75/25). The purified product was triturated with ether, the solid collected by filtration, washed with ether and dried under vacuum to give 7-((2-chloro-6-methyl-4-pyridyl)methoxy)-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-6-methoxyquinazoline (373 mg, 78%).
-
- MS-ESI: 513 [MH]+
- A mixture of 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (112 mg, 0.35 mmol), potassium carbonate (138 mg, 1 mmol) and 4-(chloromethyl)pyridine hydrochloride (59 mg, 0.36 mmol) in DMF (2 ml) was heated at 80° C. for 1 hour. The mixture was allowed to cool and partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5) to give 4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-((4-pyridyl)methoxy)quinazoline (115 mg, 80%).
- m.p. 197-198° C.
-
- MS-ESI: 412 [MH]+
Elemental Analysis: Found C 59.5 H 3.9 N 9.6 C21H15N3O3ClF 0.8H2O Requires C 59.2 H 3.9 N 9.9% - The starting material was prepared as follows:
- 4-Chloro-2-fluoro-phenol (264 mg, 1.8 mmol) was added to a solution of 7-benzyloxy-4-chloro-6-methoxyquinazoline hydrochloride (506 mg, 1.5 mmol), (prepared as described for the starting material in Example 1), in pyridine (8 ml) and the mixture heated at reflux for 45 minutes. The solvent was removed by evaporation and the residue partitioned between ethyl acetate and water. The organic layer was washed with 0.1M hydrochloric acid, water and brine, dried (MgSO4) and the solvent removed by evaporation. The solid residue was triturated with petroleum ether and the crude product collected by filtration and purified by flash chromatography eluting with methylene chloride/ether (9/1) to give 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline (474 mg, 77%) as a cream solid.
- m.p. 179-180° C.
-
- MS-ESI: 411 [MH]+
Elemental analysis: Found C 63.4 H 4.1 N 6.8 C22H16ClFN2O3 Requires C 63.6 H 3.9 N 6.7% 0.06H2O 0.05CH2Cl2 - A solution of 7-benzyloxy-4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazoline (451 mg, 1.1 mmol) in TFA (4.5 ml) was heated at reflux for 3 hours. The mixture was diluted with toluene and the volatiles removed by evaporation. The residue was triturated with methylene chloride, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluorophenoxy)-7-hydroxy-6-methoxyquinazoline (320 mg, 90%).
-
- MS-ESI: 321 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (320 mg, 1 mmol), (prepared as described for the starting material in Example 24), potassium carbonate (414 mg, 3 mmol), potassium iodide (40 mg) and 4-(chloromethyl)pyridine hydrochloride (250 mg, 1.5 mmol) in DMF (15 ml) was heated at 60° C. for 2 hours. The mixture was allowed to cool and partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was suspended in ethanol (20 ml) and concentrated hydrochloric acid (0.5 ml) was added. The volatiles were removed by evaporation and the solid residue was azeotroped with toluene. The solid product was recrystallised from isopropanol to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((4-pyridyl)methoxy)quinazoline hydrochloride (335 mg, 70%).
-
- MS-ESI: 411 [MH]+
Elemental Analysis: Found C 51.0 H 3.9 N 11.2 C21H16N4O2ClF Requires C 51.4 H 3.9 N 11.4% 0.5H2O 1.95HCl - Diethyl azodicarboxylate (261 mg, 1.5 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 2-(N-(2,6-dimethyl-4-pyridyl)-N-methylamino)ethanol (125 mg, 0.7 mmol) in methylene chloride (5 ml) and the mixture stirred for 2 hours at ambient temperature. Methanol (10 drops) was added and the mixture was poured on to a column of neutral aluminium oxide and the product was separated by elution with methylene chloride/acetonitrile/methanol (60/35/35). The purified solid product was triturated with ether and collected by filtration. The solid was dissolved in methylene chloride/methanol and a solution of 3M ethereal hydrogen chloride (1 ml) was added. The solid was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(2-(N-(2,6-dimethyl-4-pyridyl)-N-methylamino)ethoxy)-6-methoxyquinazoline (170 mg, 61%).
- m.p. 208-212° C.
-
- MS-ESI: 482 [MH]+
Elemental Analysis: Found C 52.2 H 5.2 N 12.2 C25H25N5O2ClF 1H2O 2HCl Requires C 52.4 H 5.1 N 12.2% - The starting material was prepared as follows:
- A solution of 4-chloro-2,6-dimethylpyridine (849 mg, 6 mmol), (J. Het. Chem. 1990, 1841), in 2-(methylamino)ethanol (1.35 g, 18 mmol) and 3M ethereal hydrogen chloride (3 drops) was heated at 140° C. for 1 hour. The reaction mixture was allowed to cool and was diluted with water. The insolubles were removed by filtration and the aqueous filtrate was poured onto a suspension of magnesium sulphate (50 g) in ethyl acetate (100 ml). The insolubles were removed by filtration and the filtrate dried (MgSO4) and the solvent removed by evaporation. The solid residue was triturated with ether, collected by filtration and dried under vacuum at 50° C. to give 2-(N-(2,6-dimethyl-4-pyridyl)-N-methylamino)ethanol (960 mg, 90%).
- m.p. 139-144° C.
-
- MS-ESI: 181 [MH]+
- Diethyl azodicarboxylate (261 mg, 1.5 mmol) was added dropwise to a suspension of of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 2-(N-(4-pyridyl)amino)ethanol (97 mg, 0.7 mmol) in methylene chloride (8 ml) and the mixture stirred for 2 hours at ambient temperature. The mixture was diluted with ethyl acetate (5 ml), the solid product was collected by filtration and purified by chromatography on an aluminium oxide column eluting with methylene chloride/acetonitrile/methanol (60/35/5). The purified solid was triturated with ether and collected by filtration. The solid was dissolved in a mixture of methylene chloride/methanol and 3M ethereal hydrogen chloride (0.5 ml) was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-(4-pyridyl)amino)ethoxy)quinazoline hydrochloride (95 mg, 37%).
-
- MS-ESI: 440 [MH]+
Elemental Analysis: Found C 50.0 H 4.3 N 13.2 C22H19N5O2ClF 0.8H2O 2HCl Requires C 50.0 H 4.3 N 13.2% - The starting material was prepared as follows:
- Using a procedure analogous to that described for the starting material in Example 46, 4-chloropyridine (3 g, 20 mmol) was treated with aminoethanol (6.1 g, 0.1mol) to give 2-(N-(4-pyridyl))aminoethanol (400 mg, 25%).
- m.p. 110-111° C.
-
- MS-ESI: 138 [MH]+
- Using a procedure analogous to that described in Example 47, 3-(N-methyl-N-(4-pyridyl)amino)propanol (116 mg, 0.7 mmol) was treated with 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(N-methyl-N-(4-pyridyl)amino)propoxy)quinazoline hydrochloride (150 mg, 55%).
- m.p. 243-248° C.
-
- MS-ESI: 468 [MH]+
Elemental Analysis: Found C 51.4 H 5.1 N 12.9 C24H23N5O2ClF 1.2H2O Requires C 51.4 H 4.9 N 12.5% 1.95HCl - The starting material was prepared as follows:
- Using a procedure analogous to that described for the starting material in Example 46, 4-chloropyridine (885 mg, 59 mmol) and 3-(methylamino)propanol (2.1 g, 0.23 mmol), (Tetrahedron Lett. 1994, 35, 1545-1548), were heated for 8 hours to give 3-(N-methyl-N-(4-pyridyl)amino)propanol (979 mg, 61%).
-
- MS-ESI: 166 [MH]+
- Diethyl azodicarboxylate (261 mg, 1.5 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 1-(2-hydroxyethyl)-2-methylimidazole (88 mg, 0.7 mmol), (Chem.Abs. 1964, 60, 2949), in methylene chloride (8 ml) and the mixture stirred for 2 hours at ambient temperature. The mixture was diluted with ether (8 ml) and the solid product was collected by filtration. The solid was dissolved in methylene chloride/methanol and a solution of 3M ethereal hydrogen chloride (0.5 ml)was added. The resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(2-methylimidazol-1-yl)ethoxy)quinazoline hydrochloride (180 mg, 72%).
-
- MS-ESI: 428 [MH]+
Elemental Analysis: Found C 47.9 H 4.7 N 13.3 C21H19N5O2ClF 1.4H2O 2.1HCl Requires C 47.6 H 4.6 N 13.2% - Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a solution of 1-(3-hydroxypropyl)imidazole (102 mg, 0.81 mmol), (EP 0060696 A1), 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.62 mmol), (prepared as described for the starting material in Example 24), and triphenylphosphine (492 mg, 1.8 mmol) in methylene chloride (4 ml) and the mixture stirred for 2 hours at ambient temperature. The solvent was removed by evaporation and the residue was purified by column chromatography eluting with methylene chloride/acetonitrile/methanol (60/35/5). The purified solid was dissolved in methylene chloride/methanol and 5M ethereal hydrogen chloride (2 ml) was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(3-(imidazol-1-yl)propoxy)-6-methoxyquinazoline hydrochloride (114 mg, 36%).
-
- MS-ESI: 428 [MH]+
Elemental Analysis: Found C 48.2 H 4.5 N 13.2 C21H19N5O2ClF 1.2H2O 1.9HCl Requires C 48.6 H 4.5 N 13.5% - 7-(2-Bromoethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (98 mg, 0.23 mmol) was added to a solution of 4-methyl-4H-1,2,4-triazole-3-thiol (40 mg, 0.34 mmol) and potassium-t-butoxide (36 mg, 0.32 mmol) in DMF (1 ml) and the mixture heated at 40° C. for 30 minutes. The reaction mixture was allowed to cool and was partitioned between ammonium chloride and ethyl acetate. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with a gradient of methylene chloride/methanol (95/50 to 80/20). The purified solid product was triturated with ether and collected by filtration. The solid was dissolved in methylene chloride/methanol and 3M ethereal hydrogen chloride (0.5 ml) was added. The volatiles were removed by evaporation and the residue was crystallised from methylene chloride and ether. The solid was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-methyl-4H-1,2,4-triazol-3-ylthio)ethoxy)-quinazoline hydrochloride (90 mg, 79%).
-
- MS-ESI: 461 [MH]+
Elemental Analysis: Found C 43.7 H 3.9 N 14.9 C20H18N6O2ClFS 1H2O 2HCl Requires C 43.5 H 4.0 N 15.2% - The starting material was prepared as follows:
- 1,2-Dibromoethane (725 mg, 4 mmol) was added by portions of 70 μl every 30 minutes to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (320 mg, 1 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate (552 mg, 4 mmol) in DMF (5 ml) heated at 35° C. The mixture was stirred for a further 30 minutes after the completion of the addition and then partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was triturated with petroleum ether/ether, the solid was collected by filtration and dried under vacuum to give 7-(2-bromoethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (200 mg, 47%).
-
- MS-ESI: 428 [MH]+
- Using an analogous procedure to that described in Example 51, 7-(2-bromoethoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (98 mg, 0.23 mmol), (prepared as described for the starting material in Example 51), was treated with 5-mercapto-1-methyltetrazole (40 mg, 0.35 mmol) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1-methyltetrazol-5-ylthio)ethoxy)-quinazoline hydrochloride (50 mg, 44%).
-
- MS-ESI: 462 [MH]+
Elemental Analysis: Found C 45.1 H 3.7 N 19.3 C19H17N7O2ClFS 0.5H2O 1HCl Requires C 45.0 H 3.8 N 19.3% - Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a solution of 2-methyl-1-(3-hydroxypropyl)imidazole (131 mg, 0.93 mmol), (EP 0060696 A1), triphenylphosphine (492 mg, 1.8 mmol) and 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.62 mmol), (prepared as described for the starting material in Example 24), in methylene chloride (4 ml) and the mixture stirred for 2 hours at ambient temperature. Further 2-methyl-1-(3-hydroxypropyl)imidazole (43 mg, 0.31 mmol), triphenylphosphine (82 mg, 0.31 mmol) and diethyl azodicarboxylate (50 μl, 0.31 mmol) were added and the mixture stirred for a further 3 hours. The volatiles were removed by evaporation and the residue was purified by column chromatography eluting with methylene chloride/methanol (93/7). The purified solid was dissolved in methylene chloride and 3M ethereal hydrogen chloride (2 ml) was added. The volatiles were removed by evaporation and the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-methylimidazol-1-yl)propoxy)quinazoline hydrochloride (104 mg, 32%).
-
- MS-ESI: 442 [MH]+
Elemental Analysis: Found C 49.8 H 5.0 N 12.5 C22H21N5O2ClF 1H2O 2HCl Requires C 50.1 H 5.0 N 12.7% 0.23 ether - A solution of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(methylaminoethoxy)quinazoline hydrochloride hydrate (135 mg, 0.3 mmol) and 2-chloropyrimidine (66 mg, 0.6 mmol) in N,N-diisopropylethylamine (2 ml) was heated at reflux for 1 hour. The mixture was allowed to cool and was triturated with ether. The solid product was collected by filtration and purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified oil was crystallised from ether and the solid collected by filtration. The solid was dissolved in methylene chloride/methanol and a solution of 3M ethereal hydrogen chloride (0.5 ml) was added. The suspension was diluted with ether, the solid product collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-(pyrimidin-2-yl)amino)ethoxy)quinazoline hydrochloride (52 mg, 33%).
-
- MS-ESI: 455 [MH]+
Elemental Analysis: Found C 49.8 H 4.4 N 15.9 C22H20N6O2ClF 1.1H2O 1.5HCl Requires C 49.9 H 4.5 N 15.9% - The starting material was prepared as follows:
- A solution of di-t-butyl dicarbonate (4.52 g, 20 mmol) in THF (10 ml) was added to a solution of 2-(methylamino)ethanol (1.5 g, 20 mmol) in water (10 ml) and THF (10 ml) and the mixture was stirred for 18 hours at ambient temperature. The organic solvents was removed by evaporation and the residue was partitioned between water and ether. The organic layer was separated, washed with 0.1M hydrochloric acid and brine, dried (MgSO4) and the solvent removed by evaporation to give 2-(N-methyl-N-t-butoxycarbonylamino)ethanol (3 g, 85%) as an oil.
-
- MS-ESI: 176 [MH]+
- A solution of 2-(N-methyl-N-t-butoxycarbonylamino)ethanol (116 mg, 0.7 mmol) in methylene chloride (1 ml) was added to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), and triphenylphosphine (393 mg, 1.5 mmol) in methylene chloride (5 ml). Diethyl azodicarboxylate (261 mg, 1.5 mmol) was then added dropwise and the mixture was stirred at ambient temperature for 4 hours. The reaction mixture was poured onto a column of silica and eluted with a gradient of methylene chloride/acetonitrile/methanol (70/30/0 to 70/20/10). The partially purified product was further purified by column chromatography eluting with a gradient of methylene chloride/ether/methanol (60/40/0 to 60/10/30). The pure oil was crystallised from ether, collected by filtration and washed with ether to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-t-butoxycarbonylamino)ethoxy)quinazoline (450 mg, 63%).
- m.p. 194-196° C.
-
- MS-ESI: 499 [MNa]+
Elemental Analysis: Found C 57.2 H 5.7 N 11.5 C23H26N4O4ClF 0.3H2O Requires C 57.3 H 5.6 N 11.6% - TFA (4 ml) was added to a solution of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-t-butoxycarbonylamino)ethoxy)quinazoline (390 mg, 0.82 mmol) in methylene chloride (4 ml) and the mixture stirred for 2 hours at ambient temperature. Toluene was added and the volatiles were removed by evaporation. The residue was dissolved in methylene chloride and 3M ethereal hydrogen chloride (1 ml) was added. The resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(methylamino)ethoxy)quinazoline hydrochloride hydrate (290 mg; 79%).
-
- MS-ESI: 377 [MH]+
Elemental Analysis: Found C 45.8 H 5.0 N 12.0 C18H18N4O2ClF 1.1H2O2HCl Requires C 46.0 H 4.8 N 11.9% - Isonicotinoyl chloride (36 mg, 0.2 mmol) was added to a suspension of 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(methylamino)ethoxy)quinazoline hydrochloride hydrate (90 mg, 0.1 mmol), (prepared as described for the starting material in Example 54), in methylene chloride (3 ml) and triethylamine (80 mg, 0.8 mmol) was then added dropwise. The mixture was stirred for 30 minutes at ambient temperature and the solvent was then removed by evaporation. The residue was partitioned between ethyl acetate and water, the organic layer was separated, washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was dissolved in methylene chloride/methanol and 3M ethereal hydrogen chloride (0.5 ml) was added. The suspension was diluted with ether, the precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-(4-pyridylcarbonyl)amino)ethoxy)quinazoline hydrochloride (75 mg, 67%).
-
- MS-ESI: 482 [MH]+
Elemental Analysis: Found C 51.7 H 4.6 N 12.0 C24H21N5O3ClF 1H2O 1.7HCl Requires C 51.5 H 4.6 N 12.3% - 0.1 ether
- A mixture of 7-(4-pyridylthio)-3,4-dihydroquinazolin-4-one (100 mg, 0.4 mmol), thionyl chloride (20 ml) and DMF (0.1 ml) was heated at reflux for 1.5 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene. A solution of 3-hydroxy-4-methylaniline (53 mg, 0.04 mmol) in isopropanol (10 ml) was added to the solid residue and the mixture was heated at reflux for 2 hours. The mixture was allowed to cool and the precipitated product collected by filtration, washed with isopropanol and dried to give 4-(3-hydroxy-4-methylanilino)-7-(4-pyridylthio)quinazoline hydrochloride(103 mg, 73%).
-
- MS-ESI: 361 [MH]+
Elemental analysis: Found C 53.2 H 4.6 N 11.8 C20H16N4OS 1H2O 2HCl Requires C 53.2 H 4.4 N 12.4% - The starting material was prepared as follows:
- A solution of 2-amino-4-fluorobenzoic acid (3 g, 19.3 mmol) in formamide (30 ml) was heated at 150° C. for 6 hours. The reaction mixture was poured onto ice/water 1/1 (250 ml). The precipitated solid was collected by filtration, washed with water and dried to give 7-fluoro-3,4-dihydroquinazolin-4-one (2.6 g, 82%).
- Sodium hydride (3.3 g of a 50% suspension in mineral oil, 69 mmol) was added to a solution of 4-mercaptopyridine (8.12 g, 73 mmol) in DMF (100 ml) and the mixture stirred for 30 minutes. 7-Fluoro-3,4-dihydroquinazolin-4-one (1.5 g, 9 mmol) was added and the reaction heated at 100° C. for 4 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The organic extracts were washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (97/3) to give 7-(4-pyridylthio)-3,4-dihydroquinazolin-4-one (500 mg, 6%).
-
- MS-ESI: 256 [MH]+
- A mixture of 4-chloro-2-fluoro-3-hydroxyaniline (118 mg, 0.7mmol), (EP 061741 A2), and 4-chloro-6-methoxy-7-((4-pyridyl)methoxy)quinazoline (200 mg, 0.7 mmol), (prepared as described for the starting material in Example 13), in isopropanol (10 ml) and ethereal hydrogen chloride (5 ml) was heated at 80° C. for 2 hours and the mixture was allowed to cool. The precipitated product was collected by filtration, washed with isopropanol and dried to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((4-pyridyl)methoxy)quinazoline hydrochloride (110 mg, 31%).
-
- MS-ESI: 427 [MH]+
- A mixture of 7-((2-chloro-4-pyridyl)methoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (150 mg, 0.47mmol), phosphoryl chloride (0.2 ml) and N,N-dimethylaniline (0.2 ml) in toluene (5 ml) was heated at reflux for 1 hour. The volatiles were removed by evaporation and the residue was partitioned between ethyl acetate and saturated sodium hydrogen carbonate solution. The organic layer was separated, dried (MgSO4) and the solvent removed by evaporation. A solution of 2-fluoro-5-hydroxy-4-methylaniline (67 mg, 0.47 mmol), (prepared as described for the starting material in Example 13), in isopropanol (10 ml) was added to the solid residue and the mixture was heated at reflux for 2 hours. The mixture was allowed to cool and the precipitated product collected by filtration, washed with acetone and dried to give 7-((2-chloro-4-pyridyl)methoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (70 mg, 30%).
- m.p. 245-250° C.
-
- MS-ESI: 441 [MH]+
Elemental analysis: Found C 53.7 H 4.0 N 10.9 C22H18N4O3FCl 1H2O 1HCl Requires C 53.4 H 4.3 N 11.3% - The starting material was prepared as follows:
- Oxalyl chloride (0.3 ml) was added to a mixture of 4-(2-chloropyridine)carboxylic acid (950 mg, 6 mmol) and DMF (0.05 ml) in methylene chloride (20 ml) and the mixture strirred at ambient temperature for 1 hour. The volatiles were removed by evaporation and ethanol (10 ml) was added to the residue and the mixture stirred at ambient temperature for 18 hours. Water was added and the mixture was extracted with ethyl acetate (3×25 ml). The extracts were combined, dried (MgSO4) and the solvent removed by evaporation to give ethyl 4-(2-chloropyridine)carboxylate (700 mg, 63%) as a brown oil.
-
- Lithium aluminium hydride (5 ml of a 1M solution in ether, 5 mmol) was added dropwise to a stirred solution of ethyl 4-(2-chloropyridine)carboxylate (700 mg, 3.8 mmol) in ether (10 ml) at 0° C. The mixture was allowed to warm to ambient temperature, wet ether and 2M sodium hydroxide solution (2 ml). The insolubles were removed by filtration, the organic phase was separated and the aqueous layer was extracted with ether (3×25 ml). The extracts were combined, dried (MgSO4) and the solvent removed by evaporation to give 2-chloro-4-hydroxymethylpyridine (180 mg, 33%) as a brown oil which crystallised on standing.
-
- A mixture of 2-chloro-4-hydroxymethylpyridine (180 mg, 1.25 mmol), thionyl chloride (0.2 ml) in toluene (10 ml) was stirred at ambient tempertaure for 1 hour. The volatiles were removed by evaporation to give 2-chloro-4-chloromethylpyridine hydrochloride (180 mg, 0.9 mmol). A mixture of 7-hydroxy-6-methoxy-4-phenoxyquinazoline (268 mg, 1 mmol), (prepared as described for the starting material in Example 13), potassium carbonate (680 mg, 5 mmol) and DMF (10 ml) was added to this crude product and the mixture was heated at 90° C. for 1 hour. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate (3×70 ml). The extracts were combined, washed with water (×3) and brine, dried (MgSO4) and the solvent removed by evaporation to give 7-((2-chloro-4-pyridyl)methoxy)-6-methoxy-4-phenoxyquinazoline (260 mg, 66%) as a solid.
-
- MS-ESI: 394 [MH]+
- A mixture of 7-((2-chloro-4-pyridyl)methoxy)-6-methoxy-4-phenoxyquinazoline (260 mg, 0.7 mmol) and 2M hydrochloric acid (15 ml) was heated at 85° C. for 2 hours. The mixture was allowed to cool and adjusted to pH6-7 with sodium hydrogen carbonate solution. The resulting precipitate was collected by filtration and dried to give 7-((2-chloro-4-pyridyl)methoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (160 mg, 76%).
-
- MS-ESI: 318 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (950 mg, 3 mmol), (prepared as described for the starting material in Example 24), 2-bromo-4-bromomethylpyridine (765 mg, 3 mmol) and potassium carbonate (2.38 g 17 mmol) in DMF (10 ml) was heated at 80° C. for 2 hours. The mixture was allowed to cool, poured into water and extracted with ethyl acetate. The combined extracts were dried (MgSO4) and the solvent removed by evaporation and azeotroped with toluene. The residue was triturated with ethyl acetate/hexane and the solid product collected by filtration, washed with ethyl acetate/hexane and dried to give 7-((2-bromo-4-pyridyl)methoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline (647 mg, 44%).
- m.p. 210-212° C.
-
- MS-ESI: 489 [MH]+
Elemental analysis: Found C 52.0 H 3.2 N 11.2 C21H15N4O2BrClF Requires C 51.5 H 3.1 N 11.4% - The starting material was prepared as follows:
- A mixture of 2-bromo 4-methylpyridine (12.2 g), N-bromosuccinimide (30 g) and 2,2′-azobis(2-methylpropionitrile) (100 mg) in carbon tetrachloride (200 ml) was heated at reflux for 2.5 hours. The mixture was allowed to cool and the insoluble material removed by filtration. The solvent was removed from the filtrate by evaporation and the residue was purified by filtration through a silica pad eluting with ethyl acetate/hexane (10/1) to give 2-bromo-4-bromomethylpyridine.
-
- MS-ESI: 250 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (600 mg, 2 mmol), (prepared as described for the starting material in Example 24), 4-chloromethyl-2-cyanopyridine hydrochloride (620 mg, 3 mmol) and potassium carbonate (1.0 g 7 mmol) in DMF (8 ml) was heated at 80° C. for 30 minutes. The mixture was allowed to cool, poured into water and extracted with ethyl acetate. The combined extracts were dried (MgSO4) and the solvent removed by evaporation and azeotroped with toluene. The residue was triturated with ethyl acetate/hexane, the solid product collected by filtration and purified by column chromatography eluting with ethyl acetate and further chromatography eluting with methylene chloride/methanol (99/1). The purified product was recrystallised from ethyl acetate/hexane to give 4-(4-chloro-2-fluoroanilino)-7-((2-cyano-4-pyridyl)methoxy)-6-methoxyquinazoline (35 mg, 4%).
- m.p. 209-213° C.
-
- MS-ESI: 436 [MH]+
Elemental analysis: Found C 60.3 H 3.4 N 16.1 C22H15N5O2ClF Requires C 60.6 H 3.5 N 16.1% - The starting material was prepared as follows:
- Tetrabutyl ammonium fluoride (9 ml of a 1M solution in THF, 9 mmol) was added to a solution of 2-cyano-4-dimethyl-t-butylsilyloxymethylpyridine (1.4 g, 5.6 mmol), (J.Het. Chem. 1993, 30, 631), in THF (15 ml) and the mixture was stirred for 2 hours at ambient temperature. Water was added and the volatiles were removed by evaporation. The residue was partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer extracted with ethyl acetate. The combined extracts were dried (MgSO4) and the solvent removed by evaporation to give 2-cyano-4-hydroxymethylpyridine (0.55 g, 73%).
-
- A mixture of 2-cyano-4-hydroxymethylpyridine (0.5 1 g, 3.8mmol) and thionyl chloride (0.6 ml) in toluene (20 ml) was stirred at room temperature for 1 hour. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 4-chloromethyl-2-cyanopyridine hydrochloride (620 mg, 86%).
-
- A mixture of 7-((6-chloro-2-oxo-1,2-dihydropyrid-4-yl)methoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (190 mg, 0.4 mmol), thionyl chloride (5 ml) and DMF (0.1 ml) was heated at reflux for 2 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene. A solution of 4-chloro-2-fluoroaniline (1 ml) in isopropanol (15 ml) was added to the solid residue and the mixture was heated at reflux for 3 hours. The mixture was allowed to cool and the precipitated product collected by filtration, washed with isopropanol and dried to give 4-(4-chloro-2-fluoroanilino)-7-((6-chloro-2-oxo-1,2-dihydropyrid-4-yl)methoxy)-6-methoxyquinazoline hydrochloride (110 mg, 41%).
- m.p. 271-273° C. (decomp.)
-
- MS-ESI: 461 [MH]+
- The starting material was prepared as follows:
- A mixture of 2,6-dichloro-4-hydroxymethylpyridine (1.72 g, 16 mmol) and 40% aqueous sodium hydroxide solution (5 ml) in methanol (50 ml) was heated at reflux for 24 hours. The mixture was allowed to cool and the volatiles removed by evaporation. The residue was extracted with ethyl acetate and the solvent removed from the extracts by evaporation. The residue was recrystallised from ethyl acetate/hexane to give 2-chloro-4-hydroxymethyl-6-methoxypyridine (490 mg, 28%).
-
- Thionyl chloride (1.0 ml) was added to a solution of 2-chloro-4-hydroxymethyl-6-methoxypyridine (0.9 g, 5.2 mmol) in toluene (10 ml) and the mixture stirred at ambient temperature for 1 hour. The volatiles were removed by evaporation, the residue was azeotroped with toluene and dried under vacuum to give 2-chloro-4-chloromethyl-6-methoxypyridine hydrochloride (0.88 g, 74%). a
-
- A mixture of 7-hydroxy-6-methoxy-4-phenoxyquinazoline (1.1 g, 4.1 mmol), (prepared as described for the starting material in Example 13), 2-chloro-4-chloromethyl-6-methoxypyridine hydrochloride (0.88 g, 3.9 mmol) and potassium carbonate (2.0 g, 14 mmol) in DMF (20ml) was heated at 80° C. for 1 hour. The mixture was allowed to cool, diluted with water and the precipitated product collected by filtration, washed with water and dried to give 7-((2-chloro-6-methoxy-4-pyridyl)methoxy)-6-methoxy-4-phenoxyquinazoline (1.38 g, 79%).
-
- MS-ESI: 424 [MH]+
- A mixture of 7-((2-chloro-6-methoxy-4-pyridyl)methoxy)-6-methoxy-4-phenoxyquinazoline (400 mg, 0.95 mmol) and 2M hydrochloric acid (20 ml) was heated at reflux for 3 hours. The mixture was allowed to cool and adjusted to pH6-7 with aqueous ammonia solution. The resulting precipitate was collected by filtration washed with water and dried to give crude 7-((6-chloro-2-oxo-1,2-dihydropyrid-4-yl)methoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (190 mg, 60%).
- Thionyl chloride (0.6 ml) was added to a solution of 4-hydroxymethyl-2-methoxypyridine (0.59 g, 4.2 mmol) in toluene (10 ml) and the mixture stirred at ambient temperature for 1.5 hours. The volatiles were removed by evaporation and the residue was azeotroped with toluene and dried under vacuum to give crude 4-chloromethyl-2-methoxypyridine hydrochloride (0.50 g, 2.6 mmol) which was used directly. This product was then added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (420 mg, 1.3 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate (1.0 g 7 mmol) in DMF (8 ml) and the resulting mixture was heated at 75° C. for 2 hours. The mixture was allowed to cool, diluted with water and the precipitated solid collected by filtration, washed with water and dried to give 4-(4-chloro-2-fluoroanilino)-7-((2-methoxy-4-pyridyl)methoxy)-6-methoxyquinaoline (140 mg, 25%).
- m.p. 202-204° C.
-
- MS-ESI: 441 [MH]+
Elemental analysis: Found C 59.9 H 4.1 N 12.4 C22H18N4O3ClF Requires C 59.9 H 4.1 N 12.7% - The starting material was prepared as follows:
- A mixture of ethyl 2-hydroxy-pyridine-4-carboxylate (1.0 g, 6 mmol), (Chem. Abs. 1957, 8740c), methyl iodide (1 ml) and silver(I)carbonate (1.64 g) in toluene (20 ml) was heated at reflux for 2 hours. The mixture was allowed to cool and the insolubles removed by filtration through diatomaceous earth and the pad was washed through with ethyl acetate. The filtrate was washed with water, dried (MgSO4) and the solvent removed by evaporation to give ethyl 2-methoxy-pyridine-4-carboxylate (0.93 g, 86%) as a yellow oil.
-
- MS-ESI: 182 [MH]+
- A solution of ethyl 2-methoxy-pyridine-4-carboxylate (0.93 g, 5 mmol) in ether (5 ml) was added to lithium aluminium hydride (0.3 g, 8 mmol) in ether (10 ml) cooled to 5° C. and the mixture stirred for 2 hours. Water was added, the mixture was filtered through diatomaceous earth and the pad was washed through with ethyl acetate. The filtrate was extracted with ethyl acetate and the combined extracts were washed with brine, dried (MgSO4) and the solvent removed by evaporation to give 4-hydroxymethyl-2-methoxypyridine (0.64 g, 89%) as a yellow oil.
-
- Thionyl chloride (0.3 ml) was added to a solution of 4-hydroxymethyl-2-methylpyridine (240 mg, 1.9 mmol) in toluene (10 ml) and the mixture stirred at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give crude 4-chloromethyl-2-methylpyridine hydrochloride which was used directly. This product was then added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (510 mg, 1.6 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate (1.4 g 10 mmol) in DMF (8 ml) for 90 hours. The mixture was diluted with water and the precipitated solid collected by filtration, washed with water and dried to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((2-methyl-4-pyridyl)methoxy)quinazoline (290 mg, 43%), a sample was recrystallised from ethyl acetate/hexane.
- m.p. 221-224° C.
-
Elemental analysis: Found C 61.7 H 4.2 N 13.2 C22H18N4O2ClF Requires C 62.2 H 4.3 N 13.2% - The starting material was prepared as follows:
- Oxalyl chloride (1.9 g, 15 mmol) was added to 2-chloro-6-methyl-pyridine-4-carboxylic acid (1.7 g, 10 mmol) in methylene chloride (30 ml) and the mixture stirred for 2 hours. The volatiles were removed by evaporation and methanol (20 ml) added to the residue. The mixture was stirred for 1 hour and the volatiles removed by evaporation to give methyl 2-chloro-6-methyl-pyridine-4-carboxylate (1.85 g, 100%) as an off-white solid.
-
- MS-ESI: 186 [MH]+
- A mixture of methyl 2-chloro-6-methyl-pyridine-4-carboxylate (1.8 g, 10 mmol) and 10% palladium-on-charcoal catalyst (200 mg) in methanol (100 ml) was stirred under hydrogen at 5 atmospheres pressure. The catalyst was removed by filtration and the volatiles removed from the filtrate by evaporation. The residue was treated with 10% aqueous sodium hydroxide solution and extracted with ether (3×30 ml). The combined extracts were dried (MgSO4) and the solvent removed by evaporation to give methyl 2-methyl-pyridine-4-carboxylate (800 mg, 53%) as an oil.
- A solution of methyl 2-methyl-pyridine-4-carboxylate (800 mg, 6 mmol) in ether (5 ml) was added to lithium aluminium hydride (340 mg, 9 mmol) in ether (10 ml) cooled to 5° C. and the mixture stirred for 2 hours. Water was added, the mixture was filtered through diatomaceous earth and the pad was washed through with ethyl acetate. The filtrate was extracted with ethyl acetate and the combined extracts were washed with brine, dried (MgSO4) and the solvent removed by evaporation to give 4-hydroxymethyl-2-methylpyridine (240 mg, 38%) as a yellow oil.
-
- MS-ESI: 124 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 0.9 mmol), (prepared as described for the starting material in Example 24), 2-(2-chloroethylthio)-1-methylimidazole hydrochloride (203 mg, 0.95 mmol) and potassium carbonate (303 mg 2.2 mmol) in NMP (20 ml) was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (100/0 increasing to 90/10) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1-methylimidazol-2-ylthio)ethoxy)quinazoline (75 mg, 17%) as a solid.
-
- MS-ESI: 460 [MH]+
Elemental analysis: Found C 52.8 H 4.0 N 14.3 C21H19N5O2ClFS 1H2O Requires C 52.8 H 4.4 N 14.7% - The starting material was prepared as follows:
- 2-Chloroethanol (3 g, 37 mmol) was added to a solution of 2-mercapto-1-methylimidazole (3.45 g, 30 mmol) in 2M aqueous sodium hydroxide solution (30 ml) and the mixture heated at 100° C. for 2 hours. The mixture was allowed to cool and extracted with ethyl acetate. The combined extracts were dried (MgSO4) and the solvent removed by evaporation to give 2-(2-hydroxyethylthio)-1-methylimidazole (3.9 g, 82%).
-
- Thionyl chloride (1.41 ml, 19 mmol) was slowly added to a solution of 2-(2-hydroxyethylthio)-1-methylimidazole (1.81 g, 11 mmol) in trichloromethane(20 ml) at 5° C. The mixture was stirred for 1 hour at 5° C. and then for 3 hours at ambient temperature. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 2-(2-chloroethylthio)-1-methylimidazole hydrochloride (1.5 g, 77%).
-
- Thionyl chloride (0.55 ml, 7.5 mmol) was added to a solution of 1-(3-hydroxypropyl) 1,2dihyro-2-pyridone (770 mg, 5 mmol) in trichloromethane (15 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give crude 1-(3-chloropropyl)-1,2-dihydro-2-pyridone (500 mg) which was used directly. Part of this product (206 mg, 1.2mmol) was then added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 1.0 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate (303 mg, 2.2 mmol) in NMP (20 ml) and the reaction mixture was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 95/5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(2-oxo-1,2-dihydro-1-pyridyl)propoxy)quinazoline (194 mg, 50%).
- m.p. 216-218° C.
-
- MS-ESI: 455 [MH]+
Elemental analysis: Found C 59.4 H 4.6 N 12.1 C23H20N4O3ClF 0.5H2O Requires C 59.6 H 4.6 N 12.1% - The starting material was prepared as follows:
- Sodium hydride (1.31 g of a 50% suspension in mineral oil, 27mmol) was added to a solution of 2-hydroxypyridine (2.35 g, 24 mmol) in DMF (50 ml) and the mixture stirred for 30 minutes. 2-(3-Bromopropoxy)tetrahydropyran (5.0 g, 22.5 mmol), (J. Chem. Soc. 1963, 3440), was added and the mixture heated at 100° C. for 3 hours and then stirred at ambient temperature for 18 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give: 1-(3-(2-tetrahydropyranyloxy)propyl)-1,2-dihydro-2-pyridone (1.6 g, 30%).
-
- MS-ESI: 238 [MH]+
- and
- 2-(3-(2-tetrahydropyranyloxy)propyloxy)pyridine (1.43 g, 27%).
-
- MS-ESI: 238 [MH]+
- A solution of 1-(3-(2-tetrahydropyranyloxy)propyl)-1,2-dihydro-2-pyridone (1.0 g, 4.5 mmol) in acetic acid (8 ml), THF (4 ml). and water (2 ml) was heated at 50° C. for 4 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 1-(3-hydroxypropyl)-1,2-dihydro-2-pyridone (680 mg, 99%) as an off-white solid.
-
- Thionyl chloride (0.80 ml, 11 mmol) was added to a solution of 2-(3-hydroxypropylthio)-1-methylimidazole (1.25 g, 7.3 mmol) in trichloromethane (25 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give crude 2-(3-chloropropylthio)-1-methylimidazole hydrochloride (1.0 g) which was used directly. Part of this product (226 mg, 1.0 mmol) was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 1.0 mmol), (prepared as described for the starting material in Example 24), and potassium carbonate.(303 mg 2.2 mmol) in NMP (20 ml) and the mixture was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were wahed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (100/0 increasing to 95/5) to give 4-(4-chloro-2-fluoroanilino)-methoxy-7-(3-(1-methylimidazol-2-ylthio)propoxy)quinazoline (29 mg, 6%).
- m.p. 199-201° C.
-
- MS-ESI: 474 [MH]+
Elemental analysis: Found C 50.9 H 4.8 N 13.2 C22H21N5O2ClFS 2.5H2O Requires C 50.9 H 5.1 N 13.5% - The starting material was prepared as follows:
- Sodium hydride (0.95 g of a 50% suspension in mineral oil, 20 mmol) was added to a solution of 2-mercapto-1-methylimidazole (2.26 g, 19 mmol) in DMF (100 ml) and the mixture stirred for 30 minutes. 2-(3-Bromopropoxy)tetrahydropyran (5.0 g, 22.5 mmol), (J. Chem. Soc. 1963, 3440), was added and the mixture heated at 100° C. for 3 hours and then stirred at ambient temperature for 18 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give 1-methyl-2-(3-(2-tetrahydropyranyloxy)propylthio)imidazole (2.5 g, 55%).
-
- A solution of 1-methyl-2-(3-(2-tetrahydropyranyloxy)propylthio)imidazole (2.0 g, 7.8 mmol) in acetic acid (8 ml), THF (4 ml) and water (2 ml) was heated at 50° C. for 4 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 2-(3-hydroxypropylthio)-1-methylimidazole (1.3 g, 100%) as an off-white solid.
-
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 1.0 mmol), (prepared as described for the starting material in Example 24), 4-(3-chloropropoxy)pyridine hydrochloride (206 mg, 1.0 mmol) and potassium carbonate (303 mg, 2.2 mmol) in NMP (20 ml) was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 95/5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(4-pyridyloxy)propoxy)quinazoline (257 mg, 56%).
- m.p. 138-140° C.
-
- MS-ESI: 455 [MH]+
Elemental analysis: Found C 58.4 H 4.7 N 11.8 C23H20N4O3ClF 1H2O Requires C 58.4 H 4.7 N 11.8% - The starting material was prepared as follows:
- A mixture of 4-chloropyridine (7 g, 47 mmol), ethylene glycol (17.9 g, 235 mmol) and sodium hydroxide (4.67 g, 195 mmol) in DMSO (80 ml) was heated at 100° C. for 24 hours. Most of the solvent was removed by evaporation and the residue was diluted with ice water. The aqueous mixture was extracted with ethyl acetate, the extracts combined, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give 4-(3-hydroxypropoxy)pyridine (3.2 g, 45%).
- Thionyl chloride (2.2 ml, 30 mmol) was added slowly to a solution of 4-(3-hydroxypropoxy)pyridine (3.1 g, 20 mmol) in trichloromethane (40 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give 4-(3-chloropropoxy)pyridine hydrochloride (3.81 g, 91%) as a solid.
-
- MS-ESI: 172 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 1.0 mmol), (prepared as described for the starting material in Example 24), 4-(2-chloroethylthio)pyridine hydrochloride (252 mg, 1.2 mmol) and potassium carbonate (454 mg, 3.3 mmol) in NMP (30 ml) was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate/methanol mixtures (100/0 increasing to 75/25) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(4-pyridylthio)ethoxy)quinazoline (13 mg, 3%).
- m.p. 182-186° C.
-
- MS-ESI: 457 [MH]+
- The starting material was prepared as follows:
- Sodium hydride (890 mg of a 50% suspension in mineral oil. 19 mmol) was added to a solution of 4-mercaptopyridine (2.34 g, 21 mmol) in DMF (75 ml) and the mixture stirred for 30 minutes. 2-(2-Bromoethoxy)tetrahydropyran (4.0 g, 19 mmol), (J. Am. Chem. Soc. 1948, 70, 4187), was added and the mixture heated at 100° C. for 3 hours and then stirred at ambient temperature for 18 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give 4-(2-(tetrahydropyran-2-yloxy)ethylthio)pyridine (2.8 g, 56%).
-
- A solution of 4-(2-(tetrahydropyran-2-yloxy)ethylthio)pyridine (2.73 g, 11 mmol) in acetic acid (8 ml), THF (4 ml) and water (2 ml) was heated at 50° C. for 4 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 4-(2-hydroxyethylthio)pyridine (1.39 g, 79%) as an off-white solid.
-
- Thionyl chloride (0.98 ml, 13.5 mmol) was added slowly to a solution of 4-(2-hydroxyethylthio)pyridine (1.39 g, 9.0 mmol) in trichloromethane (25 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give 4-(2-chloroethylthio)pyridine hydrochloride (500 mg, 26%) as a solid.
-
- MS-ESI: 174 [MH]+
- A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (350 mg, 1.0 mmol), (prepared as described for the starting material in Example 24), 3-(2-chloroethoxy)pyridine hydrochloride (234 mg, 1.2 mmol) and potassium carbonate (456 mg, 3.3 mmol) in NMP (20 ml) was heated at 90° C. for 2 hours. The mixture was allowed to cool, diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 95/5) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-pyridyloxy)ethoxy)quinazoline (95 mg, 20%).
- m.p. 188-190° C.
-
- MS-ESI: 441 [MH]+
Elemental analysis: Found C 55.0 H 3.9 N 11.8 C22H18N4O3ClF 2H2O Requires C 55.4 H 4.6 N 11.7% - The starting material was prepared as follows:
- Sodium hydride (1.02 g of a 50% suspension in mineral oil, 42 mmol) was added to a solution of 3-hydroxypyridine (2.01 g, 21 mmol) in DMF (50 ml) and the mixture stirred for 30 minutes. 2-(2-Bromoethoxy)tetrahydropyran (4.0 g, l9 mmol), (J. Am. Chem. Soc. 1948, 70, 4187), was added and the mixture heated at 100° C. for 3 hours and then stirred at ambient temperature for 18 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol mixtures (100/0 increasing to 97/3) to give 3-(2-(tetrahydropyran-2-yloxy)ethoxy)pyridine (2.28 g, 48%).
-
- MS-ESI: 224 [MH]+
- A solution of 3-(2-(tetrahydropyran-2-yloxy)ethoxy)pyridine (1.54 g, 7 mmol) in acetic acid (8 ml), THF (4 ml) and water (2 ml) was heated at 50° C. for 4 hours. The volatiles were removed by evaporation and the residue azeotroped with toluene to give 3-(2-hydroxyethoxy)pyridine (820 mg, 86%) as an off-white solid.
-
- MS-ESI: 140 [MH]+
- Thionyl chloride (0.89 ml, 12 mmol) was added slowly to a solution of 3-(2-hydroxyethoxy)pyridine (1.13 g, 8 mmol) in trichloromethane (20 ml) at 5° C. The mixture was stirred at 5° C. for 1 hour and then at ambient temperature for 2 hours. The volatiles were removed by evaporation, the residue azeotroped with toluene and dried under vacuum to give 3-(2-chloroethoxy)pyridine hydrochloride (300 mg, 19%) as a solid.
-
- 2-Fluoro-5-hydroxy-4-methylaniline (170 mg, 1.2 mmol), (prepared as described for the starting material in Example 13), was added to a solution of 7-benzyloxy-4-chloroquinazoline hydrochloride (307 mg, 1 mmol) in 2-pentanol (5 ml) and the mixture stirred at 120° C. for 2 hours. The mixture was allowed to cool and the resulting precipitate was collected by filtration, washed with isopropanol and then ether and dried under vacuum at 70° C. to give 7-benzyloxy-4-(2-fluoro-5-hydroxy-4-methylanilino)quinazoline hydrochloride (331 mg, 80%).
-
- MS-ESI: 376 [MH]+
Elemental analysis: Found C 63.7 H 4.8 N 10.0 C22H18N3O2F 1HCl Requires C 64.2 H 4.7 N 10.2% - The starting material was prepared as follows:
- Sodium (368 mg, 16 mmol) was added to benzyl alcohol (10 ml, 96 mmol) and the mixture was heated at 148° C. for 30 minutes. 7-Fluoro-3,4-dihydroquinazolin-4-one (656 mg, 4 mmol), (J. Chem. Soc. section B 1967, 449), was added and the mixture maintained at 148° C. for 24 hours. The reaction mixture was allowed to cool, the solution was poured on to water (170 ml) and the aqueous mixture adjusted to pH3 with concentrated hydrochloric acid. The precipitate was collected by filtration, washed with water, ether and dried under vacuum to give 7-benzyloxy-3,4-dihydroquinazolin-4-one (890 mg, 89%) as a white solid.
- m.p. 267-269° C.
-
- MS-ESI: 252 [MH]+
Elemental analysis: Found C 71.4 H 4.9 N 10.7 C15H12N2O2 0.04H2O Requires C 71.2 H 4.8 N 11.1% - A mixture of 7-benzyloxy-3,4-dihydroquinazolin-4-one (800 mg, 3.17 mmol) and DMF (100μl) in thionyl chloride (20 ml, 0.27 mmol) was heated at reflux for 3 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene and dried under vacuum to give 7-benzyloxy-4-chloroquinazoline hydrochloride (835 mg, 86%) as a cream solid.
- m.p. 131-132° C.
-
- MS-ESI: 270 [MH]+
- Using an analogous procedure to that described in Example 70, 7-benzyloxy-4-chloroquinazoline hydrochloride (307 mg, 1 mmol), (prepared as described for the starting material in Example 70), was treated with 4-chloro-2-fluoro-5-hydroxyaniline (193 mg, 1.2 mmol), (EP 061741 A2), to give 7-benzyloxy-4-(4-chloro-2-fluoro-5-hydroxyanilino)quinazoline hydrochloride (407 mg, 94%).
- m.p. 253-257° C.
-
- MS-ESI: 396 [MH]+
Elemental analysis: Found C 57.8 H 3.8 N 9.7 C21H15N3O2ClF 0.3H2O 1HCl Requires C 57.6 H 3.8 N 9.6% - Using an analogous procedure to that described in Example 36, 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (224 mg, 0.6 mmol), (prepared as described for the starting material in Example 22), was treated with 4-bromomethyl-1,2-difluorobenzene (149 mg, 0.72 mmol) to give 7-(3,4-difluorobenzyoxy)-4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazoline hydrochloride (90 mg, 31%).
-
- MS-ESI: 442 [MH]+
Elemental analysis: Found C 58.0 H 4.3 N 8.7 C23H18N3O3F3 Requires C 58.3 H 4.1 N 8.8 0.9HCl 0.08 isopropanol - Tetrabutylammonium fluoride (563 μl of a 1M solution in THF, 0.62 mmol) was added to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline (207 mg, 0.31 mmol) in THF (5 ml) cooled at 5° C. and the mixture was then stirred for 1 hour at ambient temperature. Water was added and the volatiles were removed by evaporation. The solid residue was dissolved in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (0.3 ml) was added. The solvent was removed by evaporation, the solid residue was resuspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline hydrochloride (99 mg, 63%).
-
- MS-ESI: 430 [MH]+
Elemental analysis: Found C 45.8 H 4.3 N 12.9 C20H17N5O3ClF 1.4H2O 2HCl Requires C 45.5 H 4.2 N 13.3% - The starting material was prepared as follows:
- Diethyl azodicarboxylate (219 μl, 1.4 mmol) was added dropwise to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (400 mg, 0.7 mmol), (prepared as described for the starting material in Example 33), 2-hydroxymethyl-1-methylimidazole (82 mg, 0.83 mmol), (J. Chem. Soc. 1927,3128-3136), and triphenylphosphine (365 mg, 1.4 mmol) in methylene chloride (12 ml) cooled at 0° C. The mixture was stirred for 1 hour at ambient temperature and further 2-hydroxymethyl-1-methylimidazole (68 mg, 0.69 mmol), triphenylphosphine (91 mg, 0.34 mmol) and diethyl azodicarboxylate (54 μl, 0.34 mmol) were added. The mixture was stirred for 1 hour at ambient temperature and the solvent was removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (94/6) to give 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxy-7-((1-methylimidazol-2-yl)methoxy)quinazoline (116 mg, 25%).
-
- A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxyquinazoline hydrochloride (400 mg, 0.98 mmol), 2-chloromethyl-1-methylimidazole hydrochloride (210 mg, 1.25 mmol), potassium carbonate (580 mg, 4.2 mmol) and potassium iodide (17 mg, 0.1 mmol) in DMF (20 ml) was stirred at 65° C. for 4.5 hours followed by 17 hours at ambient temperature. The solvent was removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with water, brine, dried (MgSO4) and the solvent removed by evaporation. The solid residue was purified by column chromatography eluting with methylene chloride/methanol (.97/3) to give a yellow solid (258 mg). This solid was dissolved in methanol (5 ml) and a 1M aqueous sodium hydroxide solution (660 μl, 0.66 mmol) was added. The mixture was stirred for 15 minutes, then water was added and the mixture adjusted to pH7 with concentrated hydrochloric acid. The aqueous mixture was extracted with ethyl acetate and the combined organic extract was washed with water, brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/methanol (95/5). The purified solid product was dissolved in methanol and methanolic hydrogen chloride (1.5 ml of a 7.5M solution) was added. The volatiles were removed by evaporation, the solid residue was suspended in pentane, collected by filtration, washed with pentane and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-((1-methylimidazol-2-yl)methoxy)quinazoline hydrochloride (105 mg, 44%).
-
- MS-ESI: 380 [MH]+
Elemental analysis: Found C 52.2 H 5.0 N 15.1 C20H18N5O2F 0.9H2O 1.8HCl Requires C 52.1 H 4.7 N 15.2% - The starting material was prepared as follows:
- Sodium (368 mg, 16mmol) was added to benzyl alcohol (10 ml, 96 mmol) and the mixture was heated at 148° C. for 30 minutes, 7-fluoro-3,4-dihydroquinazolin-4-one (656 mg, 4 mmol), (J. Chem. Soc. section B 1967, 449), was added and the mixture maintained at 148° C. for 24 hours. The reaction mixture was allowed to cool, the solution was poured on to water (170 ml) and the aqueous mixture adjusted to pH3 with concentrated hydrochloric acid. The precipitate was collected by filtration, washed with water, then ether and dried under vacuum to give 7-benzyloxy-3,4-dihydroquinazolin-4-one (890 mg, 89%) as a white solid.
- m.p. 267-269° C.
-
- MS-ESI: 252 [MH]+
Elemental analysis: Found C 71.4 H 4.9 N 10.7 C15H12N2O2 0.04H2O Requires C 71.2 H 4.8 N 11.1% - A mixture of 7-benzyloxy-3,4-dihydroquinazolin-4-one (800 mg, 3.17 mmol) and DMF (100 μl) in thionyl chloride (20 ml, 0.27 mmol) was heated at reflux for 3 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene and dried under vacuum to give 7-benzyloxy-4-chloroquinazoline hydrochloride (835 mg, 86%) as a cream solid.
- m.p. 131-132° C.
-
- MS-ESI: 270 [MH]+
- 2-Fluoro-5-methoxycarbonyloxy-4-methylaniline (883 mg, 4.4 mmol), (prepared as described for the starting material in Example 12), was added to a solution of 7-benzyloxy-4-chloroquinazoline hydrochloride(1 g, 3.7 mmol) in 2-pentanol (15 ml) at 120° C. and the mixture was then heated at reflux for 4 hours. The mixture was allowed to cool and the precipitate was collected by filtration, washed with isopropanol followed by ether and dried under vacuum to give 7-benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (1.65 g, 97%) as a cream solid.
- m.p. 219-220° C.
-
- MS-ESI: 434 [MH]+
Elemental analysis: Found C 60.1 H 4.9 N 8.5 C24H20N3O4F 1HCl 0.5H2O Requires C 60.2 H 4.6 N 8.8% - 7-Benzyloxy-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (1.53 g, 3.25 mmol) and 10% palladium-on-charcoal catalyst (180 mg) in a mixture of methanol (75 ml), DMF (6 ml) and trichloromethane (30 ml) was stirred under hydrogen at 1.5 atmospheres pressure for 45 minutes. The catalyst was removed by filtration through diatomaceous earth and the solvent removed from the filtrate by evaporation. The residue was triturated with ether, the resulting solid was collected by filtration and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxyquinazoline hydrochloride (1.23 g, 84%) as an orange solid.
- m.p. 205-210° C.
-
- MS-ESI: 344 [MH]+
- Diethyl azodicarboxylate (244 mg, 1.4 mmol) was added dropwise to a suspension of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride (261 mg, 0.7 mmol), (prepared as described for the starting material in Example 22), triphenylphosphine (367 mg, 1.4 mmol) and 2-(1,2,4-triazol-1-yl)ethanol (95 mg, 0.84 mmol), (Ann. Pharm. Fr. 1977, 35, 503-508), in methylene chloride (5 ml). The mixture was stirred for 1 hour at ambient temperature and further triphenylphosphine (184 mg, 0.7 mmol), 2-(1,2,4-triazol-1-yl)ethanol (63 mg, 0.56 mmol) and diethyl azodicarboxylate (122 mg, 0.7 mmol) were added. The mixture was stirred for a further 2.5 hours and the solvent was removed by evaporation. The residue was dissolved in methanol (5 ml) and 2M aqueous sodium hydroxide solution (2 ml) was added. The mixture was stirred for 20 minutes and the mixture was partitioned between ether and water. The aqueous layer was acidified to pH7 with 2M hydrochloric acid and the resulting precipitate was collected by filtration, washed with water, and dried under vacuum. The resulting solid was dissolved in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (0.5 ml) was added. The volatiles were removed by evaporation, the solid was resuspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline hydrochloride (180 mg, 56%).
-
- MS-ESI: 411 [MH]+
Elemental analysis: Found C 53.2 H 4.8 N 18.4 C20H19N6O3F 0.1H2O 1.2HCl Requires C 52.7 H 4.5 N 18.4% - Tetrabutylammonium fluoride (608 μl of a 1M solution in THF, 0.67 mmol) was added to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline (224 mg, 0.33 mmol) in THF (5 ml) cooled at 5° C. After stirring for 1 hour at ambient temperature, water was added. The THF was removed by evaporation. The precipitate was collected by filtration and dried by azeotroping with ethanol. The solid was dissolved in methylene chloride/methanol and a solution of 5M hydrochloric acid in isopropanol was added. The volatiles were removed by evaporation. The residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline hydrochloride (132 mg, 85%).
- m.p. 277-281° C.
-
- MS-ESI: 432 [MH]+
Elemental analysis: Found C 51.0 H 3.5 N 8.9 C20H15N3O3ClFS 0.1H2O lHCl Requires C 51.1 H 3.5 N 8.9% - The starting material was prepared as follows:
- Diethyl azodicarboxylate (274 μl, 1.7 mmol) was added dropwise to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (400 mg, 0.7 mmol), (prepared as described for the starting material in Example 33), 3-thiophenemethanol (119 mg, 1 mmol) triphenylphosphine (456 mg, 1.7 mmol) in methylene chloride (12 ml) cooled at 0° C. The mixture was stirred for 2 hours at ambient temperature, the solvent was removed by evaporation and the residue was purified by column chromatography eluting with methylene chloride/ether (95/5). The purified product was triturated with petroleum ether/ethyl acetate (8/2) and the solid product was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline (223 mg, 47%).
-
- Diethyl azodicarboxylate (274 μl, 1.7 mmol) was added dropwise to a solution of 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (400 mg, 0.7 mmol), (prepared as described for the starting material in Example 33), triphenylphosphine (456 ml, 1.7 mmol), 2-(4-pyridyl)ethanol (128 mg, 1 mmol), (Zhur. Obshchei. Khim. 1958, 28, 103-110), in methylene chloride (12 ml) cooled at 0° C. The mixture was stirred for 2 hours at ambient temperature and the solvent was removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (97/3) to give a white solid (416 mg). A portion of this solid (390 mg) was dissolved in THF (6 ml), the solution was cooled to 0° C. and tetrabutylammonium fluoride (1.1 ml of a 1M solution in THF, 1.1 mmol) was added and the mixture was stirred for 2 hours at ambient temperature. Water was added, the organic solvent was removed by evaporation and the resulting precipitate was collected by filtration. The solid was dissolved in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (0.5 ml) was added. The volatiles were removed by evaporation and the solid was resuspended in isopropanol and collected by filtration, washed with isopropanol and ether and dried under vacuum to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-(2-(4-pyridyl)ethoxy)quinazoline hydrochloride (123 mg, 42%).
-
- MS-ESI: 441 [MH]+
Elemental analysis: Found C 50.4 H 4.7 N 10.0 C22H18N4O3ClF 1.1H2O 1.8HCl Requires C 50.5 H 4.5 N 10.4% 0.23 isopropanol - Using an analogous procedure to that described in Example 77, 4-(4-chloro-5-diphenyl-t-butylsilyloxy-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (300 mg, 0.52 mmol), (prepared as described for the starting material in Example 33), was treated with 4-hydroxymethyl-2-methylthiazole (100 mg, 0.87 mmol) to give 4-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxy-7-((2-methylthiazol-4-yl)methoxy)quinazoline hydrochloride (132 mg, 52%).
-
- MS-ESI: 447 [MH]+
Elemental analysis: Found C 48.2 H 3.7 N 11.2 C20H16N4O3ClFS Requires C 47.9 H 3.7 N 11.2% 0.6H2O 1.2HCl - The starting material was prepared as follows:
- A solution of 4-chloromethyl-2-methylthiazole (1.84 g, 10 mmol) in water (9 ml) and concentrated hydrochloric acid (2 ml) was heated at reflux for 20 hours. The mixture was allowed to cool and was adjusted to pH5 with 2M aqueous sodium hydroxide solution and the mixture was extracted with ethyl acetate. The organic extract was washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (97/3) to give 4-hydroxymethyl-2-methylthiazole (800 mg, 54%).
-
- Diethyl azodicarboxylate (197 μl, 1.2 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.6 mmol), (prepared as described for the starting material in Example 24), 3-thiophenemethanol (107 mg, 0.93 mmol) and triphenylphosphine (328 mg, 1.2 mmol) in methylene chloride (6 ml) cooled at 0° C. The mixture was stirred for 2 hours at ambient temperature and further triphenylphosphine (157 mg, 0.57 mmol), 3-thiophenemethanol (107 mg, 0.93 mmol) and diethyl azodicarboxylate (98.5 μl, 0.59 mmol) were added. The mixture was stirred for 2 hours at ambient temperature and the solvent was removed by evaporation. The residue was dissolved in ethyl acetate and the solution was washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/ethyl acetate (4/6). The resulting oil was dissolved in ether and a 5M solution of hydrogen chloride in isopropanol (1 ml) was added. The resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-((3-thienyl)methoxy)quinazoline hydrochloride (59 mg, 20%).
-
- MS-ESI: 416 [MH]+
Elemental analysis: Found C 53.5 H 3.7 N 9.0 C20H15N3O2ClFS 0.95HCl Requires C 53.3 H 3.6 N 9.3% - A mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (250 mg, 0.78 mmol), (prepared as described for the starting material in Example 24), 2-acetamido-4-chloromethylthiazole (164 mg, 0.86 mmol) and potassium carbonate (216 mg, 1.5 mmol) in DMF (5 ml)was stirred at 40° C. for 7 hours. The mixture was partitioned between ethyl acetate and water and the aqueous layer was adjusted to pH7 with 2M hydrochloric acid. The organic phase was washed with water, brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified solid was dissolved in a mixture of methylene chloride and methanol and a 5M solution of hydrogen chloride in isopropanol (1.0 ml) was added. The volatiles were removed by evaporation to give a solid, which was triturated with ether, collected by filtration and dried under vacuum to give 7-((2-acetamidothiazol-4-yl)methoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (96 mg, 24%).
- m.p. 194-202° C.
-
- MS-ESI: 474 [MH]+
Elemental analysis: Found C 46.9 H 3.8 N 13.2 C21H17N5O3ClFS 1.1H2O Requires C 47.3 H 3.8 N 13.1% 1.1HCl - Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (300 mg, 0.93 mmol), (prepared as described for the starting material in Example 24), 2-(1,2,4-triazol-1-yl)ethanol (159 mg, 1.4 mmol), (Ann. Pharm. Fr. 1977, 35, 503-508), and triphenylphosphine (492 mg, 1.8 mmol) in methylene chloride (10 ml). The mixture was stirred for 2 hours at ambient temperature and further triphenylphosphine (246 mg, 0.9 mmol) and diethyl azodicarboxylate (147 μl, 0.9 mmol) were added. The mixture was stirred for 1 hour at ambient temperature and the resulting precipitate was collected by filtration, washed with methylene chloride and ether and dried under vacuum. This solid was suspended in methylene chloride/methanol and a 5M solution of hydrogen chloride in isopropanol (1.0 ml) was added. The volatiles were removed by evaporation, the residue was triturated with ether. The resulting solid was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline hydrochloride (219 mg, 52%).
- m.p. 169-174° C.
-
- MS-ESI: 415 [MH]+
Elemental analysis: Found C 47.0 H 4.3 N 16.5 C19H16N6O2ClF 1.6 1H2O 1HCl Requires C 47.0 H 4.4 N 16.4% 0.35isopropanol - Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a solution of 1-(3-hydroxypropyl)-[1,2,4]-triazole (119 mg, 0.93 mmol), (EP0060696 A1), 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.62 mmol), (prepared as described for the starting material in Example 24), and triphenylphosphine (492 g, 1.8 mmol) in methylene chloride (4 ml) and the mixture stirred for 3 hours at ambient temperature. The mixture was purified by column chromatography eluting with methylene chloride/acetonitrile/methanol (60/32/8). The purified product was triturated with a mixture of pentane and ether, collected by filtration and dried under vacuum to gives white solid. This solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1 ml of a 5M solution) was added. The volatiles were removed by evaporation. The solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(1,2,4-triazol-1-yl)propoxy)quinazoline hydrochloride (121 mg, 39%).
-
- MS-ESI: 429 [MH]+
Elemental analysis: Found C 47.8 H 4.2 N 16.6 C20H18N6O2ClF 0.2H2O 2HCl Requires C 47.5 H 4.1 N 16.6% - Diethyl azodicarboxylate (209 mg, 1.2 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (128 mg, 0.4 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (314 mg, 1.2 mmol) and 2-(N-methyl-N-(pyridazin-4-yl)amino)ethanol (80 mg, 0.52 mmol) in methylene chloride (5 ml) and the mixture stirred for 2 hours at ambient temperature. The solvent was removed by evaporation, the residue was triturated with ether and the resulting solid was collected by filtration. The solid was purified by column chromatography eluting with methylene chloride/methanol (9/1 followed by 8/2) to give a white solid. This solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (0.5 ml of a 4M solution) was added. The volatiles were removed by evaporation, the residue was triturated with ether, collected by filtration and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-(pyridazin-4-yl)amino)ethoxy)quinazoline hydrochloride (110 mg, 60%).
-
Elemental analysis: Found C 47.2 H 4.6 N 14.7 C22H20N6O2ClF 1.5H2O Requires C 47.2 H 4.5 N 15.0% 2.15HCl - The starting material was prepared as follows:
- A solution of 4-bromo-3,6-dichloro-pyridazine (1.11 g, 5 mmol), (J.Chem. Soc., Perkin Trans I, 1974, 696), and 2-(methylamino)ethanol (0.75 g, 10 mmol) in isopropanol (10 ml) was heated at reflux for 30 minutes. The solvent was removed by evaporation, the residue was partitioned between methylene chloride and water and the aqueous layer was adjusted to pH9 with solid potassium carbonate. The organic layer was separated, washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was triturated with ether, collected by filtration and dried under vacuum to give 2-(N-(3,6-dichloropyridazin-4-yl)-N-methylamino)ethanol (1 g, 90%).
-
- MS-ESI: 221 [MH]+
- A mixture of 2-(N-(3,6-dichloropyridazin-4-yl)-N-methvlamino)ethanol (444 mg, 2 mmol) and 10% palladium-on-charcoal catalyst (150 mg) in ethanol (15 ml), methanol (5 ml) and aqueous ammonia (15 ml) was stirred under hydrogen at 3 atmospheres pressure for 4 hours. The catalyst was removed by filtration and the solvent removed from the filtrate by evaporation. The residue was dissolved in methylene chloride, the insoluble material was removed by filtration and the solvent was removed from the filtrate by evaporation. The residue was purified by column chromatography on neutral aluminum oxide eluting with methylene chloride/methanol (95/5 followed by 90/10). The purified product was triturated with petroleum ether, the solid product was collected by filtration and dried under vacuum to give 2-(N-methyl-N-(pyridazin-4-yl)amino)ethanol (275 mg, 91%).
-
- MS-ESI: 153 [MH]+
- 2M Aqueous sodium hydroxide solution (560 μl, 1.1 mmol) was added to a solution of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-((4-pyridyl)carboxamido)quinazoline (250 mg, 0.56 mmol) in methanol (7 ml) cooled at 0° C. and the mixture then stirred for 1 hour at ambient temperature. The mixture was diluted with water and the mixture adjusted to pH6 with 2M hydrochloric acid. The resulting solid was collected by filtration, washed with water and dried under vacuum. The solid was dissolved in methylene chloride/methanol and isopropanolic hydrogen chloride (0.7 ml of a 5M solution) was added. The volatiles were removed by evaporation, the solid residue was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-((4-pyridyl)carboxamido)quinazoline hydrochloride (241 mg, 93%).
- MS-ESI: 390 [MH]+
-
Elemental analysis: Found C 52.0 H 4.3 N 14.3 C21H16N5O2F 1.2H2O 1.95HCl Requires C 52.3 H 4.3 N 14.5% - The starting material was prepared as follows:
- A mixture of 7-nitro-3,4-dihydroquinazolin4-one (J. Chem. Soc. 1950, 1104-1111) (5 g, 26 mmol) in thionyl chloride (50 ml) and DMF (1 ml) was heated at reflux for 1.5 hours. Excess thionyl chloride was removed by evaporation and the residue azeotroped with toluene. The residue was suspended in ether, collected by filtration and dried under vacuum to give 4-chloro-7-nitroquinazoline hydrochloride (6.4 g, 100%).
-
- MS-ESI: 209 [MH]+
- A solution of 4-chloro-7-nitroquinazoline hydrochloride (2.46 g, 10 mmol) and 2-fluoro-5-methoxycarbonyloxy-4-methylaniline (2.2 g, 11 mmol), (prepared as described for the starting material in Example 12), in isopropanol (25 ml) was heated at 50° C. for 1 hour. The mixture was allowed to cool, the precipitated solid was collected by filtration recrystallised from methylene chloride/methanol/isopropanol to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-nitroquinazoline hydrochloride (1.8 g, 45%) as a yellow solid.
-
- MS-ESI: 373 [MH]+
Elemental analysis: Found C 50.0 H 3.6 N 13.8 C17H13N4O5F 1HCl Requires C 50.0 H 3.5 N 13.7% - A mixture of 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-nitroquinazoline hydrochloride (5.3 g, 13 mmol) and 10% palladium-on-charcoal catalyst (1 g) in ethanol (100 ml), ethanolic hydrogen chloride (1.8 ml of a 7M solution) and methanol (20 ml) was stirred under hydrogen at 1.7 atmospheres pressure for 75 minutes. The catalyst was removed by filtration through diatomaceous earth and the filter pad thoroughly washed with methylene chloride, methanol and ether and the solvent was removed from the filtrate by evaporation to give 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (4.8 g, 97%) as a yellow solid.
-
- MS-ESI: 343 [MH]+
- A solution of 7-amino-4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)quinazoline hydrochloride (0.45 g, 1.2 mmol) and isonicotinoyl chloride hydrochloride (296 mg, 1.66 mmol) in pyridine (15 ml) was stirred for 2 hours at ambient temperature, followed by 1 hour at 40° C. Further isonicotinoyl chloride hydrochloride (84 mg, 0.46 mmol) was added and the mixture was stirred at 40° C. for 2 hours. The volatiles were removed by evaporation, the mixture was diluted with water. The aqueous mixture was adjusted to pH7 and extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/methanol (95/5 followed by 92/8). The purified solid was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 4-(2-fluoro-5-methoxycarbonyloxy-4-methylanilino)-7-((4-pyridyl)carboxamido)quinazoline (264 mg, 49%).
-
- 4-Chloro-2-fluoroaniline (77 mg, 0.53 mmol) was added to a solution of 4-chloro-6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)quinazoline hydrochloride (140 mg, 0.35 mmol) in isopropanol (5 ml) and the mixture heated at reflux for 1 hour. The solvent was removed by evaporation and the residue was partitioned between ethyl acetate and saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by flash chromatography eluting with methylene chloride/methanol (95/5). The purified solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1 ml of a 5M solution) was added. The volatiles were removed by evaporation, the residue was triturated with ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yI)amino)ethoxy)quinazoline hydrochloride (75 mg, 39%).
-
- MS-ESI: 469 [MH]+
- The starting material was prepared as follows:
- Sodium hydride (1.44 g of a 60% suspension in mineral oil, 36 mmol) was added in portions over 20 minutes to a solution of 7-benzyloxy-3,4-dihydroquinazolin-4-one (8.46 g, 30 mmol), (prepared as described for the starting material in Example 70), in DMF (70 ml) and the mixture stirred for 1.5 hours. Chloromethyl pivalate (5.65 g, 37.5 mmol) was added dropwise and the mixture stirred 2 hours at ambient temperature. The mixture was diluted with ethyl acetate (100 ml) and poured onto ice/water (400 ml) and 2M hydrochloric acid (4 ml). The organic layer was separated and the aqueous layer extracted with ethyl acetate, the combined extracts were washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was triturated with a mixture of ether and petroleum ether, the solid was collected by filtration and dried under vacuum to give 7-benzyloxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (10 g, 84%).
-
- A mixture of 7-benzyloxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (7 g, 17.7 mmol) and 10% palladium-on-charcoal catalyst (700 mg) in ethyl acetate (250 ml), DMF (50 ml), methanol (50 ml) and acetic acid (0.7 ml) was stirred under hydrogen at atmospheric pressure for 40 minutes. The catalyst was removed by filtration and the solvent removed from the filtrate by evaporation. The residue was triturated with ether, collected by filtration and dried under vacuum to give 7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (4.36 g, 80%).
-
- Diethyl azodicarboxylate (679 mg, 3.9mmol) was added dropwise to a suspension of 7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (918 mg, 3 mmol), triphenylphosphine (1 g, 3.9 mmol) and 2-(N-methyl-N-(t-butylcarbonyl)amino)ethanol (682 mg, 3.9 mmol), prepared as described below, in methylene chloride (20 ml) and the mixture stirred for 1 hour at ambient temperature. Further 2-(N-methyl-N-(t-butylcarbonyl)amino)ethanol (105 mg, 0.6 mmol), triphenylphosphine (786 mg, 3 mmol) and diethyl azodicarboxylate (522 mg, 3 mmol) were added and the mixture stirred for 30 minutes at ambient temperature. The mixture was concentrated to half volume by evaporation and purified by column chromatography eluting with methylene chloride/ether (7/3 increasing to 1/1) to give 6-methoxy-7-(2-(N-methyl-N-(t-butylcarbonyl)amino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (1.3 g, 98%).
-
- A solution of 6-methoxy-7-(2-(N-methyl-N-(t-butylcarbonyl)amino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (1.39 g, 3 mmol) in methylene chloride (4 ml) and TFA (4 ml) was stirred at ambient temperature for 1 hour. Toluene was added, and the volatiles were removed by evaporation. The residue was triturated with ether and the resulting solid was collected by filtration. The solid was dissolved in water, sodium hydrogen carbonate was added and the aqueous mixture was extracted with methylene chloride. The organic extract was dried (MgSO4) and the solvent removed by evaporation. The residue was triturated with ether and the solid was collected by filtration to give 6-methoxy-7-(2-(methylamino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (800 mg, 73%).
-
- MS-ESI: 364 [MH]+
- A solution of 6-methoxy-7-(2-(methylamino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (363 mg, 1 mmol) and 4-chloro-6-methylpyrimidine (257 mg, 2 mmol), (J. Het. Chem., 1969, 6, 879), in N,N-diisopropylethylamine (2 ml was heated at reflux for 30 minutes. The volatiles were removed by evaporation and the residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5) to give 6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (365 mg, 80%). H NMR Spectrum: (CDCl3) 1.19(s, 9H); 2.36(s, 3H); 3.18(s, 3H); 3.95(s, 3H); 4.09(t, 2H); 4.34(t, 2H); 5.9(s, 2H); 6.3(s, 1H); 7.14(s, 1H); 7.63(s, 1H); 8.17(s, 1H); 8.5(s, 1H)
- MS-ESI: 456 [MH]+
- A solution of 6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (365 mg, 0.8 mmol) in methanolic ammonia (30 ml of a 3M solution) was stirred at ambient temperature for 16 hours. The volatiles were removed by evaporation, the residue was triturated with ether, the solid was collected by filtration, washed with ether and dried under vacuum to give 6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)-3,4-dihydroquinazolin-4-one (250 mg, 92%).
-
- MS-ESI: 342 [MH]+
- A mixture of 6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin-4-yl)amino)ethoxy)-3,4-dihydroquinazolin-4-one (250 mg, 0.73 mmol) in thionyl chloride (5 ml) and DMF (0.1 ml) was heated at reflux for 1 hour. The mixture was diluted with toluene and the volatiles were removed by evaporation. The residue was triturated with methylene chloride/ether, the solid was collected by filtration and dried under vacuum to give 4-chloro-6-methoxy-7-(2-(N-methyl-N-(6-methylpyrimidin4-yl)amino)ethoxy)quinazoline hydrochloride (260 mg, 90%).
- 2-(N-methyl-N-(t-butylcarbonyl)amino)ethanol was prepared as follows:
- A solution of di-t-butyldicarbonate (4.52 g, 20 mmol) in THF (10 ml) was added to a solution of 2-(N-methylamino)ethanol (1.5 g, 20 mmol) in a mixture of water (10 ml) and THF (10 ml). The mixture was stirred at ambient temperature for 18 hours, the THF was removed by evaporation and the aqueous residue was partitioned between ether and water. The organic layer was washed with water, brine, dried (MgSO4) and evaporated to give 2-(N-methyl-N-(t-butylcarbonyl)amino)ethanol (3 g, 85%).
-
- MS-ES: 176 [MH]+
- Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.62 mmol), (prepared as described for the starting material in Example 24), 2-(3,5-dimethyl-[1,2,4]-triazol-4-yl)ethanol (114 mg, 0.81 mmol), (EP 0329357 A1), and triphenylphosphine (492 mg, 1.8 mmol) in methylene chloride (4 ml) and the mixture stirred for 1 hour at ambient temperature. The precipitated solid was collected by filtration, washed with ether and dried under vacuum. The solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (2 ml of 4.5M solution) was added. The volatiles were removed by evaporation, the residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-7-(2-(3,5-dimethyl-[1,2,4]-triazol-4-yl)ethoxy)-6-methoxyquinazoline hydrochloride (184 mg, 54%).
-
- MS-ESI: 443 [MH]+
Elemental Analysis: Found C 48.0 H 4.6 N 16.1 C21H20N6O2ClF 1H2O Requires C 47.7 H 4.6 N 15.9% 1.85HCl - Diethyl azodicarboxylate (295 μl, 1.8 mmol) was added dropwise to a solution of the 75/25 mixture of 2-(2,4-dimethylimidazol-1-yl)ethanol and 2-(2,5-dimethylimidazol-1-yl)ethanol (114 mg, 0.81 mmol), 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.62 mmol), (prepared as described for the starting material in Example 24), and triphenylphosphine (492 mg, 1.8 mmol) in methylene chloride (4 ml) and the mixture stirred for 4 hours at ambient temperature. Further triphenylphosphine (49 mg, 0.18 mmol), mixture of imidazolylethanols (26 mg, 0.18 mmol) and diethyl azodicarboxylate (29μl, 0.18 mmol) were added and the mixture stirred for 1 hour. The precipitated solid was collected by filtration, washed with methylene chloride, and dried under vacuum. The solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1.5 ml of a 4.5M solution) was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give a 75/25 mixture of 4-(4-chloro-2-fluoroanilino)-7-(2-(2,4-dimethylimidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride and 4-(4-chloro-2-fluoroanilino)-7-(2-(2,5-dimethylimidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride (159 mg, 48%).
-
- MS-ESI: 442 [MH]+
Elemental analysis: Found C 49.9 H 4.6 N 13.3 C22H21N5O2ClF 1.1H2O Requires C 50.1 H 4.8 N 13.3% 1.85HCl - The starting material was prepared as follows:
- 2,4-Dimethylimidazole (1.5 g, 15.6 mmol) was added in portions to a suspension of sodium hydride (936 mg of a 60% suspension in mineral oil, 23 mmol) in DMF (8 ml) and the mixture was stirred for 30 minutes at ambient temperature. 2-Bromoethanol (1.66 ml, 23 mmol) was added and the mixture stirred at 100° C. for 16 hours. The solvent was removed by evaporation and concentrated hydrochloric acid (1 ml) was added to the residue. The resulting solid was triturated with methylene chloride, collected by filtration and dried under vacuum. The solid was purified by column chromatography on neutral alumina eluting with methylene chloride/methanol (97/3) and then column chromatography eluting with methylene chloride/methanol (93/7 followed by 90/10) to give a 75/25 mixture of 2-(2,4-dimethylimidazol-1-yl)ethanol and 2-(2,5-dimethylimidazol-1-yl)ethanol (650 mg, 29%).
- MS-ESI: 140 [MH]+
- Diethyl azodicarboxylate (236 μl, 1.5 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 2-(3-pyridyl)ethanol (86 mg, 0.7 mmol), (J.Heterocycl. Chem. 1992, 29, 1663), in methylene chloride (6 ml) and the mixture stirred for 4 hours at ambient temperature. The mixture was poured directly on to a silica column and eluted with methylene chloride/acetonitrile/methanol (60/35/5). The purified solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1.5 ml of a 4.5M solution) was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(3-pyridyl)ethoxy)quinazoline hydrochloride (154 mg, 52%).
-
- MS-ESI: 425 [MH]+
Elemental analysis: Found C 52.7 H 4.3 C22H18N4O2ClF O.8H2O 1.8HCl Requires C 52.3 H 4.3% - Diethyl azodicarboxylate (236 μl, 1.5 mmol) was added dropwise to a suspension of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (160 mg, 0.5 mmol), (prepared as described for the starting material in Example 24), triphenylphosphine (393 mg, 1.5 mmol) and 2-(6-methyl-2-pyridyl)ethanol (96 mg, 0.7 mmol), (J. Chem. Soc. A, 1971, 388), in methylene chloride (6 ml) and the mixture stirred for 16 hours at ambient temperature. The mixture was poured directly on to a silica column and eluted with methylene chloride/methanol (95/5). The purified solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1.5 ml of a 4.5M solution) was added. The mixture was diluted with ether and the resulting precipitate was collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(6-methyl-2-pyridyl)ethoxy)quinazoline hydrochloride (97 mg, 34%).
-
- MS-ESI: 439 [MH]+
Elemental Analysis: Found C 52.7 H 4.5 N 10.7 C23H20N4O2ClF 1H2O Requires C 52.9 H 4.6 N 10.7% 1.8HCl - A mixture of 4-chloro-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (49 mg, 0.16 mmol) and 3-hydroxyaniline (21 mg, 0.19 mmol) in isopropanol (3 ml) and isopropanolic hydrogen chloride (0.2 ml of a 5M solution) was stirred at 80° C. for 1 hour. The precipitated solid was collected by filtration, washed with isopropanol and ether and dried under vacuum to give 4-(3-hydroxyanilino)-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride (56 mg, 93%).
-
- MS-ESI: 378 [MH]+
Elemental Analysis: Found C 52.7 H 4.9 N 15.1 C20H19N5O3 0.6H2O 1.85HCl Requires C 52.7 H 4.9 N 15.4% - The starting material was prepared as follows:
- Diethyl azodicarboxylate (435 mg, 2.5 mmol) was added dropwise to a suspension of 7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (612 mg, 2 mmol), (prepared as described for the starting material in Example 85), 2-(imidazol-1-yl)ethanol (280 mg, 2.5 mmol), (J. Med. Chem. 1993, 25 4052-4060), and triphenylphosphine (655 mg, 2.5 mmol) in methylene chloride (10 ml) at 5° C. The mixture was stirred for 10 minutes at 5° C. and then 1 hour at ambient temperature. The mixture was poured directly on to a silica column and eluted with methylene chloride/methanol (95/5) to give 7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (640 mg, 80%).
-
- MS-ESI: 423 [MNa]+
Elemental Analysis: Found C 58.3 H 6.4 N 13.9 C20H24N4O5 0.7H2O Requires C 58.2 H 6.2 N 13.6% - A solution of 7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one (640 mg, 1.6 mmol) in saturated methanolic ammonia (10 ml) was stirred for 15 hours at ambient temperature. The volatiles were removed by evaporation, the solid was triturated with ether, collected by filtration and dried under vacuum to give 7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (412 mg, 90%).
-
- MS-ESI: 287 [MH]+
Elemental Analysis: Found C 57.8 H 5.2 N 19.3 C14H14N4O3 0.3H2O Requires C 57.7 H 5.1 N 19.2% - A mixture of 7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-3,4-dihydroquinazolin-4-one (412 mg, 1.44 mmol), thionyl chloride (5 ml) and DMF (0.2 ml) was heated at reflux for 1 hour. The mixture was diluted with toluene and the volatiles were removed by evaporation. The residue was suspended in methylene chloride, cooled to 0° C. and aqueous sodium hydrogen carbonate solution was added. The resulting precipitate was collected by filtration and dried under vacuum to give 4-chloro-7-(2-(imidazol-1-yl)ethoxy)-6-methoxyquinazoline (258 mg, 59%).
-
- MS-ESI: 327 [MNa]+
- Diethyl azodicarboxylate (220 μl, 1.4 mmol) was added dropwise to a solution of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (150 mg, 0.47 mmol), (prepared as described for the starting material in Example 24), 2-(1,2,4-triazol-4-yl)ethanol (64 mg, 0.56 mmol) and triphenylphosphine (369 mg, 1.4 mmol) in methylene chloride (5 ml) and the mixture stirred for 30 minutes at ambient temperature. Further 2-(1,2,4-triazol4-yl)ethanol (16 mg, 0.14 mmol), triphenylphosphine (37 mg, 0.14 mmol) and diethyl azodicarboxylate (22 μl, 0.14 mmol) was added and the mixture stirred for 1 hour at ambient temperature. The precipitated solid was collected by filtration, washed with methylene chloride and methanol and dried under vacuum. The solid was dissolved in methylene chloride/methanol and ethereal hydrogen chloride (1.5 ml of a 2.2M solution) was added. The volatiles were removed by evaporation, the solid residue was suspended in ether, collected by filtration, washed with ether and dried under vacuum to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(2-(1,2,4-triazol-4-yl)ethoxy)quinazoline hydrochloride (93 mg, 40%).
-
- MS-ESI: 415 [MH]+
Elemental analysis: Found C 45.9 H 3.7 N 17.1 C19H16N6O2ClF 0.5H2O 2HCl Requires C 45.9 H 3.9 N 16.9% - The starting material was prepared as follows:
- A solution of N,N-dimethylformamide azine (1 g, 7 mmol), (J. Chem. Soc. C, 1967, 1664), p-toluene sulphonic acid (45 mg) and ethanolamine (4.3 g, 70 mmol) in benzene (15 ml) was heated at reflux for 8 hours. The mixture was allowed to cool, the solvent was removed by evaporation and the residue was purified by column chromatography eluting with methylene chloride/methanol (90/10 followed by 85/15) to give 2-(1,2,4-triazol-4-yl)ethanol (328 mg, 41%).
-
- MS-ESI: 113 [MH]+
- 1,1′-(azodicarbonyl)dipiperidine (480 mg, 1.9 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (200 mg, 0.63 mmol), 3-benzyloxypropanol (150 μl, 0.95 mmol) and tributylphosphine (459 μl, 1.86 mmol) in methylene chloride (20 ml) at 5° C. The reaction was stirred for 1 hour at 5° C. and then for 18 hours at ambient temperature. The mixture was diluted with ether and stirred for 15 minutes. The insolubles were removed by filtration and the volatiles were removed from the filtrate by evaporation. The residue was partitioned between ethyl acetate and water, and the organic layer was separated, dried (MgSO4) and the solvent removed by evaporation. A 1 M solution of ethereal hydrogen chloride was added to the residue, the resulting solution was reduced in volume by evaporation and the resulting precipitate was collected by filtration and dried to give 7-(3-benzyloxypropoxy)-4-(4-chloro-2-fluoroanilino)-6-methoxyquinazoline hydrochloride (90 mg, 31%).
-
- MS-ESI: 468 [MH]+
- 1,1′-(azodicarbonyl)dipiperidine (840 mg, 3 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (315 mg, 1 mmol), ethyl 4-hydroxymethyl-2-pyridinecarboxylate (250 mg, 1.4 mmol), (J. Het. Chem. 1993, 30, 631-635) and tributylphosphine (800 μl, 3 mmol) in methylene chloride (50 ml) at 0° C. The mixture was allowed to warm to ambient temperature over 2 hours, the insolubles were removed by filtration and the filtrate was washed with water and brine, dried (Na2SO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (10:0 increasing to 9:1). The purified product was recrystallised from methylene chloride/hexane to give 4-(4-chloro-2-fluoroanilino)-7-(2-ethoxycarbonylpyrid-4-yl)methoxy-6-methoxyquinazoline (285 mg, 60%).
- m.p. 212-214° C.
-
Elemental analysis: Found C 58.9 H 4.4 N 12.0 C24H20ClFN4O4 0.5H2O Requires C 58.7 H 4.4 N 11.5% - 1,1′-(azodicarbonyl)dipiperidine (1.68 g, 6 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (640 mg, 2 mmol), 4-hydroxymethyl-2-(methylamino)pyridine (385 mg, 2.8 mmol) and tributylphosphine (1.6 ml, 6 mmol) in methylene chloride (50 ml) at 0° C. The mixture was allowed to warm to ambient temperature over 2 hours, the insolubles were removed by filtration and the filtrate was washed with water and brine, dried (Na2SO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (10:0 increasing to 9:1). The purified product was dissolved in acetone/methanol and a 1M solution of ethereal hydrogen chloride was added. The resulting precipitate was collected by filtration and dried to give 4-(4-chloro-2-fluoroanilino)-7-(2-(methylamino)pyrid-4-yl)methoxy-6-methoxyquinazoline hydrochloride (395 mg, 45%).
-
- MS-ESI: 440 [MH]+
- The starting material was prepared as follows:
- A mixture of 2-chloro-4-hydroxymethylpyridine (1.0 g, 7 mmol), (prepared as described for the starting material in Example 58), and methylamine (30 ml of a 30% solution in ethanol) was heated in a Carius tube for 16 hours at 200° C. The mixture was allowed to cool and the mixture partitioned between saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was separated, dried (MgSO4) and the volatiles removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate to give 4-hydroxymethyl-2-(methylamino)pyridine (440 mg, 46%) as a yellow oil.
-
- 1,1′-(azodicarbonyl)dipiperidine (1.68 g, 6 mmol) was added in portions to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (640 mg, 2 mmol), 4-hydroxymethyl-2-(dimethylamino)pyridine (426 mg, 2.8 mmol) and tributylphosphine (1.6 ml, 6 mmol) in methylene chloride (50 ml) at 0° C. The mixture was allowed to warm to ambient temperature over 2 hours, the insolubles were removed by filtration and the filtrate was washed with water and brine, dried (Na2SO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (100:0 increasing to 95:5). The purified product was dissolved in acetone/methanol and a 1M solution of ethereal hydrogen chloride was added. The resulting precipitate was collected by filtration and dried to give 4-(4-chloro-2-fluoroanilino)-7-(2-(dimethylamino)pyrid-4-yl)methoxy-6-methoxyquinazoline hydrochloride (305 mg, 30%).
- m.p. 290° C.
-
- MS-ESI: 454 [MH]+
Elemental analysis: Found C 47.2 H 4.9 N 12.1 C23H21ClFN5O2 3 HCl H2O Requires C 47.6 H 4.5 N 12.1% - The starting material was prepared as follows:
- A mixture of 2-chloro-4-hydroxymethylpyridine (1.0 g, 7 mmol), (prepared as described for the starting material in Example 58), and dimethylamine (30 ml of a 30% solution in ethanol) was heated in a Carius tube for 16 hours at 200° C. The mixture was allowed to cool and the mixture partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried (MgSO4) and the volatiles removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate to give 4-hydroxymethyl-2-(dimethylamino)pyridine (1 g, 94%) as a yellow oil.
-
- MS-ESI: 153 [MH]+
- A mixture of 4-(3-hydroxyprop-2-en-1-yl)pyridine (180 mg, 1.3 mmol) and thionyl chloride (0.3 ml) in toluene (10 ml) was stirred at room temperature for 2 hours. The volatiles were removed by evaporation to give crude 4-(3-chloroprop-2-en-1-yl)pyridine hydrochloride (180 mg, 0.94 mmol)) This product was added to a mixture of 4-(4-chloro-2-fluoroanilino)-7-hydroxy-6-methoxyquinazoline (500 mg, 1.6 mmol) and potassium carbonate (500 mg, 4.9 mmol) in DMF (20 ml) and the mixture stirred at 100° C. for 1 hour. The reaction mixture was allowed to cool and partitioned between ethyl acetate and water. The organic layer was 0 separated, washed with water and brine, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (100/0 increasing to 95/5) and then by reverse phase (C18) HPLC eluting with methanol/water (30/70 increasing to 50/50) to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-(pyrid-4-yl)prop-2-en-1-yloxy)quinazoline (15 mg, 4%).
-
- MS-ESI: 437 [MH]+
- The starting material was prepared as follows:
- n-Butyllithium (25 ml of a 1.6M solution in hexane, 40 mmol) was added dropwise to a stirred suspension of 2-hydroxyethyltriphenylphosphonium bromide (7.74 g, 20 mmol) in THF (50 ml) at −70° C. and the mixture allowed to warm to −30° C. and stirred for 2 hours. 4-Pyridinecarboxaldehyde (2.16 g, 20 mmol) was added to the resulting red solution. and the mixture stirred for 1 hour at −30° C. and then cooled to −70° C. n-Butyllithium (12.5 ml of a 1.6M solution in hexane, 20 mmol) was added and the reaction mixture stirred at −70° C. for 1 hour. The mixture was quenched with isopropanol and allowed to warm to ambient temperature. Saturated aqueous ammonium chloride solution was added, the organic layer separated and the aqueous layer extracted with ethyl acetate (3×50 ml). The combined extracts were washed with brine and dried (MgSO4) and the volatiles removed by evaporation. The residue was purified by column chromatography eluting with ethyl acetate to give 4-(3-hydroxyprop-2-en-1-yl)pyridine
- MS-ESI: 136 [MH]+
- A suspension of 4-chloro-7-(2-(1,2,4-triazol-1-yl)ethoxy)-6-methoxyquinazoline (214 mg, 0.7 mmol), 4-bromo-2-fluoroaniline (160 mg, 0.84 mmol) in isopropanolic hydrogen chloride (1 ml of a 5M solution) and isopropanol (5 ml) was heated at 80° C. for 1 hour. The mixture was allowed to cool, the precipitate was collected by filtration, washed with isopropanol and then ether and dried under vacuum at 70° C. to give 4-(4-bromo-2-fluoroanilino)-7-(2-(1,2,4-triazol-1-yl)ethoxy)-6-methoxyquinazoline hydrochloride: (55 mg, 15%).
-
- MS-ESI: 459 [MH]+
Elemental analysis Found C 41.8 H 3.4 N 15.6 C19H16BrFN6O2 0.8H2O 1.9HCl Requires C 42.0 H 3.6 N 15.5% - The starting material was prepared as follows:
- Diethyl azodicarboxylate (1.1 ml, 7 mmol) was added dropwise to a solution of 7-hydroxy-6-methoxy-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one-(1.7 g, 5.55 mmol), 2-(1,2,4-triazol-1-yl)ethanol (791 mg, 7 mmol), (Ann. Pharm. Fr. 1977,35,503-508) and triphenylphosphine (1.8 g, 7 mmol) cooled at 5° C. The mixture was allowed to warm to ambient temperature and stirred for 1 hour. The mixture was poured directly on to a column of silica and eluted with methylene chloride/methanol (95/5) to give 6-methoxy-3-((pivaloyloxy)methyl)-7-(2-(1,2,4-triazol-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (1.64 g, 74%).
-
- MS-ESI: 424 [MNa]+
Elemental analysis Found C 56.5 H 6.0 N 17.6 C19H23N5O5 Requires C 56.9 H 5.8 N 17.% - A solution of 6-methoxy-3-((pivaloyloxy)methyl)-7-(2-(1,2,4-triazol-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (1.6 g, 4 mmol) in saturated methanolic ammonia (25 ml) was stirred at ambient temperature for 2 days. The volatiles were removed by evaporation, the solid residue was triturated with ether, collected by filtration and dried under vacuum to give 6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (1.11 g, 98%)
-
- MS-EI: 287 [M]+
Elemental analysis Found C 53.9 H 4.6 N 24.6 C13H13N5O3 Requires C 54.4 H 4.6 N 24.4 - A solution of 6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)-3,4-dihydroquinazolin-4-one (1.11 g, 3.86 mmol) and DMF (0.6 ml) in thionyl chloride (15 ml) was heated at reflux for 1 hour. The mixture was allowed to cool, toluene was added and the volatiles were removed by evaporation. The residue was partitioned between methylene chloride and water and the aqueous layer was adjusted to pH8.5 with saturated aqueous sodium hydrogen carbonate solution. The organic layer was separated, washed with brine, dried (MgSO4), and the solvent removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/methanol (95/5). The purified solid was triturated with ether, collected by filtration, washed with water and then ether, and dried under vacuum to give 4-chloro-6-methoxy-7-(2-(1,2,4-triazol-1-yl)ethoxy)quinazoline (756 mg, 65%).
-
- MS-ESI: 306 [MH]+
- The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:
(a) Tablet I mg/tablet Compound X 100 Lactose Ph.Eur 182.75 Croscarmellose sodium 12.0 Maize starch paste (5% w/v paste) 2.25 Magnesium stearate 3.0 (b) Tablet II mg/tablet Compound X 50 Lactose Ph.Eur 223.75 Croscarmellose sodium 6.0 Maize starch 15.0 Polyvinylpyrrolidone (5% w/v paste) 2.25 Magnesium stearate 3.0 (c) Tablet III mg/tablet Compound X 1.0 Lactose Ph.Eur 93.25 Croscarmellose sodium 4.0 Maize starch paste (5% w/v paste) 0.75 Magnesium stearate 1.0 (d) Capsule mg/capsule Compound X 10 Lactose Ph.Eur 488.5 Magnesium stearate 1.5 (e) Injection I (50 mg/ml) Compound X 5.0% w/v 1N Sodium hydroxide solution 15.0% v/v 0.1N Hydrochloric acid (to adjust pH to 7.6) Polyethylene glycol 400 4.5% w/v Water for injection to 100% (f) Injection II (10 mg/ml) Compound X 1.0% w/v Sodium phosphate BP 3.6% w/v 0.1N Sodium hydroxide solution 15.0% v/v Water for injection to 100% (g) Injection III (1 mg/ml, buffered to pH6) CompoundX 0.1% w/v Sodium phosphate BP 2.26% w/v Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection to 100%
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/877,005 US6362336B1 (en) | 1995-12-18 | 2001-06-11 | Chemical compounds |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95402846.0 | 1995-12-18 | ||
EP95402846 | 1995-12-18 | ||
EP95402846 | 1995-12-18 | ||
EP96402190 | 1996-10-15 | ||
EP96402190 | 1996-10-15 | ||
EP96402190.1 | 1996-10-15 | ||
US08/768,887 US5962458A (en) | 1995-12-18 | 1996-12-17 | Substituted quinazolines |
US09/203,764 US6071921A (en) | 1995-12-18 | 1998-12-02 | Chemical compounds |
US09/500,470 US6258951B1 (en) | 1995-12-18 | 2000-02-09 | Chemical compounds |
US09/877,005 US6362336B1 (en) | 1995-12-18 | 2001-06-11 | Chemical compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/500,470 Division US6258951B1 (en) | 1995-12-18 | 2000-02-09 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020032208A1 true US20020032208A1 (en) | 2002-03-14 |
US6362336B1 US6362336B1 (en) | 2002-03-26 |
Family
ID=26140602
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/768,887 Expired - Lifetime US5962458A (en) | 1995-12-18 | 1996-12-17 | Substituted quinazolines |
US09/203,764 Expired - Lifetime US6071921A (en) | 1995-12-18 | 1998-12-02 | Chemical compounds |
US09/500,470 Expired - Lifetime US6258951B1 (en) | 1995-12-18 | 2000-02-09 | Chemical compounds |
US09/877,005 Expired - Lifetime US6362336B1 (en) | 1995-12-18 | 2001-06-11 | Chemical compounds |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/768,887 Expired - Lifetime US5962458A (en) | 1995-12-18 | 1996-12-17 | Substituted quinazolines |
US09/203,764 Expired - Lifetime US6071921A (en) | 1995-12-18 | 1998-12-02 | Chemical compounds |
US09/500,470 Expired - Lifetime US6258951B1 (en) | 1995-12-18 | 2000-02-09 | Chemical compounds |
Country Status (29)
Country | Link |
---|---|
US (4) | US5962458A (en) |
EP (1) | EP0873319B1 (en) |
JP (1) | JP4291413B2 (en) |
KR (1) | KR100530311B1 (en) |
CN (1) | CN1133625C (en) |
AT (1) | ATE203524T1 (en) |
AU (1) | AU712370B2 (en) |
BR (1) | BR9612043A (en) |
CA (1) | CA2237005C (en) |
CZ (1) | CZ291100B6 (en) |
DE (1) | DE69614147T2 (en) |
DK (1) | DK0873319T3 (en) |
ES (1) | ES2162656T3 (en) |
GB (1) | GB9624482D0 (en) |
GR (1) | GR3036954T3 (en) |
HU (1) | HUP9901243A3 (en) |
IL (1) | IL124925A0 (en) |
MX (1) | MX9804247A (en) |
MY (1) | MY132405A (en) |
NO (1) | NO311358B1 (en) |
NZ (1) | NZ324007A (en) |
PL (1) | PL192309B1 (en) |
PT (1) | PT873319E (en) |
RU (1) | RU2194701C2 (en) |
SI (1) | SI0873319T1 (en) |
SK (1) | SK282443B6 (en) |
TR (1) | TR199801115T2 (en) |
TW (1) | TW411274B (en) |
WO (1) | WO1997022596A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020173509A1 (en) * | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US20050107358A1 (en) * | 2003-02-20 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20070054928A1 (en) * | 2003-09-26 | 2007-03-08 | Exelixis, Inc. | c-Met modulators and methods of use |
US20090318480A1 (en) * | 2006-09-18 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US20090318373A1 (en) * | 2002-07-15 | 2009-12-24 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
US20100069414A1 (en) * | 1999-06-21 | 2010-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US9089571B2 (en) | 2005-11-11 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US10736886B2 (en) | 2009-08-07 | 2020-08-11 | Exelixis, Inc. | Methods of using c-Met modulators |
Families Citing this family (520)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228871B1 (en) | 1995-07-10 | 2001-05-08 | Merck & Co., Inc. | Angiogenesis inhibitors |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
TR199801530T2 (en) | 1996-02-13 | 1998-11-23 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors. |
PT885198E (en) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | 4-ANYLINOQUINAZOLINE DERIVATIVES |
PL190489B1 (en) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
JP3404749B2 (en) | 1996-06-27 | 2003-05-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | N- [4- (heteroarylmethyl) phenyl] -heteroarylamine |
DE69733825T2 (en) | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | CHINOLIN DERIVATIVES VEZÖGERN THE EFFECT OF GROWTH FACTORS SUCH AS VEGF |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
JP2009007364A (en) * | 1996-10-15 | 2009-01-15 | Astrazeneca Uk Ltd | Quinazoline derivative |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
DE69838172T2 (en) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2772763B1 (en) * | 1997-12-24 | 2004-01-23 | Sod Conseils Rech Applic | NOVEL TETRACYCLIC CAMPTOTHECIN ANALOGS, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
OA12147A (en) | 1998-06-02 | 2006-05-05 | Osi Pharm Inc | PyrroloÄ2,3dÜpyrimidine compositions and their use. |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US20040067227A1 (en) * | 2001-11-02 | 2004-04-08 | Goldstein Allan L. | Inhibition or reversal of skin aging by actin-sequestering peptides |
JP3270834B2 (en) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
HU230000B1 (en) | 1999-02-10 | 2015-04-28 | Astrazeneca Ab | Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
WO2001021596A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
PL354923A1 (en) * | 1999-09-21 | 2004-03-22 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
SE9903544D0 (en) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
UA72946C2 (en) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf) |
UA74803C2 (en) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use |
JP2003518023A (en) | 1999-11-30 | 2003-06-03 | パーカー ヒューズ インスティテュート | Inhibitors of thrombin-induced platelet aggregation |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
JP2003521543A (en) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
AUPQ592100A0 (en) * | 2000-02-29 | 2000-03-23 | Council Of The Queensland Institute Of Medical Research, The | A method of treatment and prophylaxis |
US7498335B2 (en) | 2000-03-06 | 2009-03-03 | Astrazeneca Ab | Method of producing an antiangiogenic or vascular permeability reducing effect |
US20070021392A1 (en) * | 2000-03-31 | 2007-01-25 | Davis Peter D | Divided dose therapies with vascular damaging activity |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
JP4970689B2 (en) * | 2000-04-07 | 2012-07-11 | アストラゼネカ アクチボラグ | Quinazoline compounds |
UA73993C2 (en) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition |
AR028948A1 (en) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | NEW COMPOUNDS |
CA2419301C (en) | 2000-08-21 | 2009-12-08 | Astrazeneca Ab | Quinazoline derivatives |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042058A1 (en) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
AU2001293233A1 (en) * | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
BRPI0113757B8 (en) | 2000-09-11 | 2017-11-07 | Chiron Corp | quinolinone derivatives as tyrosine kinase inhibitors |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
SE0003828D0 (en) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
JP4564713B2 (en) | 2000-11-01 | 2010-10-20 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof |
WO2002043735A1 (en) * | 2000-11-29 | 2002-06-06 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US6680324B2 (en) * | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
PL214667B1 (en) | 2000-12-21 | 2013-08-30 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
ATE464322T1 (en) | 2001-01-05 | 2010-04-15 | Pfizer | ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR RECEPTOR I |
US20070050857A1 (en) * | 2001-02-28 | 2007-03-01 | Hayward Nick K | Method of treatment and prophylaxis |
MXPA03008560A (en) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Single-stage pfc + ballast control circuit/general purpose power converter. |
WO2002092578A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
JP4836368B2 (en) * | 2001-08-30 | 2011-12-14 | 広栄化学工業株式会社 | Method for producing methylhydroxyalkylpyridines |
CN100343238C (en) * | 2001-11-03 | 2007-10-17 | 阿斯特拉曾尼卡有限公司 | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
DE60234118D1 (en) * | 2001-11-30 | 2009-12-03 | Osi Pharm Inc | Compounds specific for adenosine A1 and A3 receptors and their applications |
ATE519748T1 (en) * | 2001-12-19 | 2011-08-15 | Ube Industries | METHOD FOR PRODUCING QUINAZOLIN-4-ONE AND DERIVATIVES THEREOF |
JP4440642B2 (en) | 2001-12-20 | 2010-03-24 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Pyrimidine A2b selective antagonist compounds, their synthesis and use |
CN101973998A (en) * | 2001-12-20 | 2011-02-16 | Osi药物公司 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
JP4389204B2 (en) * | 2002-01-28 | 2009-12-24 | 宇部興産株式会社 | Method for producing quinazolin-4-one derivative |
AU2003202094B2 (en) * | 2002-02-01 | 2009-10-08 | Astrazeneca Ab | Quinazoline compounds |
EP1483268A2 (en) | 2002-03-01 | 2004-12-08 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (en) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
US6936641B2 (en) * | 2002-06-25 | 2005-08-30 | Johnson & Johnson Vision Care, Inc. | Macromer forming catalysts |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
CN1688549A (en) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | Compound having TGF-beta inhibitory activity and medicinal composition containing the same |
EP2573079A3 (en) * | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
WO2004018435A1 (en) | 2002-08-24 | 2004-03-04 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
JP4593464B2 (en) * | 2002-11-04 | 2010-12-08 | アストラゼネカ アクチボラグ | Quinazoline derivatives as Src tyrosine kinase inhibitors |
WO2004043389A2 (en) * | 2002-11-13 | 2004-05-27 | Chiron Corporation | Methods of treating cancer and related methods |
OA12977A (en) | 2002-12-19 | 2006-10-13 | Pfizer | 2-(1H-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthamic diseases. |
ATE438644T1 (en) | 2002-12-24 | 2009-08-15 | Astrazeneca Ab | CHINAZOLINE DERIVATIVES |
PL216368B1 (en) | 2003-02-26 | 2014-03-31 | Sugen | Aminoheteroaryl compounds as protein kinase inhibitors |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
CA2876822C (en) | 2003-08-27 | 2015-11-17 | David Shima | Combination therapy for the treatment of ocular neovascular disorders |
WO2005021554A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
JP2007505873A (en) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | Quinazoline derivatives as tyrosine kinase inhibitors |
PL1667991T3 (en) | 2003-09-16 | 2008-12-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0414532B1 (en) * | 2003-09-19 | 2018-06-05 | Astrazeneca Ab | QUINAZOLIN DERIVATIVE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION, AND USE OF A QUINAZOLIN DERIVATIVE COMPOUND |
BRPI0414735A (en) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | quinazoline derivative, compound, pharmaceutical composition, use of quinazoline derivative, method for producing an antiproliferative effect on a warm-blooded animal, and process for the preparation of a quinazoline derivative |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
CN1898240B (en) * | 2003-10-15 | 2011-08-03 | Osi制药公司 | Imidazopyrazine tyrosine kinase inhibitors |
WO2005046590A2 (en) * | 2003-11-07 | 2005-05-26 | Chiron Corporation | Methods for synthesizing quinolinone compounds |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
NZ547009A (en) | 2003-12-23 | 2009-09-25 | Pfizer | Novel quinoline derivatives |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
WO2005066163A2 (en) | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
TW200536851A (en) * | 2004-01-23 | 2005-11-16 | Amgen Inc | Compounds and methods of use |
JP5019884B2 (en) * | 2004-02-20 | 2012-09-05 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Regulation of inflammatory and metastatic processes |
TW200538120A (en) * | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
CA2561950C (en) | 2004-04-02 | 2010-04-20 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
DK1746999T3 (en) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
WO2005118572A1 (en) * | 2004-06-04 | 2005-12-15 | Astrazeneca Ab | Quinazoline derivatives as erbb receptor tyrosine kinases |
SE0401657D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
BRPI0513200A (en) | 2004-07-16 | 2008-04-29 | Pfizer Prod Inc | use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
PT1786785E (en) | 2004-08-26 | 2010-05-21 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
MX2007002240A (en) | 2004-08-28 | 2007-04-20 | Astrazeneca Ab | Pyrimidine sulphonamide derivatives as chemokine receptor modulators. |
MX2007006230A (en) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolines and quinazoline analogs and their use as medicaments for treating cancer. |
JP4881875B2 (en) | 2004-12-14 | 2012-02-22 | アストラゼネカ アクチボラグ | Pyrazolopyrimidine compounds as antitumor agents |
CA2595610C (en) | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
KR101387985B1 (en) * | 2005-01-27 | 2014-04-25 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | Treatment of metastasized tumors |
CN101155800B (en) | 2005-02-04 | 2012-05-23 | 阿斯利康(瑞典)有限公司 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
EP1854789B1 (en) * | 2005-02-23 | 2013-10-09 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
AU2006217738A1 (en) * | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
EP1863848A4 (en) | 2005-03-31 | 2009-09-23 | Agensys Inc | Antibodies and related molecules that bind to 161p2f10b proteins |
UA95775C2 (en) | 2005-04-26 | 2011-09-12 | Пфайзер Инк. | Antibody that specifically binds to p-cadherin |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
CN1858040B (en) * | 2005-05-08 | 2011-04-06 | 中国科学院上海药物研究所 | 5,8-disubstituted quinazoline and its preparing method and use |
MX2007014206A (en) | 2005-05-13 | 2008-02-07 | Novartis Ag | Methods for treating drug resistant cancer. |
MX2007014381A (en) * | 2005-05-17 | 2008-02-06 | Novartis Ag | Methods for synthesizing heterocyclic compounds. |
CN101626767A (en) | 2005-05-18 | 2010-01-13 | 阵列生物制药公司 | The heterocycle inhibitor of MEK and using method thereof |
EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
BRPI0613563A2 (en) | 2005-07-21 | 2012-01-17 | Astrazeneca Ab | new piperidine derivatives |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
KR101536506B1 (en) | 2005-09-07 | 2015-07-14 | 암젠 프레몬트 인코포레이티드 | Human monoclonal antibodies to activin receptor-like kinase-1 |
JP2009508918A (en) | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 4- (1H-indazol-5-yl] amino) quinazoline compounds as erbB receptor tyrosine kinase inhibitors for cancer therapy |
JP5055284B2 (en) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Biological markers for predicting anti-cancer responses to insulin-like growth factor-1 receptor kinase inhibitors |
WO2007034143A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
US20090192153A1 (en) | 2005-09-22 | 2009-07-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
WO2007034917A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
US8148572B2 (en) | 2005-10-06 | 2012-04-03 | Astrazeneca Ab | Compounds |
CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
CA2632194C (en) | 2005-11-15 | 2012-01-03 | Array Biopharma Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
CN102670530A (en) | 2005-11-29 | 2012-09-19 | 诺瓦提斯公司 | Formulations of quinolinones |
AR057960A1 (en) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
JP2009517450A (en) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
WO2007063293A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
TW200730512A (en) | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
ATE552853T1 (en) | 2005-12-13 | 2012-04-15 | Medimmune Ltd | PROTEINS THAT SPECIFICALLY BIND INSULIN-LIKE GROWTH FACTORS AND THEIR APPLICATIONS |
TW200732296A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Novel compounds |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
BRPI0711358A2 (en) | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | cycloalkylamino acid derivatives and their pharmaceutical compositions |
EP2125722A2 (en) | 2006-05-26 | 2009-12-02 | AstraZeneca AB | Bi-aryl or aryl-heteroaryl substituted indoles |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
DE102006037478A1 (en) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2- (Heterocyclylbenzyl) -pyridazinone derivatives |
MX2009001946A (en) | 2006-08-23 | 2009-03-05 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors. |
US7851623B2 (en) * | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
EP1921070A1 (en) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
US7799954B2 (en) | 2006-11-17 | 2010-09-21 | Abraxis Bioscience, Llc | Dicarbonyl derivatives and methods of use |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
JP4604129B2 (en) | 2006-12-19 | 2010-12-22 | アストラゼネカ・アクチエボラーグ | Quinuclidinol derivatives as muscarinic receptor antagonists |
CL2008000191A1 (en) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER. |
EA200901041A1 (en) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
TW200902018A (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
DE102007025718A1 (en) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | pyridazinone derivatives |
DE102007025717A1 (en) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Aryl ether pyridazinone derivatives |
DE102007026341A1 (en) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
UA100983C2 (en) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Biphenyloxypropanoic acid as crth2 modulator and intermediates |
DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
DE102007038957A1 (en) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-thioxo-pyridazine derivatives |
DE102007041115A1 (en) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
ES2424745T3 (en) | 2007-09-07 | 2013-10-08 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
EP2207788A1 (en) | 2007-10-04 | 2010-07-21 | AstraZeneca AB | Steroidal [3, 2-c]pyrazole compounds, with glucocorticoid activity |
TWI453021B (en) | 2007-10-11 | 2014-09-21 | Astrazeneca Ab | Novel protein kinase b inhibitors |
CN101945870B (en) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-anilinoimidazopyridines and methods of use |
DE102007061963A1 (en) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | pyridazinone derivatives |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
US8486963B2 (en) | 2007-12-21 | 2013-07-16 | Genentech, Inc. | Azaindolizines and methods of use |
MX343594B (en) | 2007-12-21 | 2016-11-11 | Medimmune Ltd | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) - 173. |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
WO2009094210A1 (en) * | 2008-01-22 | 2009-07-30 | Concert Pharmaceuticals Inc. | Vandetanib derivatives |
JP2011510079A (en) * | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | Gefitinib derivative |
AU2009211523B2 (en) | 2008-02-07 | 2014-03-13 | Boehringer Ingelheim International Gmbh | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
ES2401550T3 (en) | 2008-02-28 | 2013-04-22 | Merck Patent Gmbh | Protein kinase inhibitors and use thereof |
DE102008019907A1 (en) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | pyridazinone derivatives |
JP5739802B2 (en) | 2008-05-13 | 2015-06-24 | アストラゼネカ アクチボラグ | 4- (3-Chloro-2-fluoroanilino) -7-methoxy-6-{[1- (N-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline fumarate |
ES2396613T3 (en) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopyrazines and substituted imidazotriazines |
DK2297106T3 (en) | 2008-05-27 | 2014-10-06 | Astrazeneca Ab | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASES |
DE102008025750A1 (en) | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | Dihydropyrazolderivate |
DE102008028905A1 (en) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
DE102008029734A1 (en) | 2008-06-23 | 2009-12-24 | Merck Patent Gmbh | Thiazolyl-piperidine derivatives |
UY31952A (en) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-METHYLIDENE-1,3-THIAZOLIDINE-2,4-DIONAS REPLACED AS PIM QUINASE INHIBITORS |
US8648191B2 (en) | 2008-08-08 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
DE102008037790A1 (en) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclic triazole derivatives |
DE102008038221A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-azaindole derivatives |
US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
JP5836125B2 (en) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Fully human antibodies against high molecular weight melanoma-related antigens and uses thereof |
DE102008052943A1 (en) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | azaindole derivatives |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
US9012495B2 (en) | 2008-12-11 | 2015-04-21 | Axcentua Pharmaceuticals Ab | Crystalline forms of genistein |
US7863325B2 (en) | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
US20100152197A1 (en) | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
AU2009333653B2 (en) | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
ES2603208T3 (en) | 2008-12-18 | 2017-02-24 | Merck Patent Gmbh | Tricyclic azaindoles |
DE102008063667A1 (en) | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives |
EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
DE102008062825A1 (en) | 2008-12-23 | 2010-06-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
DE102008062826A1 (en) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | pyridazinone derivatives |
DE102009003954A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | pyridazinone derivatives |
DE102009003975A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
DE102009004061A1 (en) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | pyridazinone derivatives |
MX368362B (en) | 2009-02-05 | 2019-09-30 | Immunogen Inc | Novel benzodiazepine derivatives. |
WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
UY32520A (en) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR |
CN102405214A (en) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | Preparation of c-pyrazine-methylamines |
JP2012526138A (en) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Use of OSI-906 to treat adrenocortical cancer |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
WO2011008696A2 (en) | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
WO2011014726A1 (en) | 2009-07-31 | 2011-02-03 | Osi Pharmaceuticals, Inc. | Mtor inhibitor and angiogenesis inhibitor combination therapy |
WO2011027249A2 (en) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Benzimidazole derivatives |
RU2012114094A (en) | 2009-09-11 | 2013-10-20 | Дженентек, Инк. | METHOD FOR IDENTIFICATION OF A PATIENT WITH AN INCREASED PROBABILITY OF ANSWER TO ANTI-CANCER AGENT |
ES2530732T3 (en) | 2009-09-17 | 2015-03-05 | Hoffmann La Roche | Diagnostic procedures for lung cancer |
DE102009043260A1 (en) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives |
KR20120099639A (en) | 2009-10-02 | 2012-09-11 | 아스트라제네카 아베 | 2-pyridone compounds used as inhibitors of neutrophil elastase |
DE102009049679A1 (en) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
AU2010311321B2 (en) | 2009-10-30 | 2014-11-27 | Prexton Therapeutics S.A. | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
CA2777746C (en) | 2009-11-18 | 2019-05-14 | Astrazeneca Ab | Benzoimidazole compounds and uses thereof |
KR101790767B1 (en) | 2009-11-24 | 2017-10-26 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
KR20120093428A (en) | 2009-12-14 | 2012-08-22 | 메르크 파텐트 게엠베하 | Sphingosine kinase inhibitors |
DE102009058280A1 (en) | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | thiazole |
WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
SG181643A1 (en) | 2009-12-17 | 2012-07-30 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
WO2011085641A1 (en) | 2010-01-15 | 2011-07-21 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
MX2012008328A (en) | 2010-01-19 | 2012-08-08 | Astrazeneca Ab | Pyrazine derivatives. |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
LT3150610T (en) | 2010-02-12 | 2019-11-11 | Pfizer | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
CN103068851B (en) | 2010-06-16 | 2015-03-11 | 高等教育联邦***-匹兹堡大学 | Antibodies to endoplasmin and their use |
CN104569395A (en) | 2010-07-19 | 2015-04-29 | 霍夫曼-拉罗奇有限公司 | Method to identify patient with increased likelihood of responding to anti-cancer therap |
KR20130091745A (en) | 2010-07-19 | 2013-08-19 | 에프. 호프만-라 로슈 아게 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012012750A1 (en) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
TW201219383A (en) | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
DE102010034699A1 (en) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | pyrimidine derivatives |
CN102656179B (en) | 2010-08-28 | 2015-07-29 | 苏州润新生物科技有限公司 | Bufalin derivative, its pharmaceutical composition and purposes |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
DE102010048800A1 (en) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | quinoxaline |
JP5802756B2 (en) | 2010-10-20 | 2015-11-04 | ファイザー・インク | Pyridine-2-derivatives as smoothened receptor modulators |
DE102010049595A1 (en) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | quinazoline derivatives |
JP2013542916A (en) | 2010-11-19 | 2013-11-28 | 大日本住友製薬株式会社 | Cyclic amide compounds and their use in the treatment of diseases |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
ES2575688T3 (en) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy |
JP5978226B2 (en) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | Purine derivatives |
BR112013015508B1 (en) | 2010-12-20 | 2022-04-05 | Medimmune Limited | Antibody molecule to human il-18, isolated vh domain and isolated vl domain, composition, use of an antibody molecule or isolated vh domain and isolated vl domain, isolated nucleic acid molecule, recombinant prokaryotic host cell, method for producing an antibody, and in vitro method for measuring il-18 in a sample from an individual |
EP2670763B1 (en) | 2011-02-02 | 2018-08-01 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
EP3666289A1 (en) | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
UY34013A (en) | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ? CHROMENONE COMPOUNDS WITH ANTI-TUMORAL ACTIVITY ?. |
US20140178368A1 (en) | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
MX342874B (en) | 2011-07-12 | 2016-10-17 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator. |
PL3409278T3 (en) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
SG10201910984XA (en) | 2011-07-27 | 2020-01-30 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
DE102011111400A1 (en) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclic heteroaromatic compounds |
US9295671B2 (en) | 2011-08-26 | 2016-03-29 | Neupharma, Inc. | Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer |
EP2753174A4 (en) | 2011-09-01 | 2015-05-20 | Xiangping Qian | Certain chemical entities, compositions, and methods |
JP6093768B2 (en) | 2011-09-14 | 2017-03-08 | ニューファーマ, インコーポレイテッド | Specific chemical entities, compositions and methods |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
PE20141228A1 (en) | 2011-09-22 | 2014-10-01 | Pfizer | DERIVATIVES OF PYRROLOPYRIMIDINE AND PURINE |
US20140235573A1 (en) | 2011-09-29 | 2014-08-21 | The University Of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
US9249111B2 (en) | 2011-09-30 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-RAF kinase inhibitors |
WO2013050725A1 (en) | 2011-10-04 | 2013-04-11 | King's College London | Ige anti -hmw-maa antibody |
WO2013068902A1 (en) | 2011-11-08 | 2013-05-16 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-m-csf antibodies |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2862694C (en) | 2012-01-28 | 2020-07-28 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
PT2812323T (en) | 2012-02-09 | 2016-07-13 | Merck Patent Gmbh | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
WO2013117285A1 (en) | 2012-02-09 | 2013-08-15 | Merck Patent Gmbh | Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors |
AU2013224420B2 (en) | 2012-02-21 | 2016-12-15 | Merck Patent Gmbh | Furopyridine derivatives |
EP2817306B1 (en) | 2012-02-21 | 2015-09-16 | Merck Patent GmbH | Cyclic diaminopyrimidine derivatives as syk inhibitors |
EP2817310B1 (en) | 2012-02-21 | 2018-03-21 | Merck Patent GmbH | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
JP6049768B2 (en) | 2012-03-07 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Triazolopyrazine derivatives |
PL2831077T3 (en) | 2012-03-28 | 2016-10-31 | Bicyclic pyrazinone derivatives | |
WO2013144532A1 (en) | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |
EP2834273B1 (en) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2852285B1 (en) | 2012-04-29 | 2018-08-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer |
CN104271580B (en) | 2012-05-04 | 2017-02-22 | 默克专利股份公司 | Pyrrolotriazinone derivatives |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
ES2611788T3 (en) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use |
CN104507957B (en) | 2012-07-24 | 2018-12-25 | 默克专利股份有限公司 | For treating the hydroxyl statin derivative of arthropathy |
JP6374384B2 (en) | 2012-08-07 | 2018-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Pyridopyrimidine derivatives as protein kinase inhibitors |
PL2882714T3 (en) | 2012-08-08 | 2020-02-28 | Merck Patent Gmbh | (aza-)isoquinolinone derivatives |
CA2882158A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
SG11201501464TA (en) | 2012-08-31 | 2015-03-30 | Sutro Biopharma Inc | Modified amino acids comprising an azido group |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
EP2897618B1 (en) | 2012-09-24 | 2021-11-17 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9388142B2 (en) | 2012-09-26 | 2016-07-12 | Merck Patent Gmbh | Quinazolinone derivatives as PARP inhibitors |
EP2911692B1 (en) | 2012-10-26 | 2019-08-21 | The University of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
WO2014066955A1 (en) | 2012-11-05 | 2014-05-08 | Lindley Robyn Alice | Methods for determining the cause of somatic mutagenesis |
EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2891484A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | 3-aminocyclopentane carboxamide derivatives |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AU2014211962B2 (en) | 2013-01-31 | 2017-11-16 | Bellus Health Cough Inc. | Imidazopyridine compounds and uses thereof |
EP2958901B1 (en) | 2013-02-25 | 2016-11-02 | Merck Patent GmbH | 2-amino-3,4-dihydro-quinazoline derivatives and their use as cathepsin d inhibitors |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP3566750A3 (en) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6409007B2 (en) | 2013-03-05 | 2018-10-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 9- (Aryl or heteroaryl) -2- (pyrazolyl, pyrrolidinyl or cyclopentyl) aminopurine derivatives as anticancer agents |
EP2970205B1 (en) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
WO2014144227A1 (en) | 2013-03-15 | 2014-09-18 | Magceutics, Inc. | Magnesium compositions and uses thereof for cancers |
WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US20160115146A1 (en) | 2013-06-07 | 2016-04-28 | Universite Catholique De Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
SG11201510369WA (en) | 2013-06-25 | 2016-01-28 | Univ Canberra | Methods and compositions for modulating cancer stem cells |
US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP3508204A1 (en) | 2013-08-23 | 2019-07-10 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
ES2851724T3 (en) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation |
US20160298197A1 (en) | 2013-10-01 | 2016-10-13 | Queensland University Of Technology | Kits and methods for diagnosis, screening, treatment and disease monitoring |
JP6946000B2 (en) | 2013-10-04 | 2021-10-06 | アプトース バイオサイエンシーズ, インコーポレイテッド | Compositions and Methods for the Treatment of Cancer |
US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
GB201321146D0 (en) * | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
CN104829542B (en) * | 2014-02-10 | 2018-02-02 | 中国科学院上海药物研究所 | Aniline pyrimidine class compound, its preparation method and medical usage |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
CN106536753B (en) | 2014-04-04 | 2020-07-21 | 中美冠科生物技术(太仓)有限公司 | Methods for determining responsiveness to MEK/ERK inhibitors |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
CA2947130C (en) | 2014-04-30 | 2018-10-02 | Pfizer Inc. | Cycloalkyl-linked diheterocycle derivatives |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
CN106999578B (en) | 2014-07-31 | 2022-03-04 | 美国政府(由卫生和人类服务部的部长所代表) | Human monoclonal antibodies against EPHA4 and uses thereof |
CN105330653A (en) * | 2014-08-11 | 2016-02-17 | 石药集团中奇制药技术(石家庄)有限公司 | Quinazoline derivatives |
CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
AU2015349613B2 (en) | 2014-11-17 | 2022-01-13 | The Council Of The Queensland Institute Of Medical Research | Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof |
ES2746839T3 (en) | 2014-12-18 | 2020-03-09 | Pfizer | Pyrimidine and triazine derivatives and their use as AXL inhibitors |
MA41179A (en) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | PARG INHIBITOR COMPOUNDS |
GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
CN107613769A (en) | 2015-02-17 | 2018-01-19 | 润新生物公司 | Some chemical entities, composition and method |
CA2982928A1 (en) | 2015-04-20 | 2016-10-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
CN107709344B (en) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | Nucleoside analogues for the treatment of flaviviridae and cancer |
EP4086264B1 (en) | 2015-05-18 | 2023-10-25 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
AU2016301315C1 (en) | 2015-08-03 | 2022-07-07 | Sumitomo Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
AU2016302384B2 (en) | 2015-08-04 | 2020-07-16 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
WO2017031551A1 (en) | 2015-08-26 | 2017-03-02 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
KR20180100125A (en) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | MAT2A inhibitor for treating MTAP null cancer |
US11708413B2 (en) | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
AU2017214761B2 (en) | 2016-02-01 | 2024-02-01 | Epiaxis Therapeutics Pty Ltd | Proteinaceous compounds and uses therefor |
GB201604182D0 (en) | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
BR112018068347A2 (en) | 2016-03-21 | 2019-01-15 | Astrazeneca Ab | cinolin-4-amine compounds and their use in cancer treatment |
SG11201807040WA (en) | 2016-04-07 | 2018-09-27 | Astrazeneca Ab | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
ES2925698T3 (en) | 2016-04-15 | 2022-10-19 | Cancer Research Tech Ltd | Heterocyclic compounds as RET kinase inhibitors |
GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
DK3490565T3 (en) | 2016-07-29 | 2022-07-11 | Rapt Therapeutics Inc | AZETIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF |
US10544106B2 (en) | 2016-08-15 | 2020-01-28 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018055402A1 (en) | 2016-09-22 | 2018-03-29 | Cancer Research Technology Limited | Preparation and uses of pyrimidinone derivatives |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
BR112019011284A2 (en) | 2016-12-05 | 2019-10-22 | Apros Therapeutics Inc | compound, pharmaceutical composition, methods of treating a condition, hbv and cancer, and, use of a compound. |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
AU2017379847B2 (en) | 2016-12-19 | 2022-05-26 | Sumitomo Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
US10407446B2 (en) | 2016-12-20 | 2019-09-10 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
CN110418789B (en) | 2017-02-01 | 2022-03-25 | 常州千红生化制药股份有限公司 | Derivatives of N-cycloalkyl/heterocycloalkyl-4- (imidazo [1,2-a ] pyridine) pyrimidin-2-amines as therapeutic agents |
WO2018162625A1 (en) | 2017-03-09 | 2018-09-13 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
JOP20190209A1 (en) | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
CN108864079B (en) | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | Triazine compound and pharmaceutically acceptable salt thereof |
US11161839B2 (en) | 2017-05-26 | 2021-11-02 | The Institute Of Cancer Research: Royal Cancer Hospital | 2-quinolone derived inhibitors of BCL6 |
WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
WO2019006157A1 (en) * | 2017-06-28 | 2019-01-03 | Vanderbilt University | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US11400160B2 (en) | 2017-07-05 | 2022-08-02 | E.P.O.S Iasis Research And Development Limited | Multifunctional conjugates |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
BR112020001978A2 (en) | 2017-08-01 | 2020-08-18 | Merck Patent Gmbh | thiazolopyridine derivatives as adenosine receptor antagonists |
EP3668882A1 (en) | 2017-08-18 | 2020-06-24 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
BR112020003594A2 (en) | 2017-08-21 | 2020-09-01 | Merck Patent Gmbh | benzimidazole derivatives as adenosine receptor antagonists |
TW201920123A (en) | 2017-08-21 | 2019-06-01 | 德商馬克專利公司 | Quinoxaline derivatives as adenosine receptor antagonists |
JP7196160B2 (en) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib |
JP7423513B2 (en) | 2017-09-18 | 2024-01-29 | ストロ バイオファーマ インコーポレーテッド | Anti-folate receptor α antibody conjugate and its use |
CN111344293A (en) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1, 3-dihydroimidazo [4, 5-c ] cinnolin-2-one compounds and their use in the treatment of cancer |
TWI702205B (en) | 2017-10-06 | 2020-08-21 | ***聯邦商拜奧卡德聯合股份公司 | Epidermal growth factor receptor inhibitors |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
BR112020009055A2 (en) | 2017-11-06 | 2020-11-03 | Rapt Therapeutics, Inc. | chemokine receptor modulators for positive cancer treatment for epstein-Barr virus |
EP3489222A1 (en) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazine salts, production processes and uses |
FI3488868T3 (en) | 2017-11-23 | 2023-10-20 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use |
EP3740484A4 (en) | 2018-01-15 | 2021-06-09 | Aucentra Holdings Pty Ltd | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
CN111971279A (en) | 2018-01-26 | 2020-11-20 | 拉普特医疗公司 | Chemokine receptor modulators and uses thereof |
EP3749310A4 (en) | 2018-02-08 | 2021-08-18 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
ES2939776T3 (en) | 2018-04-13 | 2023-04-26 | Cancer Research Tech Ltd | BCL6 inhibitors |
AU2019260793B2 (en) | 2018-04-27 | 2023-05-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
AR114910A1 (en) | 2018-06-04 | 2020-10-28 | Apros Therapeutics Inc | PYRIMIDINE COMPOUNDS CONTAINING ACID GROUPS |
GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
JP2021527051A (en) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | Pyrazolo-pyrimidine-amino-cycloalkyl compounds and their therapeutic use |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
MX2021000977A (en) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same. |
EP3852811A1 (en) | 2018-09-17 | 2021-07-28 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
US11084829B2 (en) | 2018-09-24 | 2021-08-10 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof |
CN112867715B (en) | 2018-10-25 | 2024-03-05 | 默克专利股份公司 | 5-azaindazole derivatives as adenosine receptor antagonists |
CN112912142A (en) | 2018-10-25 | 2021-06-04 | 默克专利股份公司 | 5-azaindazole derivatives as adenosine receptor antagonists |
GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
MX2021006544A (en) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer. |
EP3960858A4 (en) | 2018-12-25 | 2023-02-15 | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof |
AR117844A1 (en) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR |
JP2022520361A (en) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Pharmaceuticals containing heterocyclic protein kinase inhibitors |
EP3935049A1 (en) | 2019-03-07 | 2022-01-12 | Merck Patent GmbH | Carboxamide-pyrimidine derivatives as shp2 antagonists |
JP2022525149A (en) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure |
JP2022519923A (en) | 2019-03-22 | 2022-03-25 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Compositions comprising a PKM2 modulator and methods of treatment using it |
CN111747950B (en) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | Pyrimidine derivatives for the treatment of cancer |
EP3946618A1 (en) | 2019-04-05 | 2022-02-09 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
WO2020210384A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
CN114728910A (en) | 2019-08-31 | 2022-07-08 | 上海奕拓医药科技有限责任公司 | Pyrazole derivatives for FGFR inhibitor and preparation method thereof |
EP4031249A1 (en) | 2019-09-20 | 2022-07-27 | Ideaya Biosciences, Inc. | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
CA3162166A1 (en) | 2019-12-02 | 2021-06-10 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
EP4329818A1 (en) | 2021-04-30 | 2024-03-06 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
WO2022245061A1 (en) | 2021-05-17 | 2022-11-24 | 에이치케이이노엔 주식회사 | Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
WO2023131690A1 (en) | 2022-01-10 | 2023-07-13 | Merck Patent Gmbh | Substituted heterocycles as hset inhibitors |
GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023186881A1 (en) | 2022-03-29 | 2023-10-05 | Baden-Württemberg Stiftung Ggmbh | P38 map kinase inhibitors for use in the treatment of colorectal cancer |
GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
WO2023196432A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
DE68917485T2 (en) * | 1988-01-23 | 1995-02-09 | Kyowa Hakko Kogyo Kk | Pyridazinone derivatives and pharmaceutical preparations containing them. |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
CZ387292A3 (en) * | 1991-02-20 | 1994-04-13 | Pfizer | 2,4-diaminoquinazoline derivatives, process of their preparation and use as substances for increasing anti-tumorous activity |
DE4105518A1 (en) | 1991-02-22 | 1992-08-27 | Basf Ag | SULPHONYL DRUG DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DE69222637T2 (en) * | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | UP TO MONO AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH INHIBITING EFFECT ON EGF AND / OR PDGF RECEPTOR TYROSINKINASE |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
DE4208254A1 (en) * | 1992-03-14 | 1993-09-16 | Hoechst Ag | SUBSTITUTED PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL AND FUNGICIDE |
US5270466A (en) * | 1992-06-11 | 1993-12-14 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
DE4309613C2 (en) | 1993-03-24 | 1996-10-17 | Bfi Entsorgungstech | Device for distributing solid waste materials on a conveyor belt |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
CA2148082A1 (en) * | 1993-09-03 | 1995-03-09 | Daisuke Machii | Imidazoquinazoline derivatives |
GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
AU686843B2 (en) * | 1994-02-23 | 1998-02-12 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
DK0682027T3 (en) * | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidine derivatives with antiproliferative action |
TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
DE19503151A1 (en) * | 1995-02-01 | 1996-08-08 | Thomae Gmbh Dr K | New phenylamino substd. pyrimido-pyrimidine derivs. |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (en) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
WO1996029331A1 (en) * | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
WO1996030347A1 (en) * | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
WO1996031510A1 (en) * | 1995-04-03 | 1996-10-10 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
DE19513330A1 (en) * | 1995-04-03 | 1996-10-10 | Schering Ag | New process for the production of nucleosides |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US6020492A (en) * | 1995-05-12 | 2000-02-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
DE69531558T2 (en) * | 1995-06-07 | 2004-03-18 | Pfizer Inc. | HETEROCYCLIC CONDENSED PYRIMIDINE DERIVATIVES |
CA2222545A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
US6140332A (en) * | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
AR004010A1 (en) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | HETERO CYCLIC COMPOUNDS |
HUP9801177A3 (en) * | 1995-11-14 | 1998-11-30 | Pharmacia & Upjohn Spa | Tetrahydronaphthyl, indanyl and indolyl substituted pyrido[2,3-d]pyrimidine and purine derivatives, process for their preparation and pharmaceutical compositions containing them |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
-
1996
- 1996-11-25 GB GBGB9624482.7A patent/GB9624482D0/en active Pending
- 1996-12-13 AU AU11061/97A patent/AU712370B2/en not_active Ceased
- 1996-12-13 HU HU9901243A patent/HUP9901243A3/en unknown
- 1996-12-13 SI SI9630354T patent/SI0873319T1/en unknown
- 1996-12-13 PL PL327310A patent/PL192309B1/en not_active IP Right Cessation
- 1996-12-13 ES ES96941787T patent/ES2162656T3/en not_active Expired - Lifetime
- 1996-12-13 JP JP52256897A patent/JP4291413B2/en not_active Expired - Fee Related
- 1996-12-13 DE DE69614147T patent/DE69614147T2/en not_active Expired - Lifetime
- 1996-12-13 DK DK96941787T patent/DK0873319T3/en active
- 1996-12-13 EP EP96941787A patent/EP0873319B1/en not_active Expired - Lifetime
- 1996-12-13 NZ NZ324007A patent/NZ324007A/en not_active IP Right Cessation
- 1996-12-13 BR BR9612043-6A patent/BR9612043A/en not_active IP Right Cessation
- 1996-12-13 PT PT96941787T patent/PT873319E/en unknown
- 1996-12-13 TR TR1998/01115T patent/TR199801115T2/en unknown
- 1996-12-13 RU RU98113300/04A patent/RU2194701C2/en not_active IP Right Cessation
- 1996-12-13 CA CA002237005A patent/CA2237005C/en not_active Expired - Fee Related
- 1996-12-13 SK SK828-98A patent/SK282443B6/en not_active IP Right Cessation
- 1996-12-13 CN CNB961991100A patent/CN1133625C/en not_active Expired - Fee Related
- 1996-12-13 KR KR1019980704613A patent/KR100530311B1/en not_active IP Right Cessation
- 1996-12-13 AT AT96941787T patent/ATE203524T1/en active
- 1996-12-13 WO PCT/GB1996/003075 patent/WO1997022596A1/en not_active Application Discontinuation
- 1996-12-13 IL IL12492596A patent/IL124925A0/en not_active IP Right Cessation
- 1996-12-13 CZ CZ19981882A patent/CZ291100B6/en not_active IP Right Cessation
- 1996-12-17 TW TW085115569A patent/TW411274B/en not_active IP Right Cessation
- 1996-12-17 US US08/768,887 patent/US5962458A/en not_active Expired - Lifetime
- 1996-12-17 MY MYPI96005309A patent/MY132405A/en unknown
-
1998
- 1998-05-28 MX MX9804247A patent/MX9804247A/en unknown
- 1998-06-17 NO NO19982784A patent/NO311358B1/en not_active IP Right Cessation
- 1998-12-02 US US09/203,764 patent/US6071921A/en not_active Expired - Lifetime
-
2000
- 2000-02-09 US US09/500,470 patent/US6258951B1/en not_active Expired - Lifetime
-
2001
- 2001-06-11 US US09/877,005 patent/US6362336B1/en not_active Expired - Lifetime
- 2001-10-19 GR GR20010401823T patent/GR3036954T3/en unknown
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100069414A1 (en) * | 1999-06-21 | 2010-03-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US8722694B2 (en) | 1999-06-21 | 2014-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US8586608B2 (en) | 2000-12-20 | 2013-11-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20100010023A1 (en) * | 2000-12-20 | 2010-01-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
USRE43431E1 (en) | 2000-12-20 | 2012-05-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US20110046168A1 (en) * | 2000-12-20 | 2011-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them |
US20020173509A1 (en) * | 2000-12-20 | 2002-11-21 | Frank Himmelsbach | Quinazoline derivatives and phamaceutical compositions containing them |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US10266518B2 (en) | 2002-07-15 | 2019-04-23 | Symphony Evolution, Inc. | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof |
US20090318373A1 (en) * | 2002-07-15 | 2009-12-24 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
US9796704B2 (en) | 2002-07-15 | 2017-10-24 | Symphony Evolution, Inc. | Substituted quinazolines as receptor-type kinase inhibitors |
US9359332B2 (en) | 2002-07-15 | 2016-06-07 | Symphony Evolution, Inc. | Processes for the preparation of substituted quinazolines |
US8658654B2 (en) | 2002-07-15 | 2014-02-25 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US20050107358A1 (en) * | 2003-02-20 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US20070185081A1 (en) * | 2003-02-20 | 2007-08-09 | Boehringer Ingelheim International Gmbh | Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US11124482B2 (en) | 2003-09-26 | 2021-09-21 | Exelixis, Inc. | C-met modulators and methods of use |
US20110077233A1 (en) * | 2003-09-26 | 2011-03-31 | Exelixis, Inc. | C-Met Modulators and Method of Use |
US8476298B2 (en) | 2003-09-26 | 2013-07-02 | Exelixis, Inc. | c-Met modulators and method of use |
US8178532B2 (en) | 2003-09-26 | 2012-05-15 | Exelixis, Inc. | c-Met modulators and method of use |
US8067436B2 (en) | 2003-09-26 | 2011-11-29 | Exelixis, Inc. | c-Met modulators and methods of use |
US20070054928A1 (en) * | 2003-09-26 | 2007-03-08 | Exelixis, Inc. | c-Met modulators and methods of use |
US8497284B2 (en) | 2003-09-26 | 2013-07-30 | Exelixis, Inc. | C-met modulators and method of use |
US20070225307A1 (en) * | 2003-09-26 | 2007-09-27 | Exelixis, Inc. | C-met modulators and method of use |
US9174947B2 (en) | 2003-09-26 | 2015-11-03 | Exelixus, Inc. | c-Met modulators and methods of use |
US9089571B2 (en) | 2005-11-11 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US9539258B2 (en) | 2005-11-11 | 2017-01-10 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
US20090318480A1 (en) * | 2006-09-18 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
US8877764B2 (en) | 2006-09-18 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring EGFR mutations |
US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US9809549B2 (en) | 2009-01-16 | 2017-11-07 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
US11091439B2 (en) | 2009-01-16 | 2021-08-17 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
US11091440B2 (en) | 2009-01-16 | 2021-08-17 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
US11098015B2 (en) | 2009-01-16 | 2021-08-24 | Exelixis, Inc. | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
US10004743B2 (en) | 2009-07-06 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US9545381B2 (en) | 2009-07-06 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
US10736886B2 (en) | 2009-08-07 | 2020-08-11 | Exelixis, Inc. | Methods of using c-Met modulators |
US11433064B2 (en) | 2009-08-07 | 2022-09-06 | Exelixis, Inc. | Methods of using c-Met modulators |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6362336B1 (en) | Chemical compounds | |
US10457664B2 (en) | Quinazoline derivatives as VEGF inhibitors | |
EP0885198B1 (en) | 4-anilinoquinazoline derivatives | |
US6265411B1 (en) | Oxindole derivatives | |
US7087602B2 (en) | Cinnoline derivatives and use as medicine | |
EP1005470B1 (en) | Oxindolylquinazoline derivatives as angiogenesis inhibitors | |
US6184225B1 (en) | Quinazoline derivatives as VEGF inhibitors | |
US6809097B1 (en) | Quinoline derivatives inhibiting the effect of growth factors such as VEGF | |
KR20050019936A (en) | Quinazoline derivatives | |
JP2009007364A (en) | Quinazoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ZENECA LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOHMANN, JEAN-JACQUES MARCEL;HENNEQUIN, LAURENT FRANCOIS ANDRE;THOMAS, ANDREW PETER;REEL/FRAME:011892/0038;SIGNING DATES FROM 19961129 TO 19961206 Owner name: ZENECA PHARMA S.A., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOHMANN, JEAN-JACQUES MARCEL;HENNEQUIN, LAURENT FRANCOIS ANDRE;THOMAS, ANDREW PETER;REEL/FRAME:011892/0038;SIGNING DATES FROM 19961129 TO 19961206 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: ASTRAZENECA UK LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZENECA LIMITED (NOW SYNGENTA LIMITED);REEL/FRAME:016621/0859 Effective date: 20000104 Owner name: SYNGENTA LIMITED, ENGLAND Free format text: CHANGE OF NAME;ASSIGNOR:ZENECA LIMITED;REEL/FRAME:016621/0031 Effective date: 20020527 |
|
AS | Assignment |
Owner name: ASTRAZENECA SAS, FRANCE Free format text: CHANGE OF NAME;ASSIGNOR:ZENECA PHARMA SA;REEL/FRAME:016761/0075 Effective date: 20000207 Owner name: ASTRAZENECA UK LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAS, ASTRAZENECA;REEL/FRAME:016761/0071 Effective date: 20050621 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: GENZYME CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA UK LIMITED;REEL/FRAME:038629/0381 Effective date: 20150930 |